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ABSTRACT
The effects of di-2 ethylhexyl phthalate (DEHP) 
over periods of 3 days to 9 months were.examined in both 
male and female rats using biochemical, histological and 
ultrastructural techniques. Responses occurred in a 
characteristic order. Initial effects included : changes 
in the. distribution of lipid in the liver, proliferation 
of hepatic peroxisomes and induction of laurate 
hydroxylases. More slowly developing changes were (1) 
hypertrophy of the hepatocytes, (2) centrilobular loss 
of glycogen and (3) a fall in glucose-6-phosphatase 
activity. After 9 months of treatment, accumulation of 
lipid-loaded lysosomes were observed. All these changes 
were observed in rats treated with 1000 or 200 mg/kg/day 
of DEHP, but rats treated with 50 mg/kg/day of DEHP did 
not show the later changes. In addition to these sustained 
alterations, two transient changes were observed. Male 
rats, treated with 1000 mg/kg/day of DEHP showed changes 
in the biliary system as shown by electron microscopy, by 
examination of bile flow, bile enzymes and proteins. 
Furthermore, a burst of mitosis occurred immediately after 
commencement of treatment of DEHP, the magnitude and time 
of which was dose-dependent. Changes in female rats were 
qualitatively similar, but quantitatively smaller, than 
in male rats.
Mature male rats treated for 3 or 13 days with either 
DEHP or the hypolipidaemic drugs fenofibrate or clofibrate, 
showed similar changes to young rats with the exception of 
the mitotic burst which did not occur in these animals.
The initial short term effects of DEHP and the straight 
chain analogues, di-n-octyl phthalate (DN0P) and di-n- 
hexyl phthalate (DNHP) in vivo and their respective esters,
MEHP and MNHP, were reproduced in cultured hepatocytes.
There was induction of peroxisomal enzymes in response to 
treatment with DEHP or MEHP but little or no induction 
after treatment with DNOP, MNOP or .MNHP*. Accumulation of 
lipid was seen after 24 hours of treatment With MEHP,
MNOP and MNHP. However, the mitotic burst was not 
reproduced in cultured hepatocytes treated with MEHP, 
neither was there a fall in glucose-6-phosphatase activity.
There was no increase in ^2^2 Pr°duction either in 
vitro in cultured hepatocytes treated with MEHP, or in vivo 
as measured by catalase compound I in perfused liver from 
rats treated with DEHP in the diet. There was no evidence 
for mutagenic activity of DEHP or MEHP in the Ames Test.
"Treatment of isolated hepatocytes with MEHP, straight 
chain phthalate esters or clofibrate, resulted in early 
marked pertubations in lipid metabolism, namely, an increase 
in production of neutral fats and generally in fatty acid 
oxidation. This may explain the increased storage of 
lipid, in the liver. There was a marked difference in 
response between hepatocytes isolated from fed and fasted 
rats, the latter being more sensitive to all compounds. 
Indeed with fed rats there was, in some cases, a slight 
decrease in fatty acid oxidation. The effects on lipid 
metabolism were observed at concentrations which produced 
peroxisome proliferation in cultured cells.
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CHAPTER ONE
INTRODUCTION
THE USE OF PHTHALIC ACID ESTERS AND THE POTENTIAL SOURCES
OF EXPOSURE TO MAN.
The safety or potential toxicity of phthalate esters to 
man has been investigated extensively following a report of 
the hepatocarcinogenicity of di(2-ethylhexyl)phthalate (DEHP) 
in rats and mice (Kluwe et al, 1982). Phthalic acid esters 
are an important group of industrial chemicals. In 1980,
915 million pounds of phthalate esters were produced in the 
U.S.A., of which approximately 400 million pounds was DEHP. 
(Society of Plastics Industries, 1982).
The major use of phthalate esters is as plasticisers 
which impart flexibility to plastics, particularly poly(vinyl- 
chloride) (PVC) polymers. The matrix of plastics is composed 
of polymerised molecules, into which chemicals (adjuvants) 
are incorporated to allow the plastic properties of combustion 
resistance, colour enhancement, resiliency and/or flexibility. 
The ortho esters of phthalic acid are added to acheive 
flexibility, and may constitute up' to 50%, by weight, of the 
final product (Marx, 1972). Plasticisers are not firmly bound 
in the matrix and are, therefore, able potentially to migrate 
into the external environment with time and use.
Plastics containing phthalate esters have a wide variety 
of uses. Plasticised PVC is used in food wrapping, floor tiles, 
car and home furnishings, electrical insulation, industrial 
tubings, conveyor belts, and in bio-medical devices, including 
syringes, blood bags and dialysis tubings. Phthalate esters 
have applications other than as plasticisers; the major 
non-plasticiser uses of phthalate esters are as pesticide 
carriers,and in cosmetics, fragrances, industrial oils and 
insect repellants (Graham,1973; Lawrence, 1978). DEHP is also 
used as a dielectric fluid in transformers, instead of 
polychlorinated biphenyls (Lawrence, 1978).
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Thus, human exposure to phthalate esters is extensive 
and is chronic, although the actual levels of exposure are 
normally low. Exposure can result from ingestion of food 
and water, or by dermal contact (cosmetic products, insect 
repellants) or inhalation (car and home furnishings). It 
has been calculated that the daily dietary exposure to DEHP . 
is about 6 pig per person, mostly from fresh produce wraps 
(Proc. Conf. on 1 Phthalates", 1981).
Higher exposure to phthalate esters, over shorter periods 
of time, may occur through transfusion of PVC-stored blood.
This was first reported by Guess et at (1967), who found 
DEHP in the ACD (acid-citrate dextrose) solutions in PVC 
blood bags. Subsequently, Jaegar and Rubin (1972) reported 
the presence of DEHP in human blood that had been stored in 
PVC bags and in tissues of patients who had received 
transfusions of PVC-stored blood. These*authors calculated 
that a whole-body exchange transfusion, with 21 day old 
blood, would result in the intra-venous administration 
of approximately 300 mg of DEHP. Further studies (reviewed 
by Lawrence and Tuell, 1979) also support the view that DEHP 
can readily leach from plasticised PVC materials, to accumulate 
in blood in milligram quantities, and is transferred to the 
recipient patient.
The duration of contact, temperature and composition 
(e.g. lipid content) of the blood or blood product determine 
the rate at which DEHP leaches from the plastic and the 
concentration which is attained in the fluid in the bag.
Low levels of DEHP were detected in water and simple 
physiological solutions (0.1 mg/litre) in PVC containers.
DEHP levels increased markedly after agitation of the bags,
and in the presence of ethanol, but were found to be
independent of the pH of the solution.
A further source of exposure to phthalate esters , and
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DEHP, in particular, is a result of environmental contamination. 
The environmental distribution of phthalate esters is ubiquitous. 
(Mayer et al., 1972).
DEHP has been detected in air, water and soil. Thomas 
(1973) detected three phthalate esters present in air samples 
taken at the waterworks in the city of Hamilton, Ontario,
Canada, adjacent to a municipal incinerator. Di-n-biityl' -
butylcarbobutoxymethyl and di(2-ethylhexyl) phthalates 
were detected at levels of 700, 750 and 300 nanograms 
of phthalate/cubic metre of air, respectively. Concentrations 
of up to 70 ug/g of DEHP have been detected in estuarine and 
marine sediments in Europe and in the U.S.A.. Giam et at,
(1978) have also reported the presence of DEHP in fish and 
other marine organisms.
Ogner and Schnitzer (1970) found fulvic acid complexes 
of DEHP, dibutyl, dicyclohexyl and benzylbutyl phthalates in 
a soil sample from Prince Edward Island, Canada. Fulvic acid 
is a water-soluble humic material, widely distributed in soil 
and water, which, in test tube experiments, has been found 
to form stable complexes with dialkyl phthalate esters.)■ > .
CHEMICAL STRUCTURE AND PROPERTIES QF PHTHALATE ESTERS.
Phthalate esters consist of paired ester groups on a 
cyclohexatreine ring. The meta and para configurations are 
known as isophthalates and terephthalates, respectively:.-=
Ortho esters of phthalic acid are generally referred to as 
"phthalate esters".
The general structure of the phthalate esters is
ii
C-OR
where R = R* or R / R 1.
C-OR* 
li 
O
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Phthalate esters are synthesised commercially by 
condensation of appropriate alcohols with phthalic anhydride. 
The structure of di(2-ethylhexyl)phthalate, the most commonly 
used plasticiser is:
This compound has also been referred to as dioctylphthalate, 
or DOP, in the older literature. In this thesis, DnOP will 
indicate the straight chain compound, di-n-octylphthalate, 
whilst DEHP will be used to indicate di(2-ethylhexyl)phthalate, 
the branched chain compound.
Most phthalate esters are colourless liquids, with high 
boiling points, and low vapour pressures- which contributes 
to their high stability (Patty, 1967). Their solubility is 
relatively low in aqueous media, because of their lipophilic 
structures. However there are exceptions; e.g. the phthalate 
esters with short alkyl groups, such as dimethyl and 
di-n-butyl phthalate, which are appreciably soluble in water 
(0.5 g/100 ml of water) (Autian, 1973).
The molecular weight of DEHP is 391 g, the boiling point 
is about 387°C, and it has a low vapour pressure (1.2 mm Hg). 
The solubility of DEHP is dependent upon the solute. It 
is soluble in blood and in other lipoprotein containing 
materials. Suspensions of DEHP can be acheived by the use 
of non-ionic surfactants, by sonication and use of elevated 
temperatures (Thomas et al., 1978). The biodistribution of 
DEHP is affected by the physical state of DEHP, e.g. the 
particle size of DEHP in a suspension.
I t
C-0CHoCH(CH_)_CH 2 1 2 3
CH0CH_
C—0CHoCH(CHo)0CH 
II 21 2 3
o c h2c h3
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1.3. HEPATOCARCINOGENICITY OF PHTHALATE ESTERS.
Kluwe et al. (19 82) reported a significant increase in 
the incidence of liver cancer in rats and mice after 
administration of diet containing large amounts of DEHP.
Fischer F-344 rats were fed dietary concentrations of DEHP 
of 0.6% and 1.2%, and mice were fed 0.3% and 0.6% DEHP, in 
the diet, for 2 years. Statistically significant numbers of 
hepatocellular carcinomas were reported in male rats treated 
with the higher dose level and in female rats and mice 
at both dose levels. In male mice, because of the high 
incidence of hepatocellular carcinomas in the control group, 
the treated group showed no significant increase. However, 
lung metastases were observed in both male and female mice 
at both dose levels, but not in either control group.
This study has been criticised by some authors (Northup et al., 
1982), and this will be discussed in the Discussion.
Interestingly, previously published studies on phthalate 
esters had indicated no hepatocarcinogenic effect. Carpenter 
et al. (1953) administered diet containing 0.04, 0.13 and 0.4% 
DEHP to groups of 32 male and 32 female Sherman rats. This 
corresponds to an intake of about 20, 60 and 200 mg/kg/day of 
DEHP. The dose-response relationship to DEHP was investigated.
In addition, a 2 generation study was carried out, in which 
the parent generations (control rats and rats treated with 
0.4% DEHP in the diet) were treated for one year, after which 
time only 42% of the control group and 42% of the treated 
group survived. From these surviving animals the F^ generation 
was derived. The first generation was then treated with 
either control diet or with diet containing 0.4% DEHP in 
the diet, for one year, after which time the animals were 
killed. Statistically significant increases were found in 
the ratios of liver and kidney weight to body weight in both 
the parent and the F^ generations receiving 0.4% DEHP in the diet 
although no significant increase in histological abnormalities
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was observed in these animals. Some tumours were observed 
in animals from all groups, which survived for longer than 
a year, although none of these was described as malignant 
by the pathologist, and their occurrence had no relation 
to the plasticiser dose. Because of the limitations of this 
study, in terms of the small number of animals used, poor 
survival and limited reporting, compared to recent protocols 
for carcinogenicity bioassays, it cannot be concluded 
whether or not DEHP is a carcinogen.
Harris et al. (1956) carried out a 2 year study in 
which groups of 43 males and 43 female Wistar rats were treated 
with diet containing 0, 0.1 and 0.5% DEHP, which is equivalent 
to 0, 50 and 250 mg/kg body weight/day. Animals were sacrificed 
after 3, 6, 12 and 24 months. The results were similar 
to those of Carpenter et al. (1953), no tumours were observed. 
This experiment was also inadequate as a carcinogenicity 
bioassay because of the limited pathology carried out, and the 
small numbers of animals used. Hence, the negative findings 
in both of the early studies may well be due to poor 
experimental design.
THE LINK BETWEEN HEPATOCARCINOGENICITY AND PEROXISOME 
PROLIFERATION.
The finding that DEHP acts as a hepatocarcinogen in 
rodents is not unexpected, as the short term effects of DEHP 
closely resemble those of the hypolipidaemic drugs, such 
as clofibrate, which have been shown to be carcinogenic in 
rodents (Reddy and Rao, 1977; Reddy et al., 1979 and 1980; 
Svoboda and Azarnoff, 1979).
Several major short term effects of DEHP have been 
clearly identified. These include a marked proliferation of 
peroxisomes and hepatomegaly (Lake et al. , 1975; Reddy et al., 
1976; Moody and Reddy, 1978a).A large number of compounds
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have been reported to show similar effects. These compounds 
are shown in Table 1.1., and include clofibrate and its 
structural analogues, nafenopin, methyl clofenapate,
SaH-42,348 and gemofibrizol, and other hypolipidaemic . 
compounds which are structurally unrelated to clofibrate, 
tibric acid, Wy-14,643 and BR-931 (see Reddy and Lalwani, 1984). 
Another category of chemicals includes the environmental 
contaminants, such as chlorinated long chain aliphatic 
halogenated hydrocarbons (Nilsen et al., 1981), pyrethroids 
(Ortega, 1969) and poly-chlorinated biphenyls (Hansell and 
Ecobichon, 1974).
Peroxisome proliferation is also induced by high fat diets 
(Ishii et al., 1980; Neat et al., 1980), although induction 
is not as marked as that produced by the hypolipidaemic 
agents. Tumour incidence in rodents is also increased by 
high fat diets (Gellatly, 1975). Peroxisome proliferation 
is elicited by ethionine, which is a hepatocarcinogen, and 
raises hepatic lipid content (Steiner et al., 1964 ; Wood, 1965). 
Fringes and Reith (1981) reported that tri-iodothyronine 
is a peroxisome proliferating agent; tri-iodothyronine mobilises 
lipid from adipose tissue and enhances lipid transport into the 
liver. Thus, peroxisome proliferation may result from increased 
intra-hepatic lipid, which could result, in turn, from 
administration of a xenobiotic or from a change in lipid 
metabolism.
All peroxisome proliferating agents, that is xenobiotics 
which induce the proliferation of peroxisomes in liver cells, 
also typically produce similar responses to those produced 
by DEHP; namely, liver enlargement, unaccompanied by frank 
histological damage, proliferation of the smooth endoplasmic 
reticulum and hypotriglyceridemia (Cohen and Grasso, 1981), 
and after chronic administration of potent peroxisome 
proliferating agents, hepatocarcinogenesis. There is not 
yet sufficient evidence to suggest whether mild peroxisome
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TABLE 1.1.
CLASSIFICATION OF CHEMICALS IDENTIFIED AS HEPATIC PEROXISOME PROLIFERATING AGENTS.
HYPOLIPIDAEMIC DRUGS a) CLOFIBRATE AND ITS STRUCTURAL ANALOGUES.
Clofibrate
Nafenopin
Methyl clofenapate
SaH-42,348
S-8527
AT-308
Gemfibrizol
Bezafibrate
Simfibrate
Hess e t  a l . , 1965; Svoboda and Azarnoff, 1966
Reddy e t  a l . , 1973; Leighton et  a l . , 1975
Reddy, 1974
Reddy et  a l . , 1975
Sakamoto e t  a l . , 1973
Arakawa et  a l . , 1978
Schwandt e t  a l . , 1979; Reddy, 1980
Fahimi e t  a l . , 1980
Watanabe and Suga, 1980
b) COMPOUNDS STRUCTURALLY UNRELATED TO CLOFIBRATE
Tibric acid 
Wy-14,643 
BR-931 
RMI-14,514 
Chlorocyclizine 
Aspirin
Reddy and Krishnakantha, 1975 
Reddy and Krishnakantha, 1975 
Reddy e t  a l . , 1978 
Svoboda, 1978 
Hruban e t  a l . , 1974
Ishii and Suga, 1979; Hruban e t  a l . , 1966
PLASTICISERS AND RELATED COMPOUNDS.
Di(2-ethylhexyl)phthalate Lake et  a l . , 1975; Moody and Reddy, 1978; Reddy e t  a l ., 1976 
(DEHP)
Di(2-ethylhexyl)sebacate Moody and Reddy, 1978
Di(2-ethylhexyl)adipate Moody and Reddy, 1978
2-Ethylhexanol Moody and Reddy, 1978
2-Ethylaldehyde Moody and Reddy, 1978
2-Ethylhexanoic acid Moody and Reddy, 1978
ENVIRONMENTAL CONTAMINANTS.
Long chain aliphatic 
hydrocarbons 
Pyrethroids 
Polychlorinated 
hydrocarbons
Nilsen e t  a l ., 1981
Ortega et  a l . , 1969 
Hansell and Ecobichon, 1974
DIETARY MANIPULATIONS.
High fat diets 
Vitamin E deficient 
diet
Ishii et  a l . , 1980; Neat e t  a l . , 1980 
Reddy et  a l . , 1981
MISCELLANEOUS.
Ethionine
Tri-iodothyronine
Steiner et  a l . , 1964 ; Wood, 1965 
Fringes and Reith, 1980; 1981
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proliferating agents, such as aspirin, will also lead 
to the development of hepatocarcinomas, after chronic 
administration.
Reddy eiial. (1980) has postulated that these compounds 
constitute "a novel class of carcinogens", as sustained 
peroxisome proliferation and the increased appearance of 
hepatocellular carcinomas in rodent liver seem to be closely 
inter-linked.
There is little information pertaining to the potential 
risk of DEHP to man. However, there is some pertinent 
information for some of the hypolipidaemic drugs. For example, 
clofibrate has been used for more than the last 15 years 
in man, for the treatment of hyperlipidaemias with no apparent 
adverse consequences. There is no evidence, as yet, of 
increased liver cancer in humans treated with one-tenth 
of the dose of clofibrate which is hepatocarcinogenic in 
rats. Hanefeld et al. (1980) reported marked differences in 
the short term effects of clofibrate in man compared to those 
observed in rats: there was a slight proliferation of 
hepatic microbodies in human liver, after long term treatment, 
that is, 6 months to up to 7 years of treatment, but more 
striking was the significant increase in the numbers of 
mitochondria, together with alterations in the ultra­
structure, such as increased numbers of cristae. There was 
also hypertrophy of the endoplasmic reticulum. These changes 
persisted for months after cessation of treatment.
On the basis of these findings, it has been postulated that 
exposure of man to DEHP.will not result in hepatocarcinogenesis. 
This argument is currently being debated. If the above 
argument is not sustained it could result in the restriction 
of the use of phthalate esters as plasticisers. This will 
be further discussed in the Discussion.
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DEHP, as a member of the group of peroxisome 
proliferating carcinogens, has been classified as a 
non-genotoxic carcinogen as both DEHP and MEHP have 
been reported to give negative results in mutagenicity 
assays in 5 strains of S. typhimuriwn. (Simmon et al., 1977; 
Ruddick et al., 1981).
Results from sister chromatid exchange tests and 
tests of chromosomal abberations have generally given . 
negative or questionable results for DEHP and its metabolites 
(Abe and Sasaki, 1977 ; Stenchever et al., 1976 ; Ishidate 
and Odashima, 1977; Turner et al., 1974).
No clear dose-response relationship was established 
in tests of dominant lethal mutation, in which intra- 
peritoneal doses of up to 25.56 ml/kg of DEHP was used 
in mice (Dillingham and Autian, 1974).
There is no~ evidence for covalent binding of DEHP 
or its metabolites to DNA (see Discussion).
1.5. MECHANISMS OF HEPATOCARCINOGENESIS.
The following mechanism has been proposed for 
hepatocarcinogenesis for mutagenic compounds. Cancer is 
induced by a series of steps, in which a normal cell 
develops into a neoplastic cell, from which a tumour 
develops.
RARE
CHEMICAL
ACTIVATION
TARGET- 
CELL ■
1
IF
■BIOCHEMICAL
-LESION
(DNA?)
HEPATOCELLULAR
CARCINCMA
After Farber, 1982
1st Nodule
within
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Rare Neoplastic 
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RARE EVENT #2
The first step involves the induction of biochemical 
and molecular events by activated carcinogens. Most carcinogens 
require metabolism to reactive products, which are usually 
positively charged and have an affinity for sites of high 
electron density. They react with many different sites in 
DNA, RNA,proteins and other cellular constituents (Miller,1978) . 
Reactions with DNA are thought to be of especial importance 
in the initiation of carcinogenesis (Rajalakshmi et al.,
1982). However if exposure to a hepatocarcinogen, at a 
non-necrogenic dose, is not followed by one round of cell 
replication within 2 days, the biochemical lesions disappear 
and initiation does not occur (1A). If cell proliferation 
occurs (2), a permanent change is induced in some of the 
hepatocytes, allowing the subsequent evolution of hepatocellular
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carcinomas, which manifests itself in 3 ways:(a) appearance 
of cancer (Craddock, 1976), (b) appearance or increase in 
the number of islands of hepatocytes with altered histo- 
chemical properties (see Emmelot and Scherer, 1980; Scherer 
et al., 1972) or (c) in the appearance of hepatocytes that 
can be stimulated to proliferate to form focal proliferations 
(see Farber and Cameron, 1980; Farber, 1980). Cell proliferation 
can occur either by a primary mitogenic event, such as 
partial hepatectomy, with a chemical mitogen; or as a secondary 
response to cell death. With non-necrogenic carcinogenic 
stimuli the rate limiting step is not exposure to the chemical 
but the occurrence of cell damage and cell regeneration.
Cancer develops by selective stimulation (3A)(promotion) 
of initiated hepatocytes to form nodules. The initiated 
hepatocytes persist, if no selective stimulation occurs.
If selective stimulation occurs, initiated hepatocytes 
proliferate to form nodules (3B). The promoting environment 
may stimulate initiated cells to respond, whilst inhibiting 
normal cells, or there may be differential stimulation - 
some chemicals which are mitogens for the liver, e.g. 
a-hexachlorocyclohexane, stimulate initiated hepatocytes 
to respond whilst uninitiated hepatocytes lose their response 
after one or two cell cycles. Proliferating foci may simply 
persist as small foci, or they may show progressive growth 
stimulation to form larger collections of altered hepatocytes, 
hyperplastic nodules,remodelling or maturation to normal- 
looking liver may occur. The majority (90 - 95%) of nodules 
undergo a complex remodelling process, called neo-differentiatior 
(Farber and Cameron, 1980), with a few hundred or thousand 
nodules in the liver; the minority that persist undergo 
progressive phenotypic changes. In the persistent nodules 
the cells become typical "ground-glass cells", with pale 
nuclei, and display a fairly uniform hypertrophy due to the 
increase in smooth endoplasmic reticulum.
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In hyperplastic nodules the hepatocytes are arranged 
in two or more cell thick plates and have many biochemical, 
cytological and histochemical markers (Farber et al., 1979). 
During remodelling they change, both architecturally and 
histochemically, to resemble normal mature liver (Farber,
1976). Hyperplastic nodules show no growth on transplantation 
or in culture. The hepatocytes are considered to be hyperplastic, 
not neoplastic, as there is no evidence that they have acquired 
independence or autonomous growth (Farber and Cameron, 1980).
The hyperplastic nodules may be transferred into syngeneic 
recipients, by intraportal injection and may be induced to 
grow only if an appropriate selection pressure is created 
(Laishes and Rolfe, 1982).
A further process that may occur is a rare event. Rare 
events are apparently irreversible cellular events, which 
occur in a small number of cells in a Targe population at 
risk. Such rare events create nodules within nodules, in 
which the new population is arranged with two or more cell 
thick plates.
This scheme illustrates that xenobiotics may act as 
"initiating" agents which convert a normal into a neoplastic \ 
cell, often via an act on cellular DNA, and/or they may act 
as promoters to facilitate the development of tumours. Thus, 
chemicals may act at both or either stage(s) to bring about 
carcinogenicity by a variety of mechanisms.
However, there are obvious differences between responses 
to different hepatocarcinogens, as treatment with some 
carcinogens does not result in the sequence of events described 
above. It has been proposed that carcinogens should be 
categorised into two types; genotoxic which react with and 
damage DNA and epigenetic, or non-genotoxic, which do not 
damage DNA but cause other biochemical effects resulting in 
tumour development (Williams, 1979).
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It is pertinent to describe, briefly, the essential 
features distinguishing genotoxic and non-genotoxic 
hepatocarcinogens, since these distinctions may be important 
in the understanding of the mechanism of hepatocarcinogenicity 
of DEHP. The most obvious distinction is that genotoxic 
carcinogens, as the term implies, interact directly, or 
through the formation of an active metabolite with DNA, or, 
alternatively, interfere with DNA replication or repair. 
Non-genotoxic carcinogens, or their metabolites, on the 
other hand, do not interact directly with DNA, but work by 
an indirect mechanism, possibly involving increased mitosis 
or peroxidative damage. An obvious characteristic of non- 
genotoxic carcinogens is that they do not act as mutagens 
or cause chromosomal aberrations.
The following table (Table 1.2.) illustrates the 
differences between genotoxic and non-genotoxic carcinogens, 
as proposed in the ECETOC Monograph, no. 4 (1982). The 
situation is much more complicated, however, and each point needs 
needs careful examination.
(1) and (2) illustrate the obvious differences between 
genotoxic and non-genotoxic carcinogens. Although it must 
be noted that individual mutagenicity tests are fallible; 
false negatives have been observed with known carcinogens, 
which appear from other evidence to act directly on DNA 
(Handbook of Mutagenicity test Procedures, 1982).
(3). It is true that a wide group of chemical compounds, 
with diverse structures act as non-genotoxic hepatocarcinogens; 
yet, from their chemical structures we have successfully 
predicted that 2 compounds would act as peroxisome proliferators, 
and based on Reddy's hypothesis, must be considered as 
hepatocarcinogens. The compounds in question were citral 
(Jackson, G. Unpublished results) and Ethyl 2[5(4-chloro- 
phenyl)pentyl]oxiran-2-carboxylate (CPOC) (Sherratt et al.,
1982 ) .
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TABLE 1.2.
COMPARISON OF THE POSTULATED PROPERTIES OF GENOTOXIC AND
NON-GENOTOXIC CARCINOGENS.
GENERAL CARCINOGENIC EFFECTS. 
GENOTOXIC CARCINOGEN. NON-GENOTOXIC CARCINOGEN.
(1) Reactivity of chemical and From chemical structure
or metabolite with genetic cannot predict chemical
material predictable from 
structure.
reactivity.
(2) Positive results from Negative results in
appropriate mutagenicity tests. mutagenicity tests.
(3) Interacts with DNA. No interaction with DNA.
(4) No apparent dose-response 
threshold, i.e. may only 
need a single exposure.
Threshold may be apparent.
(5) Organs other than the liver 
affected.
Normally only liver affected
(6) Not species-specific, more 
than one species usually 
affected.
Generally rodent-specific
HEPATOCARCINOGENIC EFFECTS.
(7) Liver tumours have a wide Liver tumours have a narrow
range of histopathological range of histopathological
type. type.
(8) Hepatotoxicity not essential 
for tumour enhancement.
Evidence of hepatotoxicity.
(9) Enhancement of effect by No enhancement of effect by
partial hepatectomy. partial hepatectomy.
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(4). This states that a threshold may be apparent, in 
theory this is correct; however, there is no experimental 
evidence, as yet, to support or deny this.
(5). Stomach and bladder cancers are brought about by 
non-genotoxic carcinogens (see Section 1.6. for a detailed 
description). Thus, the liver is not the only organ affected 
by non-genotoxic carcinogens.
(6). There is not yet sufficient experimental evidence to 
support the hypothesis that non-genotoxic carcinogens act 
specifically on rodents. In addition, hormones act as non- 
genotoxic carcinogens in man (see Section 1.6.).
(7). There is sufficient experimental evidence to support 
this point.
(8). Although there is experimental evidence that mild 
hepatotoxicity is brought about by the non-genotoxic 
hepatocarcinogens, it is not yet clear whether this is 
essential for tumour development, and until the mechanism 
by which non-genotoxic carcinogens act is elucidated, this 
remains a hypothesis to be proven.
(9). There is not yet sufficient experimental evidence to 
determine whether partial hepatectomy has an effect or 
not.
Thus, a great deal of experimental evidence is still 
required to clarify the proposed differences between 
genotoxic and non-genotoxic carcinogens. The mechanism(s) 
by which non-genotoxic carcinogens act to cause the 
development of tumours remains a mystery, although some 
understanding of their mechanism of action is beginning 
to come about (see Section 1.6.).
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1.6. NON-GENOTOXIC HEPATOCARCINOGENS.
Hepatocarcinogens may be classified according to their 
short-term effects. The classical or genotoxic hepato­
carcinogens include nitrosamines, benz(a)pyrene, aflatoxin 
and 4-aminobiphenyl. The non-genotoxic carcinogens, i.e. 
those that do not form reaction products with DNA, and give 
negative results in mutagenicity tests may be further 
divided into classes depending upon their mechanism of 
action (see Cohen and Grasso, 1981).
(1). NECROSIS-INDUCING HEPATOCARCINOGENS.
These compounds have a low potency and produce tumours 
only at dose levels of many parts per million. The tumours 
produced are all derived from hepatocytes, and unlike the 
classical hepatocarcinogens, there is a marked absence of 
primary tumours at extra-hepatic sites. There is a narrow 
dose-response range. The administration of these compounds 
does not result in hepatomegaly, rather liver necrosis is 
observed as an early response and the formation of liver 
nodules is necessary for liver tumour development.
Reuber and Glover (1970) observed that subcutaneous 
administration, to male rats of different strains, of a 
50% solution of carbon tetrachloride (CCl^), twice weekly, 
at a dose of 1.3 ml/kg body weight, resulted in the 
development of carcinomas in the liver, which were related to 
the severity of the cirrhosis and to the survival time. 
Sprague-Dawley, Black Rat, and, to a lesser extent, Wistar 
male rats died from moderate to severe cirrhosis, before 
they could develop carcinomas of the liver, whilst Japanese 
and Osborne-Mendel rats were less susceptible to the 
development of cirrhosis and survived for a longer time, 
and had hepatocellular carcinomas in the liver. Interestingly, 
lesions were also found in the spleen, thyroid and kidneys of
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some animals. Spleens were enlarged. Atrophy of the testes, 
prostate and seminal vesicles was observed and found to be 
related to the degree of cirrhosis. In 3 out of 15 Osborne- 
Mendel rats and 3 out of 15 Japanese rats treated with CCl^ 
carcinomas of the thyroid gland were observed. Multicystic 
kidneys were also observed in 3 out of 15 Japanese and in 
2 out of 15 Osborne-Mendel rats.
CC14 is not mutagenic in plate tests with S. typhimurium
TA 100, TA 135 and TA 1538, in the presence and absence of
a microsomal activating system (McCann and Ames, 1976;
McCann et at., 1975; Uehleke et at., 1977). However, CCl^
has been observed to bind, at low levels, to DNA (Diaz-Gomez
14and Castro, 1980). These authors observed that C from 
14CC1A irreversibly bound, in vivo, to liver DNA from A/J
. 14mice and Sprague Dawley rats. In v%tvo, CCl^ was bound 
to DNA in incubation mixtures containing microsomes and 
an-NADPH generating system, as well as liver slices. The 
authors suggested that the intermediates generated from 
CC14, having the reactivity of *CC13 would never be able 
to travel from a distant activation site, such as the ER, 
to the nucleus and interact with DNA, nuclear proteins 
and lipids.
Eschenbrenner and Miller (1945) examined the response 
to chloroform (CHCl^) and observed that hepatomas developed 
only in animals treated with doses high enough to induce 
necrosis, and concluded that the "cycle of necrosis and 
regeneration produced by each successive dose was responsible 
for the production of hepatomas". Reitz et at. (1980) 
confirmed that CHCl^ produced liver tumours only at dose 
levels which resulted in severe tissue damage in short 
term studies, and in addition, demonstrated that CHCl^ 
does not bind covalently to DNA nor induce DNA repair.
CHCl^ is not mutagenic in bacteria.(Van Abbe et at., 1982).
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Thus, repeated episodes of hepatocellular necrosis 
and regenerative hyperplasia may result in the development 
of hepatocellular carcinomas.
MICROSOMAL ENZYME INDUCERS.
The potency, versatility, dose-response range and 
mutagenicity of these compounds are comparable - to those 
of the necrosis-inducing compounds, but, in contrast to 
the necrosis-inducing compounds, treatment with the 
microsomal enzyme inducing compounds results in liver 
enlargement and early subcellular damage, with little 
or no necrosis (see Cohen and Grasso, 1981).
An example of this class of compounds is the synthetic 
azo food colouring, Ponceau MX, which acts as a hepatocarcinogen 
in the rat. Very similar short term effects are produced 
with the naturally occurring food flavour safrole, although 
this can, with some effort, be persuaded to give positive 
results in mutagenicity tests.
Crampton et al. (1977) investigated the effects seen in 
female Wistar Albino rats fed diets containing either 0.25%
(w/w) safrole or 1.0% Ponceau MX for periods of up to 85 
weeks. Both compounds induced hepatomegaly and immediate 
induction of drug metabolising enzymes. Hepatomegaly 
remained throughout the experiment whilst the induction of 
the metabolising enzymes system underwent a decline, so 
that by the time of the appearance of macroscopic liver 
nodules, the activity had returned to or fallen below control 
levels. After 8 weeks of treatment with safrole there was a 
marked centrilobular loss of glucose-6-phosphatase, and 
disruption of normal peri-canalicular distribution of 
lysosomal acid phosphatase, together with the presence of 
enlarged lysosomes. After 25 weeks of treatment increased 
numbers of autophagic vacuoles were observed. Such a pattern
was seen after only 1 week of treatment with Ponceau MX, 
and in both cases, similar patterns of changes were seen 
at subsequent intervals. Histological examination of livers 
from rats treated with safrole revealed individual cell 
necrosis in the centrilobular regions, which progressed to 
small foci of necrosis. Ponceau MX treatment resulted in 
slight centrilobular cell enlargement after 1 week of 
treatment and liver cell hyperplasia after 25 weeks of 
treatment. By 85 weeks after treatment commenced, frank 
histopathological changes were present; fatty changes, 
cell necrosis and proliferative lesions which appeared 
grossly as hepatic nodules in the livers of rats treated 
with safrole or Ponceau MX. Grasso and Gray (1977) demonstrated 
the progression of hyperplastic nodules, induced by treatment 
with Ponceau MX in rats, to a well-differentiated trabecular 
carcinoma.
A dose-response experiment with Ponceau MX demonstrated 
that the incidence of tumour development corresponded to 
the hepatotoxicity produced by Ponceau MX, as tumours 
developed only in animals treated with hepatotoxic levels 
of Ponceau MX (Grasso, 1979). The mechanism by which Ponceau 
MX acts as a hepatocarcinogen is not known for it is non- 
mutagenic, for micro-organisms, with or without metabolic 
activation (Rowland and Grasso, 1977). These authors also 
claim that safrole is non-mutagenic, for micro-organisms, 
with or without metabolic activation.
Cohen and Grasso (1981) have classified the peroxisome 
proliferating agents, that is, the hypolipidaemic drugs and 
phthalate esters, together with the microsomal enzyme inducers, 
for they have many characteristics in common. The initial 
hepatic response is similar with both groups of compounds, 
in that both types of compounds produce hepatomegaly, S.E.R. 
proliferation, and either microsomal enzyme induction or 
peroxisome proliferation (although peroxisome proliferating
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agents have been shown to have marked effects on the E.R.
(see Section 1.9.))- Cessation of treatment with either 
type of compound results in the reversal of the initial 
response. With Ponceau MX and safrole, after the loss of 
the microsomal enzyme induction a sequence of steps occur 
which ultimately lead to the development of hepatocellular 
carcinomas; Cohen and Grasso (1981) postulated that these 
steps were no longer adaptive and so irreversible. The 
inclusion of peroxisome proliferating agents in this class 
of compounds will be further discussed in the Discussion 
(see Section
(3). HALOGENATED HYDROCARBONS.
This group of compounds comprises of a number of 
chlorinated hydrocarbons, which include chlorinated insectisides 
as well as carbon tetrachloride, chloroform and trichlorethylene 
(see Table 1.3.), in addition to polychlorinated biphenyls, 
dibenzo-p-dioxins and polybrominated biphenyls. The latter 
3 types of compounds appear to be part of a larger group 
of hepatocarcinogens, which includes polychlorinated 
dibenzofurans, napthalenes and biphenylenes (Poland and 
Knutson, 1982 ) .
Nearly all these compounds are known to be weak liver 
carcinogens in rodent liver, although little is known about 
the pathogenesis of the lesion. Most of these compounds 
are non-mutagenic in bacteria, but their effects in 
mammalian systems are much less clear-cut. Treatment with 
the halogenated hydrocarbons causes few common effects, with 
the exception that all produce some degree of liver enlargement, 
and proliferation of smooth endoplasmic reticulum, as assessed 
by morphology and biochemically, by assay of the drug 
metabolising enzymes.
As the effects these compounds have been extensively
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TABLE 1.3.
CARCINOGENICITY AND MUTAGENICITIY OF SOME CHLORINATED AROMATIC 
AND ALIPHATIC COMPOUNDS
COMPOUND CARCINOGENIC MUTAGENIC REFERENCES
DDT + - Rinken & 
Legator, 1979
DDE + ““ Rinken & 
Legator, 1979
DDD + Rinken & 
Legator, 1979
Mirex + Rinken & 
Legator, 1979
Aldrin +
"
Rinken & 
Legator, 1979
Dieldrin ■ f Rinken & 
Legator, 1979
Heptachlor + ? Rinken & 
Legator, 1979
Lindane 
Kanachlor )
+ Rinken & 
Legator, 1979
Rinken &
Araclor )
(polychlorinated 
biphenyls)
+ Legator, 1979
TCDD + ? Poland & 
Knutson, 1982
PCNB + — Poland & 
Knutson, 1982
CC14 + Poland & 
Knutson, 1982
Trichlorethylene + — Poland & 
Knutson, 1982
Chloroform + Reitz et al. , 19 
Van Abbe et al. , 
1982.
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investigated and reported (IARC Monographs on the 
Evaluation of the Carcinogenic Risk of Chemicals to 
Humans (1979) Volume 20). The following is merely a 
summary of some of the reported effects due to this 
class of compounds.
Mirex (1,la,2,2,3,3a,4,5,5,5a,5b,6-Dodecachloroocta- 
hydro-1, 3, 4-metheno-l#-cyclobuta (cd) pentalene ) is used as an 
insectiside. It undergoes little or no metabolism, and 
therefore the toxicity is probably due to the parent compound. 
However, some derivatives from mirex are more toxic than 
the parent compound (Chu et al., 1981) and so metabolism of 
high doses may contribute to the mechanism of carcinogenicity. 
Mirex and its derivatives, chlordecone and Photomirex, 
produce similar patterns of hepatic changes
There is induction of smooth endoplasmic reticulum 
and of drug metabolising enzymes, together with a fall in 
glucose-6-phosphatase activity and in glycogen. Marked 
hepatomegaly occurs at high doses, which is thought to be 
associated with changes in the endoplasmic reticulum.
Similar changes have been reported in humans, following 
accidental intake of large amounts of chlordecone (Guzelian, 
1982). In addition, marked fatty infiltration of the peri­
portal zones, and vacuolisation of hepatocytes in the 
centrilobular areas has been observed. No changes in peroxisomes 
have been reported, but changes have been observed in 
mitochondria isolated from mirex-treated rats, including 
a stimulation of respiration and increased respiratory 
control which is similar to that found in mitochondria isolated 
from rats treated with adrin, dieldrin heptachlor and poly­
chlorinated biphenyls.(Guzelian, 1982).
Mirex, and its derivatives, also produce changes in the 
thyroid, namely reduction in follicular size and increase 
in colloid density (Chu et al., 1981);;there is a reduction
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in serum T^ with no significant alteration in 
(Villeneuve et at., 1979 ). Furthermore, chlodecone can mimic 
oestrogens in the sense that it causes testicular atrophy 
both in humans and a number of other species (Guzelian, 1982).
Ulland etal. (1977) carried out a carcinogenicity assay 
of mirex, in Charles River CD rats, which were fed 
50 or 100 mg/kg diet mirex for 24 months. There was an 
increased incidence of liver cell carcinomas in treated rats 
as compared to controls, where no neoplastic liver nodules 
were seen. Although there is sufficient evidence that mirex 
acts as a carcinogen on both rats and mice (see IARC monograph, 
volume 20) there is no clear understanding of its mechanism 
of hepatocarcinogenicity.
Despite the number of studies which have been 
carried out on DDT, there is still no clear understanding 
of the reason for its carcinogenic effect. DDT is carcinogenic 
to mice following its oral administration, causing benign 
and malignant liver neoplasms (IARC Monographs, volume 5,
1974; Kashyap et at,,. 1977), and lymphomas and lung 
nepolasms. Oral administration to rats produced liver 
neoplasms (Rossi etal., 1977; Cabral etal., 1982a). Two 
feeding studies with hamsters were negative (IARC Monographs, 
5, 1974; Cabral etcdl., 1982b).
DDT, like other chlorinated hydrocarbons, is an excellent 
inducer of microsomal enzymes. DDT is oxidised by many 
mammalian systems in a series of reactions, several of 
which appear to involve microsomal drug metabolising enzymes, 
one pathway is metabolism to DDA (2,2 bis[p-chlorophenyl] 
acetic acid) which is excreted in the urine. Metabolism 
by a different route yields DDE (1,1 dichloro2,2 bis 
[p-chlorophenyl] ethylene) which is itself a hepatocarcinogen 
and tends to be stored in fatty tissue ( Matsamura, 1975).
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(4). HORMONES.
Several hormones and hormone analogues have been 
reported to cause cancer in selected animals, including 
oestrogens, testosterone and the synthetic oestrogen, 
diethyl stilbestrol. Little is known about, the mechanism 
of action of these compounds, although they are widely 
accepted as carcinogenic. There appears to be a small 
increase in liver tumours in humans treated with oral 
contraceptives (Klatskon, 1977). Both benign and malignant 
tumours have been encountered, the vast majority of tumours 
appear to derive from hepatocytes. There is no significant 
production of a-foetal protein, in contrast to the majority 
of other human carcinomas (Ruoslahti and Seppala, 1979).
There is some evidence, although no proof, of the progression 
of the benign tumours to malignancy.
Tumours removed from women taking contraceptive steroids 
showed s. range of appearances (Ishak, 1979) which would 
refect a slow, fairly orderly progression towards carcinoma. 
The most common liver tumour observed was a benign tumour, 
usually classified as focal nodular hyperplasia. These lesions 
are well circumscribed, but not encapsulated, and are well 
differentiated from the surrounding liver, which frequently 
showed signs of compression.
(5). FOREIGN BODY CARCINOMAS.
This class of carcinogens is, possibly, the clearest 
example of non-mutagenic compounds, as there is, clearly, 
no direct interaction with DNA in their carcinogenic mechanism 
of action. The mechanism of action of foreign body carcinogens 
has been a matter for very extensive study (Grasso and 
Golberg, 1966; Brand, 1976). These compounds may be classified 
into 3 main classes:
(1) There are inert materials which are only carcinogenic
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when implanted as a continuous film.
(2) There are common body constituents which produce tumours 
when injected sub-cutaneously in concentrated solutions and 
in large volumes.
(3) There are materials which are carcinogenic when implanted 
in particulate form. This class probably includes the proven 
human carcinogen asbetos fibre.
The type of tumour produced is dependent on the site of 
implantation; because the normal sites of implantation in 
safety assessment studies are subcutaneous or within the 
bladder wall the majority of tumours observed are carcinomas, 
or closely related solid connective tissue tumours. However, 
by careful choice of the site of implantation it is possible 
to induce blood-cell tumours (in particular, plasmacytomas 
(Merwin and Redman, 1963)).' Hence, it may be possible: that 
foreign body-carcinomas can appear in any type of tissue.
Study of the early changes following implantation of 
the carcinogenic material allows division of the agents into 
2 broad sub-classes.(Grasso and Goldberg, 1966). In the first 
sub-class are agents which are carcinogenic when implanted 
in thin, continuous film and agents which are carcinogenic 
when injected in concentrated solutions. In both cases the 
site of implant becomes surrounded by a thick connective 
tissue capsule which appears essential for the development 
of the tumour. The second sub-class of agents are the 
particulate materials, where the initial effect is not a 
fibroblast, but a macrophage response, involving macrophage 
necrosis with little initial fibrosis-(Baker etal., 1961)
The events leading to formation of a tumour following 
implantation of a film of material have been extensively 
reviewed by Brand and colleagues (1975). The events that 
occur are quite distinct from those that occur in the 
vicinity of an implanted pellet of a mutagenic carcinogen 
such as di-methylbenzanthracene (Vasiliev et al., 1962).
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The initial reaction is formation of granulation tissue 
and then of a connective tissue capsule around the site of 
the implant. Subsequently, the surface of the implant is 
normally covered in a monolayer of macrophages, which are highly 
active. Later, a fibrous capsule develops which is initially 
active with many capillary loops, but becomes quiescent.
The macrophage-like cells adhering to the implant appear 
inactive. The implant remains essentially a thin structure. 
Atypical fibroblasts appear due to the implanted film, 
subsequent to the appearance of these fibroblasts, sarcomas 
appear. The time-course of this sequence of events varies 
depending upon the nature of the implant (Brand et at., 1975)
The tumours appear when the capsule is relatively quiescent, 
and the tumours appear to arise not .from macrophages, which are 
adherent to the film, or from fibroblasts which make up the 
capsule, but from some multipotential endothelial cells, either 
the mesenchymal cells of the small blood vessels which form 
in the initial stages of the response to the implant or, more 
likely, the associated pericytes. It would appear therefore 
that the tumours which develop from implants of plastic films 
arise from multipotenet stem cells which become incorporated 
into the capsule and which develop in a period in which the 
capsule, as a whole, appears fairly quiescent.(Brand et al.,
1975).
It would appear that the tumours which arise are of 
monoclonal .origin. This can be demonstarated because at a 
late stage in the carcinogenesis the pre-neoplastic cells 
adhere to the plastic film, if this is then removed from the 
original animal, cut into pieces and transplanted to other 
animal recipients, these animals develop tumours identical 
in specific chromosomal abberrations, hepatopathology and 
growth characteristics. Further experiments were carried 
out in which implants and capsules were removed at various 
times. The implant was then separated from the capsule, and 
either the implant or the capsule or both were cut into pieces
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the capsule pieces associated with fresh film, and then either 
the film associated capsule fragment or the film fragment was 
reimplanted in a fresh animal. The results showed that clones of 
altered cels were present in the capsule one month after 
implantation of the film and that the clones of altered cells 
became associated with the film surface after about 12 weeks. 
Association iwth the film surface appeared to be essential 
for if the film was removed from the implant, leaving the 
capsule, no tumours developed, whereas replacement of the 
original film by a new film allowed tumour development to 
proceed.
Development of the tumours in the capsule of implanted 
plastic films is, therefore, a multistage process. The primary 
tissue reactions which initiate the changes which ultimately 
lead to tumour development are not known. It is probable 
that the chromosomal alterations arising from the rapidly 
proliferative phase of the response are sufficient to direct 
the cells down an abnormal route of differentiation,, which 
leads to the formation of frankly nepolastic cells, by 
stages.
Thus the initiation of tumours occurs in a region of 
rapid cell proliferation, in an area relatively far removed 
from blood vessels, and that indirect damage appears to be 
associated with tumour development. Such events may occur 
in the development of tumours by the particulate materials,also, 
such as iron dextran and carboxymethyl cellulose, as the 
tumour cells are similar in appearance to those produced by 
pla.stic film inserts, (Muir and Goldberg, 1961) .
However, other evidence suggests that the mechanism of 
carcinogenesis may be rather different.. A considerable number 
of free ferritin granules are seen in the tissue and it is 
considered possible that this "free" iron may be responsible 
for increased lipid peroxidation in the tissues of animals treatec 
with iron dextran (Baker et at., 1961).
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1.7. TOXICITY OF PHTHALATE ESTERS.
The work in this thesis is concerned particularly 
with the early adverse effects of phthalate esters, DEHP 
in particular, in the rat liver. Many general aspects of 
phthalate ester toxicity, including hepatotoxicity have 
been reviewed previously (Daniel, 1978; Lawrence, 1978;
Thomas et at., 1978 ; Lawrence and Tuell, 1979 ) . DEHP and 
other phthalate esters have been reported to exert cyto­
toxic and teratogenic effects, and to cause reproductive 
dysfunction, and renal and pulmonary toxicity, in addition 
to hepatotoxicity. However, the liver and testes appear to 
be the main target organs in phthalate toxicity.
1.7.1. GENERAL TOXICITY OF PHTHALATE ESTERS.
Early reports indicate that phthalate esters have a 
low order of toxicity, generally (Hodge et at., 1942;
Hodge, 1943; Schaffer et at., 1945; Carpenter et al., 1953;
Calley et at., 1966). The has been reported for several
laboratory animals (see Table 1.4.).
DEHP, administered orally or i.v., has a low order 
of systemic toxicity (see Table 1.4.). The LD<-q following 
i.v. administration of DEHP has not been determined with 
accuracy because of the poor solubility of DEHP. Data on the 
acute effects of inhalation of DEHP is scarce, but Schaffer 
et al. (1945) found that Wistar rats tolerated a 2 hour 
exposure to air saturated with DEHP.
No adverse effects were seen in dogs after a single 
oral administration of 2 g/kg of DEHP (Schaffer et al., 1945).
A "no effect" level was established for dogs of 0.06 ml/kg/day 
of DEHP, with longer treatment periods, that is, there was no 
evidence of hepatotoxicity at this dose (Carpenter et al., 1953).
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Similar "no effect" levels were reported for rats and guinea 
pigs by the same authors. A single 5 gram dose of DEHP, 
p.o., had no effect in an adult human male, while a dose 
of 10 grams resulted in mild gastric disturbances and a 
moderate catharsis (Schaffer et al., 1945).
DEHP is poorly absorbed through the skin (Patty, 1967). 
Implantation of PVC containing DEHP, either i.m. or sub- 
dermally, provoked no inflammatory response in rabbits or 
rats (Autian, 1973).
Rubin and Chang (1978) investigated the pulmonary
toxicity of DEHP, and reported a dose-related increase
in lung oedema and in lethality, with an LD.,. of about5u
200 mg/kg in the absence of a detergent (as a solubilising 
agent for DEHP). Schulz had previously shown that i.v. 
administration of DEHP solubilised in a non-ionic detergent 
to male rats resulted in a respiratory distress syndrome, that 
progressed to death from respiratory failure (Schulz, 1975).
The LD^q for the pulmonary effect of DEHP, solubilised in 
a non-ionic detergent, was between 250 to 300 mg/kg.
The pulmonary pathology was characterised by an inflammatory 
state commonly referred to as'shock lung1 (Rubin and Chang,
1976).
MEHP, one of the major metabolites of orally administered 
DEHP, has oral values in the rat of approximately
1.5 g/kg (1.34 g/kg in female weanling rats and 1.8 g/kg 
in male weanlings) (Villeneuve et al., 1978). The authors 
did not report the cause of death of these animals. This 
dose of MEHP is close to the dose of DEHP which is carcinogenic, 
1.2 g/kg/day for 2 years; as most of an orally administered 
dose of DEHP is metabolised and presents to the liver as MEHP 
it is surprising that little acute toxicity was observed, if 
the results of Villeneuve et al. (1978) are indeed correct, 
in the carcinogenic bioassay of DEHP (kluwe et al-., 1982).
Hodge (1943 ) reported a value of 3.2 g/kg as the LDcr. of MEHP.5 U
The subacute and chronic toxicity of DEHP has been 
studied (Schaffer et al., 1945 ; Carpenter et al., 1953 ; Harris 
etal., 1956). Rats treated with 200 mg/kg/day of DEHP for 
13 weeks had growth retardation and testicular atrophy 
(Carpenter et al., 1953). Similar findings were reported by 
Schaffer et al. (1945); increased kidney and liver weights, but 
no significant histopathological findings were noted.
Harris et al.(1956) reported similar findings after chronic 
administration of DEHP in the diet. Garvin et al. (1976) 
reported no effects upon rats after treatment with 3.7 mg/kg 
i.v. twice weekly for 63 days, with DEHP.
Other phthalate esters cause growth retardation and 
increases in liver and kidney weights (Nikonorow et al.,
1973 ). Niko'riorow et al. (1973 ) treated male and female Wistar 
rats with DEHP, di-n-butylphthalate, and other plasticisers, 
which included the organotin stablisers di-(n-oct.yl) tin- 
S,S1-bis(isooctylmercaptoacetate) (DOTG) and dibenzyltin 
S,S'_bis(isooctylmercaptoacetate) (DBenzyl TG).
In a 3 month toxicity study all the compounds 
produced a statistically significant increase in 
the mean liver weights in the animals. There was no evidence 
of pathological changes, as assessed by light microscopy.
In a 12 month feeding study dietary levels of 0.35%
DEHP and 0.02% DOTG produced significant decreases in 
body weight and significant increases in kidney weight.
In addition, DEHP caused liver enlargement. Gross and 
histological examination did not show any significant 
differences in the livers, kidneys and spleens of rats 
treated with DEHP, DBP, DOTG and DBenzylTG in the diet, 
as compared to controls.
TABLE 1.4.
THE ACUTE TOXICITY OF DEHP.
SPECIES ROUTE LD5Q(g/kg) REFERENCE
Mouse i.p. 14.2 Calley etal.
9.50 Singh et al.,
26 Patty, 1967
cl13 Miripol et al
34 Patty, 1967
31 Harris et al.
20a Patty, 1967
Guinea pig dermal 10 Patty, 1967
LD^q given in millilitres/kg.
After Thomas et al. (19 78).
Rat i.p.
Rat p.o.
Rat i.v.
Rabbit p.o.
Rabbit i.p.
Rabbit dermal
1966 
1975 
, 1975.
1956
Comparison of the acute LD.^ q values of DEHP and other 
phthalate esters with their chronic LD^^ values in mice 
suggests that the phthalate esters are'several more times 
toxic chronically (see Table 1.4.); it has been suggested 
that this may be due to cumulative toxicity of the 
phthalate esters (Lawrence etal., 1975).
1.7.2. EVIDENCE OF HEPATOTOXICITY OF PHTHALATE ESTERS.
(A) HEPATOMEGALY: HYPERPLASIA AND HYPERTROPHY.
Liver enlargement is thought to be an adaptive response 
to metabolic alterations induced by xenobiotics. It occurs 
in many species after treatment with a wide range of drugs 
and other xenobiotic compounds (see Table 1.5.) (Schulte- 
Hermann, 1974).
Carpenter et al. (1953) were the first to report 
hepatomegaly, in Sherman rats, following administration of 
0.4% DEHP in the diet. Hepatomegaly was also observed in 
female, but not male, guinea pigs treated with 0.13% and
0.04% DEHP in the diet, for 1 year. It was also not observed 
in dogs given 0.06 ml DEHP/kg body weight/day for 1 year. 
Treatment of ferrets with DEHP resulted in hepatomegaly 
(Lake etal., 1976). Daniel and Bratt (1974) reported 
hepatomegaly in rats treated with a diet containing 0.5%
(500 p.p.m.) DEHP for 5 - 7  weeks. The relative liver weight 
(liver v/eight/body weight) increased during the first week 
of treatment to about 50% more than controls, and remained 
increased until DEHP-free diet was administered to the 
rats, after which it returned to control levels within 
a week. Nikonorow et al. (1973) reported an increase in 
the relative liver weights of rats treated with DEHP at 
a dose of 0.35% in the diet, and also noted a significant 
decrease in body weight. Fukuhara and Takabatake (1977) 
demonstrated a marked dose-dependent increase in the relative 
liver weights of Wistar-SLC rats fed DEHP at dietary levels
-33-
TABLE 1.5
SUBSTANCES STUDIED AS POTENTIAL STIMULATORS OF LIVER ENLARGEMENT 
AND OF DRUG METABOLISM.3
Pharmacological 
action, use.
A. Drugs
Substance Hepatomegaly
Hypnotics, Phenobarbital
sedatives, other barbiturates
anti-convulsants Methaqualone
Mephanytoin
Anaesthetics
C.N.S.
stimulants
Anti-psychotic
drugs
Antihistamines
Fungicides
Sympatholytic
drugs
Halothane 
Diethyl ether
Nikethamide
Caffeine
Chlorpromazine
Chlorcyclizine
Griseofulvin
Propanolol,
practolol
+++ 
0-+++ 
' +
++
++
0
H—b
o
++
++
+
0
Anticoagulants Coumarin derivatives +
B. Insectisides:
halogenated hydrocarbons
Aldrin
Dieldrin
DDT
Chlordane
Polychlorinated
biphenyls
Trifluoroacetic 
acid
+++
++
++
+++
++
0 +
C. Carcinogenic polycyclic
aromatic hydrocarbons
3-Methylcholanthrene ++ 
3,4-Benzpyrene +
D. Miscellaneous
Cedar oil 
Ethanol
++
+
Stimulation of 
drug metabolism
+
0- + + +
+
+ +
0 ( +)
0
+
0
+
+
Substances thought to produce "toxic" liver enlargement are 
ommitted.
dumber of + illustrates the potency of the stimulator:
0 = no effect - means decrease
After Schulte-Hermann, 1974.
greater than 0.1%. Treatment with a range of phthalate 
esters, di-ethyl (DEP), di-n-butyl(DBP), di-n-hexyl (DnHP), 
di-n-octyl (DnOP) and dicyclohexylphthalate resulted in 
hepatomegaly, whereas treatment with dimethylphthalate 
did not (Lake et al., 1980).
Liver enlargement occurred in response to treatment 
with each of the compounds listed in Table 1.1.(see Section 1.4) 
Hepatomegaly, which appears to be dose-dependent, up to a 
limit, for a given compound generally occurs within a few 
days of administering such compounds and reaches a steady 
state after 10 to 14 days (Lake et al., 1975; Reddy and 
Krishnakantha, 1975; Moody and Reddy, 1978b). The liver weight 
may account for up to 15 to 2 0% of the total body weight 
in rats and mice fed high doses of peroxisome proliferating 
agents.
It has been reported that hepatomegaly induced by these 
compounds in rats, mice and hamsters results from both 
cellular hyperplasia and hypertrophy (Fukuhara and Takabatake, 
1977 ; Moody and Reddy, 1976; Kolde, 1976; Moody et al., 1977). 
Fukuhara and Takabatake (1977) concluded that the increased 
liver weight observed after treatment with DEHP was "caused 
equally by the increase in cell number and in the cell 
volume". Moody etal. (1977) reported liver enlargement in 
mice treated with the hypolipidaemic drug, nafenopin. Increases
3
in total hepatic DNA and [ -H] thymidine labelling indices 
have also been reported after treatment of rodents with 
tibric acid, Wy-14,643 and BR-931 (Moody and Reddy, 1978a;
Reddy et al., 1978; Reddy et al., 1979).
The minimum.doses of hypolipidaemic: drugs and phthhlate 
esters to produce maximal peroxisome proliferation 
do not generally cause liver necrosis, therefore, the mitotic 
burst seen after treatment with these compounds is unlikely 
to be simply regenerative hyperplasia (Reddy and Lalwani, 1984).
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However some other untoward hepatic effects are 
observed. Commonly following high doses, in addition:to 
hepatomegaly, histopathological examination of phthalate- 
induced enlarged livers of rats reveals fatty vacuolation 
and congestion, followed by a cloudy swelling and excessive 
fatty degeneration (Carpenter et al., 1953; Omori, 1976).
Cell enlargement was reported in the livers of ferrets 
receiving DEHP orally (Lake etal., 1976). Morphological 
changes in ferrets included the formation of islands 
consisting of enlarged cells, which were twice the size of 
normal cells, and contained a nucleus which was slightly 
enlarged also. Their cytoplasm was finely granular, eosinophilic 
and evenly distributed. There was no glycogen in these 
cells. In addition, marked lysosomal disturbances were 
observed in the livers of DEHP-treated ferrets; some 
centrilobular cells contained increased numbers of lysosomes 
which were greatly enlarged.
Liver necrosis and inflammatory infiltrations were 
found in rhesus monkeys receiving plasma-solubilised DEHP
i.v. (Jacobson et al., 1977). Five months after commencement 
of treatment persistence of portal inflammatory reaction 
was noted, together with hepatocyte necrosis. A year after 
treatment commenced aggregates of chronic inflammatory 
cells were observed, with degenerating hepatocytes observed 
also. Treatment with MEHP in rats resulted in midzonal and 
periportal eosinophilic cytoplasmic inclusions and vacuolations 
with isolated necrotic hepatocytes (Chu etal., 1981a).
LIVER FUNCTION TESTS.
Garvin et al. (1976) reported no change in sulpho- 
bromophthalein (BSP) clearence, serum bilirubin or SGPT levels 
in rats treated with DEHP (3.8 mg/kg/day by i.p. injection) 
for 26 or 63 days. However, Jacobson et al. (1977) observed
abnormal BSP clearence and evidence of abnormal liver 
histopathology (See previous page) in rhesus monkeys 
transfused with blood stored in PVC blood bags, resulting 
in an average cumulative dose of 69.3 mg DEHP (21.3 mg/kg) 
infused during the year. There was no change in SGOT or SGPT 
levels in rats dosed orally with 500 mg/kg/day of DEHP 
(Zuccato et al., 1980). Lower SGOT values were observed 
in male Sprague-Dawley rats treated with MEHP for 3 months 
(Chu et al., 1981a).
EFFECTS ON PEROXISOMES.
It is essential to appreciate the biological and 
biochemical characteristics of the peroxisome in order 
to understand the significance of peroxisome proliferation; 
to elucidate the mechanism(s) by which it is brought about 
and to ascertain the link between these events and the 
•subsequent development of hepatocellular carcinomas.
THE PEROXISOME.
The peroxisome is a subcellular organelle present 
in many tissues and cells of animals and plants, including 
unicellular eucaryotes. In the earlier literature it is 
often referred to as a 'microbody', and in plants these 
organelles are referred to as glyoxysomes. The 'microbody' 
was first observed by Rhodin in 1954, in the proximal 
convoluted tubular epithelium of mouse kidney, and was 
later identified by Rouiller and Bernhard (1956) in the 
rat liver parenchymal cells. The term "peroxisome" was 
introduced by de Duve (1965) to emphasise the biochemical 
property of hydrogen peroxide production by microbody 
enzymes. The properties of peroxisomes in the liver, in 
particular, have been reviewed (see reviews by Tolbert, 1981; 
Masters and Holmes, 1977a).
FUNCTIONS OF PEROXISOMES.
The biochemical reactions of peroxisomes are both 
catabolic, many of which are oxidative reactions, and 
anabolic. A number of the end products of peroxisomal 
reactions may, in addition, serve as building blocks for 
anabolic reactions elsewhere in the cell. Peroxisomes are 
thought to play a role in respiration, gluconeogenesis, 
lipid metabolism, purine catabolism and to have several other 
metabolic functions, the physiological functions of which 
have yet to be established conclusively (Lazarow, 1980).
(For a detailed account of the enzyme composition and 
general metabolic properties of peroxisomes, see the review 
by Tolbert, 1981). A table of the composition of peroxisomes 
is shown (Table 1.6. ). The metabolic role of peroxisomes 
has been reviewed by Masters and Holmes, 1979.
a) Respiration
The peroxisomes contain a respiratory pathway, which 
was first described by de Duve and his colleagues (de Duve 
et al., 1960; Beaufay et al., 1964; de Duve and Baudhuin, 1966) . 
It is composed of a group of oxidases that use atmospheric 
oxygen to directly oxidise a variety of substrates, and 
produce hydrogen peroxide (H^O^) which is destroyed by 
catalase, as illustrated below.
catalatic 
reaction
peroxidation 
reaction
Substrates for the oxidases include lactate, glycolate, 
other a-hydroxy acids, urate, D-amino acids, acyl CoAs and 
polyamines (see Table 1.6.). can be destroyed as shown
above, either through the catalatic pathway or the peroxidation
oxidases catalase
RH.
R'H.
TABLE 1.6.
THE ENZYMATIC COMPOSITION OF HEPATIC PEROXISOMES.
Enzyme Substrate
Catalase
Oxidases (H2®2 9enerat:*-n9 ) 
Glycolate(a-hydroxy acid)
Urate
D-amino acids 
Fatty acyl-CoA*
Polyamine 
Acyl transferases 
Acyl transferases 
Carnitine acetyl-CoA 
Carnitine octanoyl-CoA 
Acy1-CoA:dihydroxyacetone-P
Catalatic:
Peroxidatic: ethanol, methanol, 
formate, nitrite
Glycolate, a-hydroxyisocaproate, 
a-hydroxy acids 
Uric acid 
D-amino acids
)Long-chain fatty acyl- 
CoA derivatives; erucoyl-CoA
(c22:1)
Spermidine and spermine
Acetyl-CoA 
CQ Acyl-CoAO
Dihydroxyacetone phosphate; 
palmitoy1-CoA
(C10'C22
Dehydrogenases 
NAD:glycerol-P 
NADP:isocitrate
Glycerol-P
Isocitrate
NAD:L-3-hydroxy fatty acyl-CoA* C^ - Cg Fatty acyl-CoAs
Other
Enoy1-CoA hydratase* 
Thiolase*
Fatty acyl-CoA synthetase
Crotony1-CoA;enoy1-CoA
(C6 " C16)
Cg - C^2 Fatty acyl-CoAs
Long chain fatty acids
Enzymes of fatty acid B-oxidation spiral. 
(After Reddy and Lalwani, 1984).
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reaction. Alcohols, formate, nitrite and quinones are substrates 
for the peroxidatic reaction. A high concentration of 
catalase, together with a low and steady formation of 
H2^2 peroxisome favours the peroxidatic reaction.
If there were no substrates available for the peroxidatic 
reaction, excess #2^2 wou^  ke destroyed catalatically. 
Peroxisomes may also participate in the re-oxidation of 
cytoplasmic NADH through coupled reactions (de Duve and 
Baudhuin, 1966).
Peroxisomal and mitochondrial respiration may be 
distinguished as follows:
a) Peroxisomal reactions do not involve the conservation
of energy, through the formation of ATP, but rather dissipate 
energy as heat thereby contributing to thermogenesis.
b) The rate of peroxisomal respiration is proportional to 
oxygen tension, in contrast to mitochondrial respiration.
c) Peroxisomal enzymes can utilise some substrates which 
are resistant to mitochondrial oxidation.
d) Peroxisomal oxygen consumption is insensitive to cyanide 
and is not subject to respiratory control.
There has been considerable discussion on the contribution 
of peroxisomes to the total oxygen utilisation. Overall 
it would seem that peroxisomal respiration may account 
for up to 20% of the liver's oxygen consumption (de Duve 
and Baudhuin, 1966; Oshino etal., 1975). One-third of 
normal oxygen utilisation occurs in peroxisomes in liver 
homogenates, therefore, peroxidatic reactions contribute 
substantially to the metabolic flux in mammalian tissues 
(Masters and Holmes, 1979). Both Oshino et al. (1973) and 
Sies (1977), by measuring the catalase compound I, the
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catalase-I^C^ intermediate, observed peroxisomal hydrogen 
peroxide production when the liver was perfused with either 
urate or glycolate. These authors concluded that "biological 
oxidations of considerable physiological significance are 
possible through the catalase system".
Hydrogen peroxide is a significant cellular metabolite.
It is produced by mitochondria, microsomes, peroxisomes 
and soluble enzymes (Chance et al., 1979 ). Several findings 
suggest a link between peroxisomal and mitochondrial 
functions. The mitochondrial respiratory chain itself 
produces H2°2' at a rate which is dependent on the metabolic 
state; the production of is highest when ADP levels
are low and respiratory carriers are reduced. This observation, 
together with the known sensitivity of the respiration chain to 
the redox state (Erecinska and Wilson, 1978), and the 
property of peroxisomes to metabolise substrates, such 
as ethanol, without using any of the reduced coenzyme store 
(Masters and Holmes, 1977b) establishes a link between 
peroxisomal function and the rate of mitochondrial 
respiration, in which rate-regulating steps may be part 
of the peroxisomal function (Masters and Holmes, 1979).
b) Lipid Metabolism.
8-oxidation of fatty acids.
An extra-mitochondrial 8-oxidation pathway for fatty 
acyl-CoA, first described in glyoxysomes from germinating 
castor bean endosperm by Cooper and Beevers (1969a, 1969b) 
has subsequently been identified in rat liver peroxisomes 
(Lazarow and de Duve, 1976; Lazarow, 1978; Osumi and Hashimoto, 
1978a, 1978b), in mouse liver (Murphy et al., 1979 ) and in 
human liver (Bronfman etal., 1979). Peroxisomes catalyse 
the 8-oxidation of fatty acids by the sequence of reactions 
shown on Figure 1.1. The location of the enzymes and their
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FIGURE 1.1
FATTY ACID —  
BINDING PROTEIN
FATTY ACIDS ^ .^ aSe. LIPIDS
fatty acyl-CoA
glycerol-P
cytosol or
iitochondria dehydrogenas
dihydroxy 
acetone-P
ATP
CoA-SH
r-ch2-ch2-co SCoA
r fat
glycerol-
FAD 
ty acyl-CoA 
oxidase 
FADH 2
R CH=CH-CO SCoAI
-CHOH-CH-CO SCoA 
NAD'nJ
nadhH.
R-CO-CH-CO SCoA
CoA SH I thiolase
R-CO CoA^CH -CO-SCoA 
(>C8)
H 2 0:
""^catalase
02 hOo + H20
bifunctional
enoylhydratase
and
L-3-hydroxy fatty 
acyl-CoA dehydrogenase
carnitine octanoyl 
transferase
. .1octanoyl carnitine + CoA
carnitine acetyl 
^transferase
acetyl carnitine + CoA
Cytoplasm (Syntheses)
I
Mitochondrial 6 oxidation 
and TCA cycle
(After Tolbert, 1981).
RATTYACID 6-OXIDATION IN LIVER PEROXISOMES
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nature are different in the peroxisomal and mitochondrial 
fatty acid B-oxidation pathways, as is the control of these 
two pathways.
In order to supply substrates for the peroxisomal 
3-oxidation system peroxisomal acyl-CoA synthetase acts 
on fatty acids to activate them to the corresponding 
acyl-CoAs (Krisans etal,, 1980). Acyl CoAs formed elsewhere 
in the cell may also enter peroxisomes for oxidation. The 
initiation of peroxisomal 3-oxidation is carnitine- 
independent, whilst for the long chain fatty acids, 
mitochondrial 3-oxidation is carnitine dependent.
In the first reaction of the peroxisomal 37-oXidation spiral 
H2C>2 is formed, the FAD-linked acy 1-CoA oxidase transfers 
the electrons to C>2 to form H2 0 2 which is decomposed by 
catalase. In mitochondria, in the corresponding reaction 
electrons are transferred from an acyl-CoA to the electron- 
transport chain, via FAD. In peroxisomes, this oxidase is 
thought to be rate-limiting and to determine the chain 
length specificity for the entire reaction sequence.
Saturated acyl-CoAs with chain lengths from 7 to 18 or 
more carbons, and long chain unsaturated acyl CoAs 
are oxidised by peroxisomes (Lazarow, 1978; Osmundsen etal,,
1979). Mitochondrial 3-oxidation uses both long and short 
chain substrates.
The next three reactions, in peroxisomes, are identical 
to those in the mitochondrial 3-oxidation spiral, but 
the enzymes involved have different substrate specificities 
and different physical properties. There is a bifunctional 
enzyme with both enoylhydratase and L-3-hydroxyfattyacyl-CoA 
dehydrogenase activities (Osumi and Hashimoto, 1979; 1980).
This differs from the mitochondrial situation, which has 
two separate enzymes. This bifunctional enzyme corresponds 
to the peroxisome specific polypeptide (M.Wt. 78,000)
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(Reddy and Kumar, 1977). The peroxisomal dehydrogenase 
is linked to NAD reduction, and may be directly measured 
in the presence of mitochondrial inhibitors (cyanide, rotenone 
or Actinomycin A), which prevent the re-oxidation of NADH by 
mitochondrial contamination.* The peroxisomal system may 
be studied by the use of mitchondrial inhibitors; either 
by measuring NAD reduction upon addition of palmitoyl-CoA 
or by measuring the initial rate of oxygen uptake, as one 
atom of C>2 is taken up per turn of the cycle. Peroxisomal 
thiolase is different from the two thiolases in mitochondria 
in that it requires the presence of 1 mM dithiothreitol 
(DTT) for maximal activity, in vitro.
Peroxisomal carnitine acyltransferase catalyses the 
transfer of short acyl groups (acetyl-, butyryl-, hexanoyl- 
and octanoyl-) between CoA and carnitine, allowing the end 
products of peroxisomal 3-oxidation to be transfered to 
mitochondria as carnitine esters, for further oxidation.
acyl-CoA + carnitine acylcarnitine + CoA
(Markwell et al,, 1973 ).
The capacity of peroxisomal 3-oxidation is the same 
order of magnitude as that of mitochondrial B-oxidation, 
and the relative physiological roles of the two systems 
have yet to be elucidated. Hryb (1981) reported that 
the contribution of peroxisomes to fatty acid oxidation 
is 10 to 30%, depending upon the age, sex of the rat, and 
upon which fatty acid is being oxidised (chain length and 
the degree of unsaturation are also major factors). It has 
been suggested that the mitochondrial function is to 
supply the energy needs of the liver by fatty acid oxidation, 
whilst peroxisomes supply acetyl-CoA for anabolic reactions, 
such as the synthesis of cholesterol.
c) Other peroxisomal reactions.
Peroxisomes play an important part in gluconeogenesis 
in plants (Beevers, 1969) and in unicellular organisms 
(Blum and Connett, 1972) and may do so in the liver as 
peroxisomes are larger and more numerous in the liver and 
kidneys, the major gluconeogenic tissues, than in other 
mammalian tissues. The formation of a-keto acids, substrates 
for gluconeogenesis, is catalysed by L-a-hydroxyacid 
oxidase, D-amino acid oxidase or an aminotransferase 
transfers, irreversibly, amino groups from leucine, 
phenylamine and other amino acids to glyoxylate to give glycine 
(de Duve and Baudhuin, 1966; Hsieh and Tolbert, 1976).
In addition, peroxisomes contain enzymes which are 
involved in etherglycerolipid synthesis (Harja etal., 1979).
Peroxisomes have also been found to play an important 
part in purine catabolism (Scott et al., 1969 ).
It is thought that peroxisomes in brown fat may play a role
in thermogenesis during adaptation to cold (Needergard et al.,
1980). Hryb (1981) has calculated that approximately 
-26.5 x 10 calories/minute/gram of liver of heat is 
produced during active peroxisomal respiration.
MORPHOLOGY OF PEROXISOMES.
Morphological descriptions of microbodies from various 
tissues have been widely reported (de Duve, 1969; de Duve 
and Baudhuin, 1966; Shnikta, 1966). Peroxisomes are more 
abundant and usually larger in size in hepatic parenchymal 
cells than in other mammaliah tissues’. They are: single­
membrane-limited organelles, spherical or slightly 
elliptical in shape, containing a fine granular matrix, 
which is electron-dense. The mean diameter of peroxisomes
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ranges from 0.2 to 1.0 lim, rat liver peroxisomes have a 
mean diameter of between 0*6 to 0.7 ym. It has been estimated 
that a normal parenchymal cell contains between 370 and 
620 peroxisomes, which take up about 1.5 to-2.0% of the 
cell volume. (Loud, 1968; Weibel. et aL, 1969). Peroxisomes v' 
constitute about 2. 5% of the total, liver protein. (Leighton 
et al. t 1968). [N.B. Within peroxisomes, catalase is the 
most abundant peroxisomal protein (16%) and the core 
accounts for 10%]. Peroxisomes have 1/4 to l/6th of the 
volume of the average mitochondrion, and for each peroxisome 
there are 2 to 4 mitochondria in any given cell.
Although there are 1membrane-like' structures (see 
Masters and Holmes, 1977a) within the peroxisome, there are 
no inner membranes, but, as indicated above, many peroxisomes 
have a core; there is a correlation between the presence 
of urate oxidase in peroxisomes and the presence of this 
core, although the converse is not always true (Hruban and 
Swift, 1964). Species that lack uricase, including humans, 
lack crystalloid cores in hepatic peroxisomes. The structure 
of the core varies in different species, in rat peroxisomes 
it consists of urate oxidase in a cylindrical paracrystalline 
array of hollow tubes, but, in other species, the tubes 
may be worm shaped or branched, rather than cylindrical.
Although not essential, in electron micrographs, the presence 
of the cores facilitates identification of peroxisomes.
Peroxisomes are distributed fairly evenly throughout 
hepatocytes and throughout hepatocytes in different areas 
of the liver lobule. However, in hepatocytes near the 
cental vein peroxisomes are slightly more numerous (Loud, 1968).
Peroxisomes tend to occur in clusters in cells and 
may appear to be interconnected (Novikoff and Shin,1964; Legg 
and Wood, 1970; Reddy and Svoboda, 1971 and 1973). They are 
often closely associated with endoplasmic reticulum, and there
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is controversy over possible continuity between.the two 
organelles. There are arguments for (Novikoff et al., 1973) 
and against (Rigatuso etal.-, 1970; Fahimi etal., 1976) 
such continuities.
To ensure positive identification of peroxisomes from 
either mitochondria or lysosomes, tissue sections can be 
stained by the alkaline 3,31-diazobenzidine cytochemical 
procedure (Novikoff and Goldfischer, 1969). Diazobenzidine 
(DAB) is used as an organic hydrogen donor for the peroxidatic 
reaction of catalase; the resulting conjugated unsaturated 
structure binds osmium tetroxide (Graham and Karnovsky, 1965).
(C) EFFECTS OF PHTHALATE ESTERS ON PEROXISOMES.
Peroxisome proliferation.
Lake et al. (1975) first reported peroxisome proliferation 
after treatment of rats with 2,000 mg/kg/day of DEHP for 
21 days. Treatment with either MEHP or 2-ethylhexanol, 
the major metabolites of DEHP, produced this effect, whilst 
treatment with phthalic acid did not (Lake et al., 1975).
Reddy et al. (1976) also reported peroxisome proliferation 
after treatment of rats with DEHP. Several subsequent 
studies have also described an increase in the number of 
peroxisomes (estimated biochemically or morphologically) 
in rats treated with DEHP (Moody and Reddy, 1978; Sakurai 
et al., 1978 ; Osumi and Hashimoto, 1979 ; Ganning et al., 1980; 
Mangham etal., 1981; Ohno etal., 1981). (see Table 1.1.)..
Moody and Reddy (1978) examined the relationship
between structure and biological activity, and observed 
. ■ hexyl
that DEHP, diethylhexyladipate (DEHA) and diethyl/sebacate
(DEHS) caused peroxisome proliferation, but that treatment with
with adipic acid and diethylphthalate (DEP) did not. In
addition, 2 -ethylhexanol and 2-ethylhexanoic acid caused
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changes comparable to those induced by DEHP, DEHA and DEHS. 
2 -ethylhexylaldehyde treatment resulted in a moderate 
proliferation of peroxisomes, but treatment with the 
straight chain analogues hexanol, hexanoic acid or hexyl 
aldehyde did not result in induction of peroxisomes.
Induction of peroxisomal enzymes.,
a) Catalase.
The total specific activity of catalase was found 
to increase two-fold after treatment with DEHP (Reddy 
et al., 1976; Moody and Reddy, 1978; Osumi and Hashimoto, 
1978, 1979). Moody and Reddy (1978) reported that the 
hepatic activity of catalase increased significantly in 
animals treated with DEHP, DEHA, DEHS, 2-ethylhexanol and 
2-ethylhexanoic acid, but not with adip'ic acid, DEP, hexanol 
or hexanoic acid.
Ganning et al. (1980) and Ganning and Dallner (1981) 
observed that the catalase activity in the peroxisome . 
fraction of the liver was depressed by DEHP. This apparent 
contradiction will be discussed in light of the authors 
own results.
b) Cyanide-insensitive palmitoyl CoA oxidase.
KCN-insensitive palmitoyl CoA oxidase activity is 
markedly induced in the liver homogenate of male Wistar 
rats (Ganning et al., 1980; Ganning and Dallner, 1981), in 
male and female Sprague-Dawley rats and in mice, but not 
in guinea pigs after treatment with 2% DEHP in the diet 
for two weeks (Osumi and Hashimoto, 1978). The effect was 
less marked in female than in male rats. The fatty acyl-CoA 
oxidising system induced by this administration of DEHP 
was found to be localised in the peroxisomes themselves 
(Osumi and Hashimoto, 1978).
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c) Carnitine acyltransferases.
Reddy et al. (1976) reported increases in peroxisome- 
associated carnitine-acetyl transferase activity after 
treatment of rats with DEHP. A fyrther study reported 
significant increases in hepatic carnitine acetyl 
transferase activity in rats treated with DEHP and DEHS, 
a slight increase occurred in rats treated with DEP, but no 
change was observed after treatment with adipic acid. 
Treatment with 2-ethylhexanol and 2-ethylhexanoic acid 
resulted in the induction of carnitine acetyl transferase 
activity, but treatment with hexanol or hexanoic acid 
did not (Moody and Reddy, 1978).
Ganning et al. (1980) and Ganning and Dallner (1981) 
also reported that carnitine acetyltransferase activity 
was stimulated, in purified peroxisome preparations from 
the livers of male rats treated with 2% DEHP in the diet 
for 2 weeks.
Shindo et al. (as quoted by Osumi and Hashimoto, 1978) 
observed that carnitine palmitoyl transferase and carnitine 
acetyltransferase activites were enhanced by one order of 
magnitude, as a result of DEHP treatment.
d) Urate oxidase.
Studies by Sakurai et al. (1978) and Osumi and 
Hashimoto (1979) indicate no change in urate oxidase 
activity, whilst Ganning and Dallner (1981) and Ganning 
etal. (1980) reported a depression in urate oxidase 
activity after treatment with DEHP. In all these studies 
the effects of DEHP on urate oxidase activity was assayed 
in rats.
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TABLE 1.7.
SUMMARY OF THE EFFECTS OF DEHP AND RELATED COMPOUNDS ON PEROXISOMES.
EFFECT COMPOUNDS WHICH CAUSE
THIS EFFECT
Peroxisome DEHP
proliferation
MEHP
2-ethylhexanol
DEHA
DEHS
2-ethylhexanoic acid
Increased DEHP
hepatic catalase
DEHA
DEHS
2-ethylhexanol 
2-ethylhexanoic acid
Decreased DEHP
peroxisomal 
catalase
Induction of KCN DEHP
insensitive PCoA 
activity
Induction of DEHP
carnitine 
acyltransferases
Fall in urate DEHP
oxidase activity
No change in urate DEHP 
oxidase activity
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r e ferences
Lake e t  a l . , 1975; Reddy e t  a l . , 1976;
Moody and Reddy, 1978; Sakurai e t a l . ,  1978 
Osumi and Hashimoto, 1979; Ganning e t a l . ,  
1980; Ganning and Dallner, 1981;
Mangham e t  a l ., 1981; Ohno et a l . , 1981.
Lake e t a l . ,  1975; Moody and Reddy, 1978.
Lake et  a l . , 1975; Moody and Reddy, 1978.
Moody and Reddy, 1978
Moody and Reddy, 1978
Moody and Reddy, 1978
Reddy e t a l . ,  1976; Moody and Reddy, 1978; 
Osumi and Hashimoto, 1979, 1980;
Sakurai e t a l . ,  1978
Moody and Reddy, 1978
Moody and Reddy, 1978
Moody and Reddy, 1978
Moody and Reddy, 1978
Ganning et  a l . , 1980; Ganning and . 
Dallner, 1981
Osumi and Hashimoto, 1979, 1980;
Ganning e t  a l . , 1980; Ganning and 
Dallner, 1981
Reddy et  a l . , 1976; Moody and Reddy, 1978; 
Ganning et  a l . , 1980; Ganning and 
Dallner, 1981
Ganning et  a l . , 1980; Ganning and 
Dallner, 1981
Sakurai et  a l . , 1978; Osumi and Hashimoto, 
1978, 1979
Morphological changes.
Ohno et al. (1981) carried out histochemical studies 
of the peroxisomes of rat liver during, and after with­
drawal of, DEHP administration. Increases in the size 
and numbers of peroxisomes were noted in livers of treated 
animals. Induced peroxisomes were larger, less intensely 
DAB positive and of a lower electron density compared to 
controls. The number and size of peroxisomes returned to 
control levels one week after cessation of treatment. In terms 
of morphology and histochemistry, the peroxisome population 
was heterogeneous. The authors postulated that "each 
peroxisome induced with DEHP might have a low content of 
catalase and a high volume of enzyme protein employed 
in fatty acyl-CoA oxidation".
(D) EFFECTS ON MITOCHONDRIA.
Xenobiotics which perturb the structure or function 
of mitochondria are likely to have an adverse effect upon 
mitochondrial respiration and so upon energy levels in 
the cell. For detailed descriptions of mitochondrial 
function and structure there are several recent reviews:
Boyer etal., 1977? Williamson, 1979; Fillingame, 1980? 
Mitchell, 1979; and Wilkstrom et al., 1981.
DEHP, MEHP (one of the major metabolites of DEHP) and 
other phthalate esters have been reported to alter . 
mitochondrial morphology and to impair mitochondrial function.
Swollen mitochondria, with shortening of cristae, were 
reported after oral administration of DEHP to rats (Lake 
et al., 1975) and in ferrets (Lake et al., 1976). Ganning 
et al. (1980) and Ganning and Dallner (1981) observed an 
increase in the number and in the protein content of 
hepatocyte mitochondria, together with an unchanged or
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inhibited mitochondrial respiratory enzyme activity.
Mangham et al. (1981) reported changes in the morphology 
of hepatic mitochondria, after treatment of male and 
female rats with DEHP. Changes included reduction of 
cristae, an increase in the number of dense bodies and 
crenation of mitochondrial membranes. Treatment with a 
dialkyl 79phthalate mixture (DA79P) resulted in degeneration 
of mitochondria, with condensation of the matrix and increased 
numbers of dense bodies.
In-vitro investigations of the inhibition of hepatic 
mitochondrial respiration have shown impairment of the 
oxidative and phosphorylation processes of rat liver 
mitochondria by phthalate esters (Ohyama, 1976; Takahashi,
1977; Inouye etal., 1978). Ohyama (1976) concluded that 
phthalate esters were electron and energy transport inhibitors, 
but not uncouplers. Di-n-butylphthalate (DBP) was the most 
potent inhibitor of respiration; the degree of inhibition 
was dependent on the carbon number of the alkyl groups. 
Phthalate esters were also found to cause uncoupling of 
oxidative phosphorylation (Inouye etal., 1978). Di-n-propyl, 
di-isopropyl, di-n-butyl (DBP) and di-isobutylphthalate 
esters strongly inhibited respiratory control and ADP:0 
ratios (N.B. The respiratory control ratios are indicative 
of coupling between oxidative and phosphorylation activities). 
DEHP and DEP had no effect.In contrast to model uncoupling 
agents, DRP enhanced K release from isolated mitochondria. 
Thus, DBP probably interacts with the membrane to cause 
a change in permeability to ions.
The effects of di and monoalkyl phthalate esters on 
mitochondrial respiratory rates were studied by Takahashi 
(1977) who reported that respiratory control ratios were 
decreased most with dialkylphthalate esters that contain 
alkyl chains of 3 or 4 carbons, i.e. di-n-propyl and 
di-n-butylphthalate, whilst DEHP had no effect. With
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mono-alkyl phthalate esters increasing numbers of carbons, 
up to 7, decreased the respiratory control ratios; MEHP was 
one of the most effective phthalate esters in decreasing 
the respiratory control ratio. It is important to remember 
when considering the results from in vitro studies that the 
in vivo administration of DEHP will result exposure of the 
liver to MEHP, if DEHP is administered orally; therefore, 
the in vitro studies with dialkyl phthalate esters may not 
be relevant to the effects observed in vivo.
In vivo decreased mitochondrial succinate dehydrogenase 
activity was observed in male rats treated with DEHP or 
MEHP, but no change resulted after treatment with 
2-ethylhexanol or phthalic acid (Lake etal., 1975).
Srivastava et al. (1975) also observed a fall in succinate 
dehydrogenase activity in rats after treatment with DEHP, 
as did Lake et al. (1976) in ferrets treated with DEHP.
DBP also depresses succinate dehydrogenase activity in rats 
(Tanaka, 1978). Mangham et al. (1981) observed depression 
of succinate dehydrogenase activity in male, but not in female, 
rats treated with either DEHP or a dialkyl 79 phthalate 
mixture (DA79P). Lake et al. (1980) stated that mitochondrial 
damage, as indicated by a depression of succinate 
dehydrogenase activity, was not a common feature of phthalate 
ester treatment, as although treatment with DEHP depressed 
succinate dehydrogenase activity, treatment with DMP,
DEP, DBP, DnHP, DnOP or DCHP did not. However, recent 
results (Mann et al., 1984) indicate that the effects of 
the straight chain phthalate esters are quite different 
from those of the branched chain phthalate esters. In the light 
of these results and the fact that other authors have 
reported that the administration of DEHP (i.p.) resulted in 
depression of 3 mitochondrial enzymes, malic dehydrogenase, 
cytochrome-c-oxidase and diaphorase (Srivastava etal., 1978) 
the depression of succinate dehydrogenase is, clearly, an 
important effect.
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EFFECTS
SPECIES
Rat
Rat
Rat
Rat
Rat
Rat
Rat
Rat
Rat
TABLE 1.8.
OF PHTHALATE ESTERS ON THE MORPHOLOGY AND ENZYMES OF MITOCHONDRIA.
ROUTE OF 
ADMINISTRATION
EFFECT REFERENCES
Oral Swelling of mitochondria, 
shortening of cristae
Lake e t  a l . , 1975
Oral Increased no. of mitochonria, ■ " Ganning ' e t c ' a l . , 1980
condensed, electron dense appearance Ganning-and Dallner,: 198
Oral Shortening of cristae, 
crenation of membranes
Mangham et  a l . , 1981
Oral Depression of succinate dehydrogenase Lake e t  a l . , 1975; 
activity Tanaka e t a l . ,  1978;
Mangham et  a l . , 1981
Oral Increase of carnitine-acyl- 
transferase activity
Ganning e t  a l . , 1980; 
Ganning and Dallner, 198
l.p. Inhibition of ATPase, diaphorase 
and cytochrome c oxidase activity
Srivastava e t a l . ,  1977; 
Srivastava e t  a l . , 1978
I n  v i t r o Mitochondrial swelling and stimulation Ohyama, 1976 
of latent ATPase activity
I n  v i t r o Inhibition of mitochondrial Srivastava e t  a l . , 1977
respiration and succinate dehydrogenase 
activity
I n  v i t r o Inhibition of mitochondrial 
respiration
Takahashi, 1977; 
Inouye e t a l . ,  1978
(After Seth, 1982).
Further effects on the mitochondria resulting 
from treatment with DEHP have been reported. Bell
and Gillies (1977) observed a 2 to 3 fold increase in
14 14 .the oxidation of C palmitoyl CoA to CC^ in hepatic
mitochondria from rats fed 0.1% DEHP in the diet.
Treatment of rabbits and pigs resulted in similar effects
in the hepatic, but not the cardiac, mitochondria. Morton
and Rubin (1980) reported an increase in the hepatic
lipid metabolising activity in the mitochondrial fraction
of rats treated with 50 p.p.m. dietary concentration of
DEHP for 7 days. Such an increase could be due to
contamination of the mitochondrial fraction with peroxisomes,
as it is difficult to acheive a pure fraction, without
any contamination.
Ganning and Dallner (1981) showed a 50-fold increase 
in the activity of mitochondrial carnitine-acyl transferase, 
in rats treated with DEHP (2% in the diet for two 
weeks).
In summary, the experimental evidence, described 
above, indicates that treatment with DEHP results in 
perturbation of mitochondria, as seen in the changes in 
morphology and in the depression of mitochondrial enzymes, 
and in particular, succinate dehydrogenase. Such changes are 
not observed after treatment with the straight chain 
phthalate esters.
(E) EFFECTS ON LYSOSOMES.
There was an increase in the number of lysosomes 
in the livers of rats treated with DEHP for 21 days 
(Mangham. et aL, 1981).
Marked lysosmal disturbances were observed in the livers 
of ferrets treated with DEHP (1,200 mg/kg/day of DEHP)
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(Lake et al.,1976). Acid phosphatase activity in the livers 
of untreated ferrets was mainly confined to the peri­
canalicular area, as revealed by histochemical studies.
In the livers of DEHP-treated ferrets acid phosphatase 
activity was depressed, principally in the centrilobular 
area, and was increased in the mid-zonal to periportal 
areas. However, in the centrilobular area, some of the 
cells contained increased numbers of lysosomes, some of 
which were greatly enlarged. Ultrastructural studies 
showed increased numbers of lysosomes in treated animals.
(F) EFFECTS ON THE ENDOPLASMIC RETICULUM.
The endoplasmic reticulum (ER) is a major cell constituent 
and is present throughout the cytoplasm as an extensive 
network of tubules, vesicles and lamellae. About 60% of 
the cytoplasmic surface of the ER is dotted with ribosomes, 
these regions are known as rough ER, and are arranged in 
parallel arrays of broad flattened cisternae. The other 40% 
is known as smooth ER and is found near the Golgi apparatus 
and consists of widely dispersed tubules and vesicles 
often associated with glycogen deposits. There is variation 
in the morphological and morphometric characteristics of 
the ER, depending upon the area of the liver lobule.
ER is extensively disrupted by homogenisation of the 
liver, in tissue homogenates ER is in the form of closed 
vesicles known as microsomes. The structural and functional 
properties of ER have been reviewed (de Pierre and Dallner, 
1975; de Pierre and Ernster, 1977).
The metabolism of xenobiotics is one of the most 
important cellular functions localised on the ER. The 
cytochrome P ^ q system (including NADPH-cytochrome P ^ q 
reductase and the many different iso-enzymes of the 
cytochrome itself), the cytochrome b^ system, epoxide
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hydrolase, UDP-glucuronosyl—transferase and an activatable 
glutathione-S-transferase avtivities are localised in the ER. 
The importance of an activatable glutathione-S-transferase 
in drug metabolism is not clear, in man GSH transferases 
are cytosolic. Induction of these systems can result 
from exposure of animals or man to large numbers of 
xenobiotics.
The ribosomes bound to the ER of the liver produce 
3 types of protein. The major proteins synthesised are 
secretory proteins, all the membrane proteins of the ER 
and much of the proteins of other intracellular organelles 
are produced by the ER. Glycosylation also takes place 
in the ER, as the ER of the liver contains a complete 
glycosylation system, which is able to synthesise branching 
oligosaccharide chains. Membrane constituents and secretory 
proteins are two types of glycoproteins- synthesised in 
the ER. Cholesterol and most phospholipids are synthesised 
in the ER, and extensive and continuous transport to 
other intracellular membranes occurs, as phospholipids 
and cholesterol form the basic bilayer construction of 
all membranes. The ER produces lipids for secretion and as 
components of various lipoproteins. As glucose-6 -phosphatase 
is localised on the ER in hepatocytes, the ER is also 
involved in the metabolism of carbohydrates.
There is much evidence to suggest that phthalate 
esters alter the morphology of the ER, and inhibit or induce 
various microsomal enzymes.
Some of the many effects of phthalate esters and 
related compounds upon the morphology and enzyme activities 
of the ER which have been reported are shown in Table 1. 
Proliferation of SER was reported after treatment of rats 
with DEHP or a dialkyl 79 phthalate mixture (DA79P) (Reddy 
et al., 1976 ; Mangham et al., 1981). Lake et al. (1975) noted
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dilatation, as well as proliferation of the SER in rats 
treated with DEHP. These authors also described changes 
in the RER; after rats were treated with DEHP dilatation 
of the RER was noted. In addition, dilatation of hepatic 
SER, but not proliferation, resulted after treatment with 
MEHP and 2-ethylhexanol, but not after phthalic acid 
treatment in rats.
Lake et al. (1975) and Ganning et al. (1980) reported 
increased microsomal protein in the livers of rats treated 
with DEHP. Glucose-6 -phosphatase activity was depressed 
after treatment with DEHP (Lake et al., 1975; Mushtaq et al.,
1980), MEHP and 2-ethylhexanol (Lake etal., 1975) and DA79P 
(Mangham et al., 1981). Loss of glucose-6 -phosphatase 
activity is considered to be a sensitive general indicator 
of hepatotoxicity.
The response of cytochrome P^q to treatment with 
DEHP varies between different studies. Lake etal. (1975) 
observed an initial increase in cytochrome P^q followed 
by a decrease to or below control values. However, Ganning 
et al.. (1980) and Mangham et al. (1981) reported increased
levels of cytochrome P4 5 Q* Zuccatto etal. (1980) reported 
no change in cytochrome P„cri levels after treatment with
4 D U
DEHP. Treatment with MEHP or phthalic acid did not alter
cytochrome P^5q levels, but treatment with 2 -ethylhexanol
resulted in an increase in cytochrome P.eri levels (Lake
4 O U
et al., 1975). DCHP treatment resulted in an increase in 
depression of cytochrome P^q levels (Lake et al., 19 80) 
whilst DA79P treatment resulted in depression of cytochrome 
P4 5 O levels in both male and female rats (Manghameet al.,
1981). The differences in response to DEHP will be discussed 
with reference to the authors own results.
DEHP neither stimulated nor inhibited mixed function 
oxidase(m.f.0 .) activities, whereas treatment with DnHP and DnOP
resulted in a depression of m.f.o. activity and DCHP 
caused a stimulation of m.f.o. activity in male rats 
(Lake et al., 1980). These results were presented in the 
from of an abstract and therefore do not give the substrates 
used in the assay of m.f.o. activities. Mangham et al.
(1981) reported that administration of DEHP resulted in 
depression of m.f.o. activities in male rats and enhancement 
of m.f.o. activities in female rats, as estimated by 
assaying the activity of aniline-4-hydroxylase. Lake etal. 
(1975) also observed a depression of aniline-4-hydroxylase 
activity in male rats treated with DEHP.
Treatment with DEHP, in male rats resulted in no change 
in biphenyl-4-hydroxylase activity, whilst treatment with 
MEHP resulted in a fall and treatment with 2-ethylhexanol 
caused a marked stimulation of biphenyl-4-hydroxylase 
activity (Lake et al., 1975).
Stimulation of P^q dependent ethoxycoumarin-O-de- 
ethylase activity, NADPH-cytochrome c reductase levels, 
nitroreductase activity, and epoxide hydrase activity 
has been described, after DEHP treatment (Mangham et al., 
1981; Ganning et al., 1980; Zuccatto et al., 1980).
The effect of DEHP on the activity of laurate 
hydroxylase will by discussed in the light of the authors 
results.
Thus, it is clear that the response of the ER to 
treatment with DEHP and related compounds, and to other 
phthalate esters, is complex.
TABLE 1.9.
EFFECTS OF PHTHALATE ESTERS AND RELATED COMPOUNDS ON ENDOPLASMIC RETICULUM IN RAT LIVER.
COMPOUND EFFECT
Proliferation of S.E.R.
Proliferation and dilatation of S.E.R. 
Dilatation of R.E.R.
Dilatation of R.E.R.
Dilatation of S.E.R.
Proliferation of S.E.R.
DEHP Increase in microsomal protein
DEHP Depression of glucose-6-phosphatase
activity
MEHP Fall in glucose-6-phosphatase activity
2-ethylhexanol Fall in glucose-6-phosphatase activity
DA79P Fall in glucose-6-phosphatase activity
DEHP t followed by + in cytochrome P ^ g
levels
DEHP Increased levels of cytochrome P ^ g
DEHP No change in cytochrome P ^ g  levels
MEHP No change in cytochrome P ^ g  levels
2-ethylhexanol Increased levels of cytochrome P ^ g
DCHP Increased levels of cytochrome P ^ g
DA79P Decrease in cytochrome P ^ g  levels
in male and females
DEHP
DEHP
DEHP
MEHP
2-ethylhexanol
DA79P
DA79P Stimulation of m.f.o. activity
(female rats)
DA79P Depression of m.f.o. activity
(male rats)
DnHP, DnOP Depression of m.f.o. activity
DCHP Stimulation of m.f.o. activity
DEHP Fall in aniline-4-hydroxylase activity
(male rats)
DEHP Stimulation of aniline-4-hydroxylase
activity (female rats)
DEHP Stimulation of 7-ethoxycoumarin-0-
de-ethylase activity
DEHP Stimulation of NADPH-cytochrome c
reductase levels
DEHP Induction of nitro-reductase activity
DEHP Induction of epoxide hydrase activity
Reddy e t aZ., 1976; Mangham e t  a l . , 1981
Lake et  a l . , 1975
Lake et  a l . , 1975
Lake e t a l . ,  1975
Lake et  a l . , 1975
Mangham et  a l . , 1981
Lake et  a l . , 1975; Ganning et  a l .  > 1981
Lake et  a l . , 1975; Mushtaq et  a l . , 1980
Mangham et  a l . , 1981
Lake et  a l . , 1975
Lake et  a l . , 1975
Mangham et  a l . , 1981
Lake et  a l . ,1975
Ganning et  a l . , 1980; Mangham et  a l . , 19;
Zuccatto et  a l . \  1980
Lake et  a l . , 1975
Lake et  a l . , 1975
Lake et  a l . , 1980
Mangham et  a l . , 1981
Mangham e t  a l . ,  1981
Mangham e t  a l . , 1981
Lake et  a l . , 1980 
Lake et  a l . , 1980
Lake et  a l . , 1975; Mangham et  a l . , 1981 
Mangham et  a l . , 1981
Mangham e t  a l . , 1981
Ganning et  a l . , 1980
Zuccatto et  a l . , 1980 
Zuccatto et  a l . , 1980
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1.8. THE EFFECTS OF PHTHALATE ESTERS ON LIPID METABOLISM.
The effects of DEHP and other phthalate esters on 
the lipid content of the liver and other organs, e.g. the 
heart and the testes, on hepatic lipid biosynthesis and 
metabolism and on serum lipid concentration have been 
extensively investigated. The initial stimulus for many 
of the investigations on the effects of phthalate esters 
on lipid metabolism came from the report, by Nazir et al.
(1971) which reported that DEHP was detected in association 
with triglycerides in beef mitochondria, and the report by 
Stein et al. (1974) which reported that DEHP was able 
to promote hepatic lipid accumulation, under certain 
conditions, and also to interact with dietary lipid by 
potentiating the growth-promoting effects of lipids in rats.
(A) EFFECTS OF PHTHALATE ESTERS ON LIVER LIPID.
Bell and co-workers carried out a series of experiments 
to study the effects of phthalate esters on sterol metabolism, 
prompted by reports that phthalate esters possessed 
teratogenic and mutagenic potential, which suggested to 
these authors that phthalate esters may interfere with 
sterologenesis, which is a key process in mammaliam 
development (Bell and co-workers, 1976-1978; Bell, 1982).
In male rats, an inhibition of cholesterol synthesis
14 . .from C-acetate was observed within 48 hours of feeding
0.5% DEHP in the diet. The degree of inhibition increased with
time, up to 70% inhibition was observed after 11 days
3
of treatment. Inhibition of H-mevalonate incorporation
into cholesterol occured to a lesser degree, over a longer
period; however, after 18 days of treatment with 1 .0 %
14DEHP in the diet incorporation of C-acetate had fallen
3
to 29% of control and H-mevalonate to 22% of control.
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DBP, as well as DEHP, but not DMP, inhibits gteroid
biosynthesis. As the inhibition of hepatic sterologenesis
3 14from H-mevalonate and C-acetate is greater with DEHP
than DBP, and as treatment with DMP does not cause
inhibition, the presence of between 2 and 4 carbon
alkyl chains appears to be the minimum requirement for  ^•
such an effect. ;
Bell (1976-1978, 1982) suggested that the site of 
action of phthalate esters may be at the level of HMG-CoA 
reductase (3-hydroxy-3-methylglutamy1-CoA reductase) which 
is the first rate limiting step in hepatic sterol synthesis, 
(see diagram below). Inhibition at this site would affect 
the flow-through of acetate to cholesterol, initially.
The inhibition could be overcome by use of exogenous 
mevalonate as a substrate. The later development of 
inhibition of sterologenesis from labelled mevalonate 
can be explained if one or more of the enzymes between 
mevalonate and cholesterol are substrate-induced and 
therefore decline in activity as mevalonate production 
diminishes.
HMGCoA
Reductase
Cholesterol <—  Lanosterol <---------- — Squalene
Cholesterol is the principal C^  sterol of the liver, 
and it is derived from units of acetyl-CoA by a sequence 
of 20 or more intermediates (Block, 1965). A simplified 
scheme, illustrated above, serves to demonstrate the 
primary rate-limiting step in the formation of squalene and 
sterols, which is the conversion of HMGCoA to mevalonate by 
HMGCoA reductase (Sabine, 1977). Secondary control sites 
beyond mevalonate may also function (Gould and Swyryd, 1966; 
Sabine, 1977; Block, 1965; Siperstein and Guest, 1960).
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The decreased synthesis of cholesterol was paralleled 
by decrease in the synthesis of lanosterol and squalene 
(Bell, 1976), which follows if phthalate esters act to 
inhibit HMGCoA reductase. Although the cholesterol synthesis 
is decreased, hepatic cholesterol content was no different 
in control male rats and male rats treated with 0.5%
DEHP in the diet for 6 days. However, decrease in hepatic 
cholesterol content resulted after a longer treatment 
period (Bell et al., 1978b). Srivastava et al. (1978) also 
reported a decrease in the hepatic content of total, free 
and esterified cholesterol in male rats dosed i.p. with DEHP.
In contrast, in an earlier report, Bell etal. (1978a) 
observed no change in the hepatic cholesterol levels 
of male rats treated with 2.5 mmoles DEHP or DBP/100 g 
of chow, for 21 days, whilst treatment with DMP, under 
the same conditions resulted in a lowered hepatic total 
cholesterol level.
Inhibition of hepatic sterologenesis was also observed 
in female rats treated with 1.0% DEHP, in the diet, for 
13 days (Bell, 1980) and in rabbits (Bell et al., 1978b). 
Inhibition of hepatic sterologenesis is not, therefore, 
sex-dependent nor is the species-dependence, if any, related 
to the ability to proliferate hepatic peroxisomes.
Alterations in sterologenesis may occur in the 
developing foetus when dams are exposed to DEHP. Foetuses taken 
by caesarian section from pregnant rats fed 0.5% DEHP, in the 
diet, from days 5 to 10 after conception were found to 
have an impairment of sterologenesis in the liver (Bell et al., 
1979a). Hepatic sterologenesis was also reduced below 
control levels in suckling rats whose dams were exposed 
to DEHP (0.5% in the diet) during gestation and the post­
natal period.
Treatment with DEHP affects the biosynthesis of fatty
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acids, phospholipids and triglycerides, in addition to
its effects on sterol synthesis. Bell and Nazir (1976)
reported that treatment with 0.5% DEHP in the diet significantly
14decreased incorporation of 1- C acetate into fatty acids,
phospholipids and triglycerides in the livers of male
14rats, and that the total C labelled lipid synthesis was
almost halved. Fractionation of the hepatic phospholipids
synthesised from- C acetate in rats fed 0.5% DEHP in the
diet showed a significant reduction in the distribution 
14
of C acetate into the phosphatidylcholine fraction of
liver phospholipids. Bell et al. (1978a) demonstrated that
rats fed DEHP showed a decrease in the esterification of 
3
H oleate into di- and tri-glycerides in liver minces.
Sakurai et al. (1978) reported an increase in the 
hepatic content of phospholipid , together with a decrease 
in the triglyceride content in male rats fed 1 and 2% DEHP 
in the diet. The rate of phospholipid synthesis increased, 
but no change in the rate of triglyceride synthesis 
was reported. All these alterations were observed in 
female Wistar rats treated with 2.0% DEHP in the diet for 
2 weeks. Yanagita. et al. (1978 ) also reported an increase 
in non-esterified fatty acids and a reduction in cholesterol 
and triglycerides in the livers of rats treated with DEHP. 
Hepatic fatty acid synthesis was increased about 2-fold, in 
r a t s .In contrast, Srivastava et al. (1978) reported that there 
was no change in total lipids and phospholipids in the 
livers of DEHP-treated rats as compared to controls.
Yanagita et al. (1979) observed a significant increase 
in hepatic phospholipids (PL) after feeding young male rats 
with a 20% casein diet containing 0.5% DEHP, for 7 days.
This increase occurred in both mitochondrial and microsomal 
fractions, but was more marked in mitochondrial fractions.
The increase is attributed to increases in phosphatidyl- 
ethanolamine (PE) and in phosphatidylcholine (PC), there
was a significant elevation of the PE/PC ratio in both 
fractions. This response was also found in rats fed 
0.1% to 0.5% DEHP, for 3 0 days, the extent of the increase 
in phospholipids was dependent upon dietary levels of 
casein and corn oil,the increase being greater on a low 
protein diet. Thus, the nutritional status of the animals 
may influence the response to DEHP. In addition, DEHP also 
caused a decrease in the concentration of hepatic triglyceride, 
which was greatest in the rats fed diets containing no or 
little essential fatty acids.
Yanagita et al. (1979) postulated that as phospholipids 
are integral components of the mitochondrial membrane, 
alterations in the concentration and fatty acid composition 
of phospholipids may influence the biological behaviour 
of the mitochondria and that the increase in hepatic 
microsomal phospholipids may be an adaptive response, in 
order to metabolise DEHP.
(B) THE EFFECTS OF DEHP ON LIPIDS OF OTHER TISSUES.
In male and female rats inhibition of sterologenesis 
occurs in the adrenal glands, and, in male rats, in the 
testes (Bell et al., 1978b; Bell, 1980). The effect 
is much less marked than that seen in the liver, inhibition 
of 20 to 25% of normal synthesis occurs, at a dose level 
of 1.0% DEHP in the diet. Impairment of sterologenesis is also 
observed in the brains of foetuses taken by caesarian section 
from pregnant rats fed 0.5% DEHP in the diet, from days 
5 to 10 after conception (Bell, 1982).
Bell and Nazir (1976) reported that in the kidney 
14incorporation of C acetate into triglycerides was reduced
by 33%, as compared to controls, whilst the synthesis of
fatty acids and phospholipids was not altered, after treatment
14with 0.5% DEHP m  the diet. The incorporation of C acetate
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into fatty acids, phospholipids and triglycerides, in vitro, 
in the heart and aorta was not affected by administration 
of DEHP. The authors concluded that the type and extent 
of the response to DEHP treatment, differs with varying 
tissues.
(C) EFFECTS OF PHTHALATE ESTERS ON PLASMA LIPIDS.
The effects of phthalates on blood lipid concentrations 
do not always parallel their effects on hepatic lipid 
content or biosynthetic rates.
DBP and DEHP cause hypocholesterolaemia in male rats 
(Bell et al. , 1978a). DEHP evokes a hypocholesterolaemic 
response in female rats also (Bell et al., 1978b). Treatment 
of male rats, with 0.5% and 1.0% DEHP in the diet results 
in a decrease of about 2 0 % in plasma cholesterol, this 
appears to be the maximum cholesterol lowering effect, 
and is attained within about one week of treatment with DEHP 
(Bell et al., 1978a, 1978b; Bell et al., 1979b). The hypo­
cholesterolaemic effect of phthalate esters does not occur in 
rabbits (Bell et al., 1978b, 1979b). The plasma cholesterol 
levels of dams exposed to 0.5% DEHP in the diet during 
gestation and the post-natal period was decreased, but it was 
not altered in their pups (Bell, 1982).
Reddy et al. (1976) observed that treatment with
0.5% DEHP resulted in a decrease in serum cholesterol, as 
well as in serum triglyceride, and that the effect was more 
marked in male rats than in male mice. Sakurai et al.(1978) 
demonstrated a fall in the level of plasma triglyceride 
in male rats fed 1 and 2% DEHP in the diet, but found no 
change in the cholesterol levels of either treatment group. 
Plasma free fatty acids and ketone bodies were increased 
in all DEHP treatment groups.
Yanagita et al. (1979) reported that treatment with 
0,1 to 0.5% DEHP, for 30 days, resulted in lower plasma 
phospholipid concentrations in treated male rats as 
compared to controls. Bell et al., (1978a) demonstrated
that male rats treated with DEHP had an increased ratio of 
serum low density lipoproteins to high density lipoproteins.
Morton and Rubin observed hypolipidaemia in rats fed 
dietary concentrations of 50 p.p.m. DEHP for 7 days. The 
authors concluded that this effect was attributable to 
the increase lipid metabolism by hepatocyte mitochondria.
1.9. THE METABOLISM OF PHTHALATE ESTERS AND ITS PROBABLE
SIGNIFICANCE IN THE POTENTIAL TOXICITY OF THESES COMPOUNDS.
(i) The form of phthalate esters to which man is exposed.
Although phthalate esters are found in food, water and 
air (see Section 1.1.) the greatest human exposure to phthalate 
esters is likely to occur by the use of plasticised medical 
devices, introducing phthalate esters into the circulation. 
Thus, toxicity studies of DEHP and other phthalate esters 
would be particularly relevant if performed using the i.v. 
route of administration. However, because of the limited 
solubility of most phthalate esters classical i.v. 
pharmacokinetic studies would be difficult to conduct.
There is no data available on the quantitative aspects of 
absorption through dermal and pulmonary tissues. Numerous 
studies show that phthalate esters are absorbed from the 
gastro-intestinal tract, the intra-peritoneal cavity and the 
lungs of laboratory animals.
(ii) Toxicokinetics i.v. in rats and mice.
Following intra-venous administration of DEHP, most 
of the dose is rapidly removed from the circulation; within 
1 0 minutes most of the dose is recovered - from the liver 
(40%), lungs (20%), spleen (3%) and the adipose tissue 
(Daniel, 1978). The retained material is subsequently eliminated 
from the tissues with a half-life of about 24 hours.
The distribution of phthalate esters has been studied 
both in vitro and in vivo. The distribution of phthalate esters 
in in vitro studies has been briefly described in the Introduction 
(see Section 1.1.). Recent studies have used plasma-solubilised 
phthalate esters, and have found that nearly all DEHP in 
blood is protein-bound, of which about 80% is lipoprotein- 
bound and the rest albumin-bound (Albro and Corbett, 1978).
MEHP, which is produced by the hydrolysis of DEHP, in blood 
by blood esterases (Rock et al., 1978 ) equilibrates between 
free and albumin-bound forms (Albro and Corbett, 1978).
Several studies have reported on the biodistribution 
of DEHP following either a single oral or i.v. dose of DEHP.
The design of some of the experiments does not allow for 
investigation of accumulation. The effect of the physico­
chemical properties of DEHP in biological systems must not be 
forgotten (Stern et al., 1977). The use of a particular 
emulsifying agent influences the biodistribution of DEHP.
Schulz and Rubin (1973) studied the disposition kinetics 
of radioactive DEHP (200 mg/kg in albumin-NaCl), injected
i.v., in the rat. The disappearance of organic extractable 
radioactivity from the blood showed distribution and elimination. 
Distribution was rapid (with a half-life for the first phase 
of 9 minutes) and found to be dose-dependent. The physical 
state of DEHP influenced the distribution of the compound, 
as with a finely emulsified preparation retention time was
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shorter than with poorly emulsified preparations. Seven days
14after an i.v. injection of [ C] DEHP in saturated saline 
solution, to mice, radioactivity was detected in urine, 
blood and several tissues (Dillingham and Autian, 1973).
Rubin and Schulz (1974) reported that 50% of theemulsified
dose was in the liver after 1 hour and 0.2% after 24 hours.
Tanaka et al. (1975) observed that after, i.v. administration 
14of [ C] DEHP to male Wistar Albino rats, the radioactivity 
was preferentially localised in the liver for a short time;
80% of the dose, whether administered i.v. or orally, was 
excreted in the urine and faeces after 5 to 7 days, and that 
after oral dosing no significant retention was found in 
organs or tissues.
Several reports indicate that the physical state of DEHP 
may influence its distribution and elimination (Stern et al., 
1974; Tanaka et al., 1975; Rubin and Schulz, 1974 ).
Miripol et al. (1975), as cited by Thomas et al. (1978),
14reported that following the i.v. administration of [ C] DEHP, 
in various dosage forms (i.e. solubilised in polysorbate 80 
suspension, in plasma with added ethanol or as the form leached 
into plasma from plastic) ( 1 0 mg/kg) the disappearance of 
radioactivity from the blood exhibited clear distribution and 
elimination phases. The volume of distribution and the 
elimination half-life were found to be dependent on the 
particular vehicle used to solubilise the plasticiser, but 
the distribution half life was independent of the solubilising 
agents.
Daniel and Bratt (1974) examined the distribution of DEHP
14in rats following i.v. administration of [ C] DEHP (1.8 pCi
14or 2.9 mg/kg in corn oil): [ C]-DEHP was preferentially 
localised in the lungs and spleen, and was eliminated with 
a half-life of 1 to 2 days.
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14Waddell et at. (1977) examined the distribution of [ C]-
DEHP following single i.v. injection of serum-solubilised 
DEHP. Autoradiograms of whole body saggital sections were 
obtained 1/ 3, 9, 24 and 168 hours after the injection and 
revealed rapid accumulation on the liver and kidney, with rapid 
excretion into the urine, intestine and bile.
(iii) Toxicokinetics-oral in rats and mice.
The extent of intestinal absorption of phthalate esters
can be estimated by monitoring urinary excretion of compounds
or metabolites after oral administration of a known amount
14of each compound. About 13% of a given oral dose of [ C]-
DEHP, in corn oil, given to rats, was recovered in organic 
solvent extracts of urine, faeces, and contents of the large 
intestine,62% was recovered in watersoluble extacts (Schulz 
and Rubin, 1973), and negligible amounts of radioactivity 
were detected in other organs. There was extensive metabolism 
of DEHP and the rate of metabolism was more rapid than the rate 
of absorption from the gastro-intestinal tract.
Daniel and Bratt (1974) reported that after administration 
14of [ C]-DEHP to rats, by gavage, 42% of the radioactivity
was excreted in the urine and 57% in the faeces,after 7 days.
A significant proportion was found in the bile (14%), during
the 4 days after dosing. These authors also examined the
tissue accumulation of DEHP, by monitoring the radioactivity in
14fat and liver after exposure to [ Cj-DEHP in the diet, at 
doses of 1000 and 5000 p.p.m. DEHP rapidly reached a steady state 
accumulation in the liver and abdominal fat, and on cessation 
of treatment, this accumulation decreased with a half-life 
of 1 to 2 days for the liver and 3 to 5 days for the abdominal 
fat.
Following oral administration of either ring-labelled 
or side-chain labelled DEHP, Wallin et at. (1974) reported
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that 50% of the radioactivity was detected in faeces and in 
the contents of the gastro-intestinal tract of the rat and the 
other 50% in the urine. Williams and Blanchfield (1974a). 
reported that, in rats, more than 90% of the concentration 
of DEHP incorporated into food was found in the urine which 
indicates that DEHP in food may be well absorbed from the 
intestine. Interestingly, less DEHP was excreted in the urine 
(40 to 50%) in animals given DEHP by gavage.
Other phthalate esters are also well absorbed from the 
intestine, these include Di(3,5-methoxyethyl)phthalate, 
butylphthalylbutylglycolate and MEHP (Ikeda et al., 1978 ;
Chu et al., 1978 ; Tanaka et al., 1978; Williams and Blanchfield, 
1974a, 1975) whereas the absorption of phthalic acid itself 
is incomplete (Williams and Blanchfield, 1974b).
Both ester linkages of phthalate esters can be hydrolysed 
to leave phthalic acid as a product; however, hydrolysis of 
a single ester group occurs much more readily than hydrolysis 
of the second. The rapid hydrolysis of orally administered 
dialkyl phthalte esters to their mono-esters has been demonstrated 
in several studies. DMP, DBP and DEHP were all hydrolysed 
to their mono-esters, and this was demonstrated to be an 
essential step before absorption can occur, using an in vitro 
method (White and Carter, 1980). Rowland et al. (1977) showed 
that the gastro-intestinal contents of rats could hydrolyse 
DMP, DEP, DBP, DnOP, DCHP and DEHP to their respective mono­
esters. The hydrolytic activity was heat labile but was not 
affected by filtration of cellular material or by bacteriocidal 
sterilisation of the gut, implying that this activity was an 
enzyme. Albro and Thomas (1973) reported a very high hydrolytic 
activity towards DEHP in pancreatic homogenates; this may 
be the primary source of gut hydrolytic activity towards 
phthalate esters. Lake et al~s{\911) suggested that orally 
ingested phthalate diesters would probably be absorbed from 
the gut, primarily as mono-esters. These authors reported 
hydrolysis of DMP, DEP, DBP, DnOP, DCHP and DEHP to the
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hydrolysis of DMP, DEP, DBP, DnOP, DCHP and DEHP to the 
corresponding mono-esters by hepatic and intestinal preparations 
from the rat.
(iv) Toxicokinetics in other non-primate species.
There has been little investigation of the toxicokinetics 
of phthalate esters in non-primate species apart from the 
rat and mouse. Lake et al. (1977) reported hydrolysis of DMP,
DEP, DBP, DnOP, DCHP and DEHP to their corresponding mono­
esters by hepatic and intestinal preparations from the the ferret 
as well as from the rat.
In the dog, Wallin et al. (1974) reported that only about 
40% of the total radioactivity appeared in the urine 24 hours 
after oral administration of either ring-labelled or side-chain 
labelled DEHP.
(v) Toxicokinetics in primates and transplacental distribution of 
phthalate esters.
In rhesus monkeys repeatedly infused i.v. with very small 
amounts (cumulative doses of 21 to 69 mg/kg) of DEHP in blood, 
significant fractions of the cumulative dose of DEHP were reporte< 
to be retained for several months in the liver (Jacobson et al., 
1977). DEHP was detected in the liver, spleen, lung and 
abdominal fat of 2 patients who had been transfused with large 
volumes of blood i.v. from DEHP-plasticised bags (Jaeger and 
Rubin, 1970); the concentrations of DEHP detected ranged from
0.025 mg/'g dry weight in spleen to 0.270 mg/g dry weight 
in abdominal fat. Jaegar and Rubin (1973) also reported that 
the liver, spleen, lungs and abdominal fat obtained as autopsy 
material from patients previously transfused with blood stored 
in PVC blood bags contained detectable amounts of DEHP. Wallin 
et al.. (1974) and Rubin and Nair (1973) have indicated that there
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is no relationship between transfusion history and tissue 
content of the human postpartum tisuue of the plasticiser, 
and patients who had no history of blood transfusions were 
not free of DEHP.
Hillman et al. (1975) detected DEHP in neonatal heart
and gastro-intestinal tissues of infants who had been transfused
with an umbilical catheter and/or had received other blood
products. Other reports indicate disagreement about the ability
of phthalate esters to cross the placenta by maternal-foetal
transfer. Singh et al.(1975) reported that radioactivity was
recovered from foetal tissues following treatment of maternal 
14 14animals with C-DEHP or C-diethylphthalate, although the 
concentrations in the foetal tissues did not exceed those 
in the maternal tissues.
It can be concluded that following either oral or i.v. 
administration DEHP can be widely distributed in the tissues. 
Distribution studies, carried out in animals, using DEHP 
solubilised in a variety of solubilising agents, indicate that 
there is no tendency for accumulation.
(vi) Metabolism and excretion of phthalate esters.
DEHP is metabolised after oral administration (Albro et al. , 
1973; Daniel and Bratt, 1974 ; Rowland et al., 1977) and after
i.v. administration. The route of administration does not, 
generally, affect, qualitatively, the metabolism of phthalate 
esters( Chu et al., 1978; Tanaka et al., 1975; Albro and Moore, 
1977). The metabolism of DEHP in different biological systems 
has been reviewed (Thomas et al., 1978 ). The metabolites, which 
are primarily excreted in the urine, differ from species to 
species (Albro et al., 1981a). Most of the studies of the 
metabolism of DEHP have been carried out in the rat. Figure 1.2. 
shows the metabolic fate of DEHP in the rat, administered orally. 
Albro et al. (1973) isolated four major urinary metabolites of
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Metabolism of DEHP (Albro et al., 1973).
DEHP, derived from u and w-1 oxidation of MEHP. The alcohol 
and ketone metabolites were not conjugated and free phthalic 
acid accounted for less than 3% of the urinary metabolites.
The same general pathways have been reported for the metabolism 
of the monoester derivatives of other phthalate esters (Williams 
and Blanchfield, 1974a, 1974b, 1975 ; Tanaka et al., 1978;
Daniel and Bratt, 1974 ; Chu et al., 1978 ; Albro and Moore, 1974) .
14Daniel and Bratt (1974) administered C-DEHP i.v. and 
detected urinary phthalic acid and other metabolites from the 
oxidation of MEHP. Williams and Blanchfield (1974a) demonstrated 
at least 7 metabolites, in addition to MEHP. Tanaka et al.
(1975) observed 4 major bands of radioactivity associated with 
4 metabolites of DEHP, after DEHP was administered to rats,
either orally or i.v.. Unchanged DEHP was excreted in the faeces,
but neither DEHP or MEHP was detected in the urine or bile.
Oba et al. (1975) found unchanged DEHP in" the faeces, and also
in the bile, but detected neither MEHP or DEHP in rat urine.
Dialkyl phthalates can be metabolised to their respective 
monoesters in many tissues, but in the liver enzymes are 
present which can hydrolyse DEHP to phthalic acid as shown below: 
(Albro and Thomas, 1973).
0
It
C-OH
C-OH 
Io
+HO-R'
The complete hydrolysis of a phthalate ester to phthalic 
acid (after Albro and Thomas, 1973).
Albro and Moore (1974) reported that following the oral 
administration of DMP, DBP or DnOP to rats, the urinary metabolite
C-OR C-OH
C-OR* C-OR"
+HO-R
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metabolites included diesters, ketodiesters and hydroxydiesters 
with phthalic acid as a minor metabolite, apart from DMP 
metabolism, where appreciable amounts of DMP is excreted as 
phthalic acid. DMP and DBP, to a lesser extent, may be 
excreted in the urine as the unchanged parent comounds; however 
increasing chain lengths of other phthalate esters requires 
increasing modification after hydrolysis to the monoester
in order to acheive sufficient polarity for renal excretion. .
Several species of animals form glucuronic acid conjugates with 
the monoester metabolite of DBP at the free carboxylate group. 
However, the rat, unlike the ferret, African Green monkey and 
man is unable to conjugate MEHP, see Table 1.10; the reason for 
this inability is not known. It should be noted that there is 
no general deficiency of glucuronate conjugate in the rat. The 
inability of the rat to excrete conjugates of DEHP has been noted 
in at least 3 strains of rat (Albro et al., 1981a; Daniel and 
Bratt, 1974)..
Rats excrete predominantly metabolites having carboxyl 
groups on the side chain (Metabolites I-V) which require 3 
to 6 oxidative steps for their formation. This would result 
in a net decrease in the ratio of NAD(P) to NAD(P )H in the 
liver during exposure to high levels of DEHP. Whereas in the 
primates there would be a net increase in this ratio, as 
primates do not carry out such extensive oxidative metabolism 
of DEHP as rats.
Peck and Albro investigated the disposition of DEHP in
primates by studying the distribution, elimination and metabolism
of DEHP, in the African Green Monkey, following bolus infusion 
14of C-DEHP-laden autologous plasma (Peck et al., 1976a, 1976b; 
Albro et al., 1981b). The predominant urinary metabolites were 
the 5-ethyl, isohexanol monoester of phthalic acid and MEHP; 
more than 80% of the urinary metabolites were glucuronidated.
In man also approximately 80% of the urinary metabolites were 
conjugated to glucuronate (Peck et al.,1978). These authors
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TABLE 1.10.
METABOLISM OF DEHP IN DIFFERENT SPECIES.
SPECIES
Rat
Rat
Rat(MEHP) 
Rat 
Rat 
Rat
CONJUGATED
METABOLITES
none
none
none
none
none
none
REFERENCES
Williams and Blanchfield, 1974
Daniel and Bratt, 1974
Chu et al., 1978
Tanaka et al., 1975
Albro and Moore, 1974
Albro et al., 1973
Ferret MEHP-glucuronide
derivatives
Lake et al., 1975
African Green MEHP-glucuronide Albro et al., 1981 
Monkey derivatives
Human MEHP-glucuronide Peck et al., 1978 
derivatives
Mouse C.D. MEHP-glucuronide Peck et al., 1978
derivatives
Guinea pig MEHP-glucuronide Peck et al., 1978
Hamster MEHP-glucuronide Peck et al., 1978 
derivative
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demonstrated that DEHP administered parenterally to primates 
and humans is rapidly converted to hydrolysed oxidation products 
of MEHP, which are rapidly excreted in the urine.
The metabolism and excretion of MEHP has been studied,
and it was found that MEHP was readily absorbed from the
rat gastro-intestinal tract (Chu et al., 1978). More than 80%
14of the orally administered dose of [ C]-MEHP was excreted 
in 24 hours; 72% of which was found in the urine and 8% in the 
faeces. MEHP, given orally to rats, yields the same metabolites 
as DEHP, after oo and oo-l oxidation.
Urinary excretion, in all species, is the major route of 
elimination of phthalate esters. However faecal elimination 
occurs and biliary excretion of phthalate esters has been 
described. Tanaka et al. (1978) demonstrated biliary excretion 
of DBP, up to 44% in 24 hours after an oral dose of 60 mg/kg 
of DBP, in rats. Extensive entero-hepatic cycling is thought to 
occur as only 5% of this dose was excreted in the faeces of rats, 
which did not undergo bile duct cannulation. Administration 
of 500 mg/kg of DBP resulted in only 5% of the dose being 
recovered in the bile, after 6 hours; thus, hepato-biliary 
excretion of DBP may be saturable or may occur only after a 
specific delay in absorption. MBP, MBP-gluconide and oxidised 
derivatives of MBP-glucuronide were found as biliary metabolites 
of DBP (Tanaka et al., 1978; Williams and Blanchfield, 1975; 
Kaneshima et al., 1978 ).
Daniel and Bratt (1974) showed that DEHP can undergo 
biliary excretion, as 14% of an orally administered dose of 
2.6 mg/kg DEHP was found in bile. Tanaka et al. (1975) reported 
that 28% of an i.v. dose of 50 mg/kg DEHP was extracted from the 
faeces, suggesting that the faeces may be an important route 
for elimination of DEHP. None of the biliary metabolites of 
DEHP were glucuronidated (Daniel and Bratt, 1974). The extent 
of biliary excretion of phthalate esters is unknown, but it
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appears that phthalate ester metabolites may be excreted 
in the bile, reabsorbed from the intestine and ultimately 
excreted in the urine.
In conclusion, the metabolism of phthalate esters, in 
particular DEHP, is clearly species-dependent., and as rats 
were unique amongst the several species in their inability to 
form glucuronic acid conjugates of MEHP, the validity of using 
rats as a model for the effects of DEHP in man must be questioned 
On the other hand, since mice can glucuronidate MEHP,but 
nonetheless respond in a similar manner to rats in terms of 
toxic injury, it would appear that the ability to conjugate 
is not related to the toxicity of phthalate esters.
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CHAPTER TWO 
MATERIALS & METHODS
2.1. MATERIALS.
DEHP, DnOP, DnHP, MEHP, MnOP and MnHP were kindly supplied 
by B. P. Chemicals, Penarth, Wales.
The hypolipidaemic drugs were donated by Dr G. Blane, 
Laboratoires Fournier, Dijon, France.
The source of all other chemicals is given in the text.
All other chemicals were of analytical grade, unless stated 
otherwise.
Most of the methods employed in this study, particularly 
in the in vivo work, were carried out using standard operating 
procedures for the Robens Institute.
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2.2. SUMMARY OF STUDIES TO BE DESCRIBED.
STUDY A: DOSE AND TIME-RESPONSE TO DEHP.
In this experiment male and female Wistar 
Albino rats (Alderley Park strain) were obtained 
from the Animal Breeding Unit, ICI, Cheshire,
UK. Animals weighed between 170 and 220 grams 
at the start of the experiment. Animals were given 
either control powdered diet (CRM, Labsure, Poole, 
Dorset, UK.) or diet containing sufficient DEHP 
to give dose levels of 50, 200 or 1,000 mg/kg 
of body weight/day. Groups of 6 control and 4 
treated animals were killed 3, 7, 14 and 28 days 
and 9 months after commencement of treatment.
STUDY B: STUDIES ON THE EFFECT OF DEHP UPON BILE.
Male Wistar Albino rats (University of Surrey
strain), weighing between 130 and 160 grams initially, 
were given either control powdered diet (Spratts 
Powdered diet no. 2, Spratts, Barking, Essex,
UK.) or diet containing sufficient DEHP to give 
a dose of 1,000 mg/kg of body weight/day. Bile 
duct cannulations were done 3 or 15 days after 
commencement of treatment, and bile collected 
for up to 4 hours.
STUDY C: STUDY OF THE RESPONSE OF MATURE RATS 
TO HYPOLIPIDAEMIC AGENTS.
Male Wistar Albino rats (Alderley Park strain)
weighing between 700 and 7 50 grams and aged about
9 months, were treated with either control powdered 
diet (Spratts Powdered diet no. 2) or diet containing 
sufficient DEHP to give a nominal dose of 1,000 
mg/kg of body weight/day or diet containing sufficient
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fenofibrate to give a nominal dose of 200 mg/kg 
of body weight/day or diet containing sufficient 
clofibrate to give a nominal dose of 400 mg/kg 
of body weight/day. Groups of 8 control and 6 
treated animals from each treatment group were 
killed 3 and 13 days after commencement of treatment.
STUDY D: STUDIES USING ISOLATED SUSPENSIONS OF 
HEPATOCYTES OR CULTURED HEPATQCYTES.
In these experiments control male Wistar 
Albino rats (University of Surrey strain), weighing 
between 2 00 and 250 grams, were used as a source 
of hepatocytes. Animals were fed Spratts pelletted 
rodent diet no. 1. In some experiments animals 
were starved for 18 to 24 hours prior to isolation 
of hepatocytes.
Both the Wistar Albino rats of the Alderley 
Park strain from ICI and the University of Surrey 
strain were originally derived from the Portland 
strain.
In all studies rats were housed in cages 
with sawdust bedding (Lee and Co., Chertsey, Surrey, 
UK.), and were allowed food and water ad libitum, 
unless otherwise noted. A 12 hour light/dark cycle 
operated (0700 - 1900 hours light) , at a temperature 
of 22°C and 50% humidity.
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2.3. PRE AND POST MORTEM TECHNIQUES.
For Study A, animals were examined and weighed on 
delivery. 3 days prior to the start of the experiment 
animals were transferred from Spratts pelletted 
rodent diet no.l to Labsure powdered diet for 
acclimatisation. They were then weighed, tailmarked 
and assigned at random to experimental groups.
Animals were subsequently weighed twice a week 
throughout the 28 day experimental period and 
thereafter once a week. Food intake was regularly 
monitored and the actual dose of DEHP ingested 
over successive 7 day periods was maintained within 
+2 0% of the nominal value by appropriate adjustment 
of the concentration of DEHP within the diet.
For Study B, animals were weighed, transferred 
from Spratts pelletted rodent diet no.l to Spratts 
powdered diet no.2, 7 days prior to the commencement 
of treatment. Food intake was monitored twice 
a week.
For Study C, using mature animals, the animals 
were weighed, transferred from Spratts pelletted 
rodent diet no.l to Spratts powdered diet no.2,
14 days prior to commencement of treatment, and 
at this time were tailmarked and assigned at random 
to experimental groups. Food intake was monitored.
In each study, animals were examined regularly; 
they were observed for changes in appearance and  ^
behaviour, or any other symptoms of toxicity produced 
by administration of the compounds.
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In Study A animals killed 3, 7, 14 and 28 
days after commencement of treatment were injected
3
mtra-peritoneally with sufficient methyl H-thymidine 
(specific activity 40 Ci/nmol) (Amersham Intl. Ltd., 
Amersham, Bucks., UK.) to give a dose of approximately 
50 yCi/kg of body weight, in a volume of 1.25 ml 
of standard saline solution. Exactly one hour 
later the rats were anaesthetized by placing them 
in an atmosphere saturated with diethyl ether, 
bled by cardiac puncture, using a 10 ml Gillette 
plastic syringe fitted with a 23 swg needle, and 
killed by cervical dislocation. Blood samples 
were taken into glass conical test tubes.
The abdominal viscera were examined and any 
changes, compared to control animals, were noted.
The liver was rapidly excised, weighed/ samples 
of liver were removed and treated for histological 
and electron microscopic examination (see section 2.13). 
The livers were re-weighed and homogenised (see 
section 2.5). The kidneys, spleen, testes, pancreas 
and pituitary were removed. The kidneys, spleen 
and testes were weighed. All organs removed were 
treated for histological examination.
Animals killed 9 months after commencement 
of treatment were anaesthetized by intra-peritoneal 
injection of Sagatal (May and Baker Ltd., Dagenham, 
London, UK.), doses of approximately 0.1 ml/100 g 
of body weight were used, and bled from the inferior 
vena cava, using a plastic 10 ml Gillette syringe 
fitted with a 23 swg needle. A more extensive 
autopsy was performed on each of these animals.
In addition to the organs removed in earlier
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kills the following were also removed and prepared 
for histological examination:the heart, lungs, 
thymus, the adrenals, the urino-genital system, 
longitudinal sections from the stomach, sections 
of the jejunum, ileum and colon, lymph nodes, 
the thyroid and parathyroids, the dorsal fat pad 
and the brachial or femoral nerves were removed 
and examined.
In Study B at the termination of the experiment 
the animals underwent bile duct cannulation (see 
section 2.4).
In Study C, at the termination of the experiment, 
the animals were killed and the autopsy examination 
performed as described for animals treated for 
9 months with DEHP.
2.4. SURGICAL PROCEDURES.
PREPARATION OF HEPATOCYTES.
The perfusion technique based on the method 
of Rao et al, 1976, was used in these experiments.
The yield was routinely over 200 million cells, 
with viabilities of more than 90%.
Reagents.
Calcium-free Krebs Ringer Phosphate buffer, pH 7.4,
containing 150 mM NaCl, 4.97 mM KC1, 1.24 mM KH^PO^,
3.73 mM NaHC03, 4.84 mM Na2HP04, 0.64 mM MgCl26H20,
0.62 mM MgSO 7H 0.
2 +Ca -free hydrogen carbonate buffer, pH 7.4, containing 
142 mM NaCl, 4.37 mM KC1, 1.24 mM KH2P04, 24.0 mM NaHC03,
0.62 mM MgS047H20 and 0.6 mM MgCl26H20.
Both solutions contained a few drops of Phenol
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Red solution (Flow Laboratories, Irvine, Scotland, UK.) 
as an indicator of pH.
250 mM CaCl2 solution.
PBSA (Phosphate buffered saline solution) (Flow 
Laboratories, Irvine, Scotland, UK.).
Method:-
... - 2+
The Ca -free Krebs Ringer Phosphate buffer 
2+and the Ca -free hydrogen carbonate buffer were 
placed in a water bath, @37°C , and gassed continuously 
with 95% C>2/ 5% C02 (British Oxygen Co., London, UK.).
The male Wistar Albino rat (University of
Surrey strain) was anaesthetized with an intra-
peritoneal injection of Sagatal (May and Baker Ltd.,
Dagenham, London, UK.) (doses were approximately
0.1 ml/100 g of body weight). Each animal was
placed so that the ventral side was exposed, and
opened by two deep lateral cuts, and the viscera
removed to the animals left side, thereby exposing
the liver. A ligature was placed around the inferior
vena cava, just above the renal veins, but was
not tied. The hepatic portal vein was then cannulated
using a 22g x 32 mm catheter (Abbocath-T, Abbott
Laboratories Ltd., Queensborough, Kent, UK.),
2 +and the liver was perfused with Ca -free Krebs 
Ringer phosphate buffer. The inferior vena cava 
was cut below the ligature, in order to prevent 
the liver from swelling. The thoracic cavity was 
exposed by carefully cutting through the rib cage;
The inferior vena cava was cannulated via the right 
atrium, with a 18g x 32 mm cannula (Abbocath-T,
Abbott Laboratories Ltd., Queensborough, Kent,UK.).
The ligature previously placed on the inferior 
vena cava was then tightened.
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2 +The liver was first perfused with Ca -free
Krebs Ringer phosphate buffer, pH 7.4, for 15
2+minutes, followed by Ca -free hydrogen carbonate
buffer, pH 7.4, for a further 15 minutes at a
rate of 30 ml/minute and was subsequently perfused
2+with 150 ml of Ca -free hydrogen carbonate buffer, 
pH 7.4, containing 100 mg collagenase and 5 mM CaCl2, 
with re-circulation for up t o 20 minutes.
The liver was then rapidly excised and placed 
in a dish containing PBSA, at a temperature of 
37°C. The outer capsule was removed, tissues teased 
apart, and the loosened mass passed through 125y 
bolting cloth. The volume was made up to a total 
of 2 00 ml with PBSA. The cells were washed by 
either allowing them to settle under gravity, 
and removing the upper layer, and resuspending 
in fresh medium, or by centrifugation- in this 
case the cells were centrifuged at 400 r.p.m. 
for 1 minute (Digifuge, V. A. Howe and Co. Ltd., 
London, UK.), and the supernatant removed, and 
the cells were resuspended in fresh medium. The 
cells were washed three times whichever procedure 
was used. Finally cells were resuspended in the 
medium appropriate for the experiment, and the 
yield and viability assessed.
Viability was measured by the Trypan Blue 
exclusion method. 100 \xl of trypan blue dye (Flow 
Laboratories, Irvine, Scotland,UK.) was added 
to 250 lil of cell suspension, mixed and a sample 
placed on a haemocytometer slide. The number of 
viable and non-viable cells were then counted; 
the viable cells, excluding trypan blue, were 
straw-coloured, and the non-viable cells blue.
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% viability was calculated as follows:
% viability = the number of viable cells counted 
the total number of cells counted
i.e. viable + non-viable cells.
Yield = the total number of cells isolated,
i.e. the number of cells/ml of cell suspension 
x the volume of cell suspension.
The number of cells/ml of cell suspension was 
calculated as follows:
total volume counted (350 yil) x area factor x total no. of
volume of cell suspension counted to give no. cells counted
(250 ul) of cells/ml in 350 \il.
Note: a source of collagenase has not been given in 
the list of reagents as the source of the most 
effective collagenase tends to change with time.
BILE DUCT CANNULATION.
Male Wistar Albino rats (University of Surrey 
strain), weighing more than 200 grams, were used 
for bile duct cannulations. The animals were 
anaesthetized with approximately 0.1 ml/100 g 
body weight of Sagatal (May and Baker Ltd.,
Dagenham, England, UK.), injected intra-peritoneally, 
placed onto a dissecting board and secured. An 
incision was made along the mid-line, up to the 
xiphisternum, exposing the liver. The bile duct 
was identified and 2 ligatures placed around it.
The duct was then cannulated by making a V-shaped 
cut with very fine scissors, and passing the end 
of a 6" piece of Portex PP25 tubing (M. W. Scientific 
Ltd., Eastleigh, Hants., UK.) down the bile
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duct towards the liver. The ligatures were tied 
off, in order to secure the cannula. The cannula 
was brought out through the right or left abdominal 
wall. The skin was closed with running sutures 
and the body wall with skin clips. The animal 
was placed on a heating pad and the rectal temperature 
and the degree of anaesthesia regularly monitored. 
Additional Sagatal was administered as necessary 
to maintain stage 4 anaesthesia. Bile was collected 
into pre-weighed vessels, for up to 5 hours, and 
bile flow estimated by weighing the collection 
vessels.
2.5. PREPARATION AND ANALYSIS OF LIVER HOMOGENATES■
2.5.1. PREPARATION OF SUBCELLULAR FRACTIONS FROM THE LIVER.
This method is based on that of de Duve,
Berthet and Beaufay (1959).
Reagents.
1 M Tfis-HCl buffer,pH 7.4.
0.25 M sucrose, containing 5 mM Tris-HCl buffer, pH 7.4.
1.5 M KC1 solution.
Method.
1) Homogenisation.
Livers excised at post-mortem were placed 
in a volume of 0.25 M sucrose containing 5 mM 
Tris-HCl buffer, pH 7.4, which was about 3 times 
the weight of the liver, and homogenised by 3 
return strokes on a Potter Elvehjem homogeniser 
using a pestle rotated at a speed of 2,400 r.p.m.
The final volume was made up so that 5 ml of 
homogenate contained material from 1 gram of liver. 
Aliquots of the homogenate were taken and either 
assayed immediately or stored at -2 0°C.
2) Preparation of S.I. fraction.
20 ml of homogenate was pipetted into a 
centrifuge tube, to which 2 0 ml of 0.25 M sucrose 
containing 5 mM Tris-HCl buffer, pH 7.4, was added. 
This was mixed and then centrifuged for 15 minutes 
at 10,000 r.p.m. in an HS 18 centrifuge (M.S.E. 
Scientific Instruments, Crawley, Sussex, UK.).
The supernatant was removed into clean centrifuge 
tubes. The pellet was resuspended by vigorous 
shaking in 10 ml of 0.25 M sucrose containing 
5 mM Tris-HCl buffer, pH 7.4. Samples were either 
analysed immediately or stored at -20°C.
3) Preparation and washing of microsomes.
The supernatant from 2) above was centrifuged 
for 60 minutes at 40,000 r.p.m. in an M.S.E. SS 65 
centrifuge. The supernatant (cytosolic fraction) 
was removed. The microsomal pellet was resuspended 
in 10 ml of 0.25 M sucrose, by 3 return strokes 
on a Potter Elvehjem homogeniser, using a pestle 
rotated at a speed of 2,400 r.p.m. The final volume 
was made up to 30 ml with 0.25 M sucrose, to which 
3.3 ml of 1.5 M KC1 was added. After mixing, the 
samples were spun at 40,000 r.p.m. for 60 minutes. 
The supernatant was removed and the microsomal 
pellet resuspended in 5 ml of 0.25 M sucrose by 
rehomogenisation. 0.5 ml aliquots were taken and 
either assayed immediately or stored in liquid 
nitrogen.
2.5.2. PROTEIN ASSAY IN TISSUE SUBFRACTIONS.
The protein concentration in crude tissue 
homogenates and in tissue fractions was determined, 
using an autoanalyser, by an adaptation of the 
Lowry method (Schuel and Schuel, 1967), which 
included a NaOH predigestion stage (Hinton and 
Norris, 1972 ) .
Reagents.
Lowry buffer: 1 M NaHC03, 0.625 M NaOH.
Copper Tartrate solution: 10 ml of CuSO^ (0.1% w/v) 
and 10 ml of (CHOHCOONa)2 2H20 (0.2% w/v) were 
mixed and made up to a volume of 100 ml with 
distilled water.
Folin Ciocalteu's Reagent (Fisons Scientific 
Apparatus, Loughborough, Leics., UK.), diluted 
1 in 3 on the day of use.
NaOH solution, 0.66 M.
Bovine Serum Albumin solution, a stock solution 
of 10 mg/ml was prepared.
Method.
The autoanalyser manifold flow diagram is 
shown in Figure 2.1.
Sampling time was 1 minute and wash (NaOH, 0.66M) 
time was 36 seconds.
The stock protein solution was diluted with 
NaOH (0.66 M) to give a range of concentrations 
of 0.2, 0.4, 0.6, 0.8, 1.0, 1.5 and 2.0 mg/ml 
bovine serum albumin. Transmission was recorded 
at 712 nm. The standard curve was used to calculate 
the amount of protein present in each sample as mg/ml.
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FIGURE 2.1.
Reagents Flow rate
(ml/min)
0.66N NaOH 
1.0 N NaOH*
sample
sample*
Lowry buffer
Copper tartrate
Folin reagent
wash
repump
0.6
1.6
1 .2*
0.23
1.2*
1.6
1.6
1.6
0.6
1.2
1.6
2.0
L- o -
■) Waste
SMC
SMC
DMC
DMC
colorimeter 
721 nm
Autoanalyser diagram for estimation of protein.
SMC = single mixing coil 
DMC = double mixing coil 
CUD = pulse suppressor
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2.5.3. DNA ESTIMATION.
This method was taken from Turner (1966) 
who adapted the method of Burton (1956).
Diphenylamine reacts with acid-hydrolysed 
DNA to give coloured compounds; the optical density 
of these compounds is measured at 600 nm- against —  
a blank and compared with the values obtained 
with standard DNA.
Reagents.
10% (v/v) perchloric acid (PCA).
5% (v/v) perchloric acid (PCA).
1.5% (w/v) diphenylamine dissolved in glacial acetic 
acid (Laboratory grade) containing 1.5% (v/v) 
concentrated sulphuric acid.
DNA standard solution (0.35 mg DNA/ml in 5% (v/v) PCA. 
Method.
0.5 ml of undiluted liver homogenate was 
precipitated with 0.5 ml of ice-cold 10% PCA, 
left on ice for 15 minutes and then spun at 
1,500 r.p.m. for 7 minutes. The precipitated 
DNA was washed five times with 5% PCA. The supernatant 
(the acid-soluble fraction) from the first spin 
was transferred to a scintillation vial, to which 
4 ml of Picofluor-36 (Packard Instrument Co. Inc., 
Caversham, Berks, UK.) was added, and counted on a 
PL-Prias counter (Packard Instrument Co. Inc.,
3
Caversham, Berks, UK.) for H.
The washed pellets were extracted twice 
with hot (80°C) 5% PCA for 15 minutes. 0.5 ml
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of extracts were added to scintillation vials
containing 4 ml of Picofluor-36, and counted
3on a PL-Prias counter for H-DNA.
The DNA content of the extracts was estimated 
as follows:   _ r
1.2 ml of the extract was added to 2.4 ml 
of 1.5% diphenylamine dissolved in glacial acetic 
acid containing 1.5% concentrated sulphuric 
acid. A standard curve to DNA was made in which 
volumes of 0.1, 0.2, 0.3, 0.4 and 0.5 ml of
3.5 mg/ml DNA were made up to 1.2 ml with 5%
PCA, to which 2.4 ml of 1.5% diphenylamine dissolved 
in glacial acetic acid containing 1.5% sulphuric 
acid was added. These standards and samples 
were mixed, and left in a dark cupboard for two 
days before reading the extinction at 600 nm.
By comparison with the standard curve, the 
amount of DNA (mg/ml) in each sample can be calculated. 
The amount of DNA per gram of liver was calculated,
3
and DNA synthesis was calculated ( H-DNA/mg DNA).
2.6. PEROXISOMAL ENZYMES.
2.6.1. CATALASE.
This method uses an automated adaptation 
of the procedure by Chantrenne (1955) by Leighton 
(1968).
Catalase catalyses the following reaction:
2 H2°2- * 2 H2° + °2
Catalase activity is determined by measuring
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the decrease in concentration, following
brief incubation at 0°C. The concentration of 
is determined by reaction with titanium 
oxysulphate to give a yellow colour.
Reagents.
1% (v/v) triton X-100 in 0.33% (w/v) B.S.A. in 2% (w/v) 
NaCl solution.
0.033 M imidazole buffer, pH 7.0, containing 0.07% (v/v) 
of 30% (v/v) .
Titanium oxysulphate solution (B.D.H., Poole, Dorset,
UK.), diluted 1 in 16 on the day of use.
0.05% (w/v) Brij-35 (Polyoxyethylene-23-lauryl ether) 
solution.
Method.
The autoanalyser manifold diagram is shown 
in Figure 2.2.
Sampling time was 1 minute and 12 seconds 
and the wash (0.05% Brij-35) time was 48 seconds.
Catalase follows first order kinetics. As 
the colour produced by reaction of H202 with 
titanium oxysulphate is proportional to 
concentration under the conditions of the assay, 
the activity may be expressed as:
Act = log(A2 - A^) - log(A2 -A^)
where no blanks have been perfomed. In the above 
equation, A^ = Absorbance of the baseline in 
the absence of 
A2 = Absorbance of baseline in presence of H2°2* 
= Absorbance of sample.
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FIGURE 2.2.
Reagent Flow rate 
(ml/minute)
triton-XlOO 
+ BSA
sample
imidazole
titanium
oxysulphate
solution
Wash (Brij) 
Repump
2 .
0.
0.
1.
3.
3.
3.
This area should 
be kept on ice
SMC
-OP-
SMCSMC
-OTP
DMC
[DMC
^  Waste
colorimeter
402 nm
Autoanalyser diagram for manifold for use in the estimation 
of catalase activity.
SMC = single mixing coil 
DMC = double mixing coil 
r. } = pulse suppressor
Catalase activity was estimated in the 
liver homogenate and in the S.I. fraction of 
the liver, by the above method. Samples were 
diluted to give protein concentrations of about 
1 mg/ml. Catalase activity estimated in the liver 
homogenate is the total catalase activity, and 
that in the S.I. fraction of the liver is the 
sedimentable catalase activity.
2.6.2. CYANIDE-INSENSITIVE PALMITOYL CoA OXIDASE.
This method is based on that of Bronfman,
Inestrosa and Leighton (1979).
Oxidation of palmitoyl-CoA results in reduction 
of FAD and NAD+. In the mitochondrial system 
these are re-oxidised by the cytochrome chain.
This is blocked by the addition of cyanide. In
peroxisomes, FAD is re-oxidised by molecular
oxygen but NADH accumulates. Assay of NADH production
in the presence of cyanide gives a measure of
the activity of the peroxisomal fatty acid oxidase
system.
Reagents.
60 mM Tris-HCl buffer, pH 8.3.
1.0% Triton X-100 (v/v) in 60 mM Tris-HCl buffer, pH 8.3. 
60 mM Tris-HCl buffer, pH 8.3, containing CoA (75 uM) ,
FAD (180 pM), NAD+ (555 pM), nicotinamide (141 mM), 
dithiothreitol (4.2 mM), KCN (3 mM) and bovine 
serum albumin (0.225 mg/ml). (Substrate cocktail).
60 mM Tris-HCl buffer, pH 8.3, containing palmitoyl-CoA 
(75 uM).
Note:when weighing out KCN appropriate precautions must 
be taken, see Section 2.6.3.
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Method.
2 ml of 60 mM Tris-HCl buffer, pH 8.3, 
containing CoA (75 pM) , FAD (180 pM), NAD+ (555 pM) , 
nicotinamide (141 mM), dithiothreitol (4.2 mM),
KCN (3 mM), and bovine serum albumin (0.225 mg/ml) 
was added to a small test tube and equilibrated 
at 37°C for a few minutes. To another test tube 
100 pi of sample (undiluted liver homogenate 
in most cases) and 100 pi of 1% triton X-100 (v/v) 
in 60 mM Tris-HCl buffer, pH 8.3, were added, 
and incubated at 37°C for 30 seconds to 2 minutes.
40 pi of the sample:triton X-100 mixture was 
then added to the equilibrated 2 ml of substrate 
cocktail, mixed and the final reaction mixture 
volume made up to 3 ml with 60 mM Tris-HCl buffer, 
pH 8.3. This was centrifuged at 1,000 r-.p.m. 
(Digifuge, V. A. Howe and Co. Ltd., London, UK.) 
for 3 minutes, and then carefully transferred 
to a spectrophotometer cuvette. The centrifugation 
procedure removes any large pieces of particulate 
matter, which interfered with the spectrophotometry. 
The reaction was followed at 340 nm, at 37°C, 
to establish a baseline. Palmitoyl-CoA (50 pM) 
was then added and the change in absorbance followed 
for at least 2 minutes.
The activity of palmitoyl-CoA oxidase was 
calculated by assuming the molar absorbance of 
NADH at 340 nm was 6.22 x 10^.
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2.6.3. ALPHA-GLYCEROPHOSPHATE DEHYDROGENASE.
This method is that of Lee and Lardy (1965).
Diaphorases catalyse the re-oxidation of 
NADH, which is produced by the oxidation of 
a-glycerophosphate when the cytochrome chain 
is blocked by KCN.
Reagents.
0.125 M phosphate buffer, pH 7.5.
10% (w/v) trichloroacetic acid (TCA).
96% ethanol.
0.125 M phosphate buffer, pH 7.5, containing 5 mM KCN. 
0.12 5 M phosphate buffer, pH 7.5, containing 5 mM KCN 
and 0.15 M sodium a-glycerophosphate.
0.05 M phosphate buffer, pH 7.5, containing 10 mg/ml 
INT (2-p-iodophenyl-3-p-nitrophenyl tetrazolium 
chloride) and 6.2 5 mg/ml PMS (phenazine methosulphate). 
Note: PMS is a possible carcinogen and the appropriate 
cautions must be taken when weighing out PMS.
KCN gives off toxic fumes which must be 
allowed to escape, into a fume cupboard, before 
weighing out KCN. Open the bottle containing 
KCN crystal in a fume cupboard, and leave with 
the lid off for several minutes before weighing 
out KCN. Wear a mask and gloves when weighing out 
KCN or PMS.
Method.
Samples of S.I. fracion of liver (see section 2.5.1) 
were mixed with 50 ul of 0.125 M phosphate buffer, 
pH 7.5, containing 5 mM KCN and 0.15 M sodium- 
a-glycerophosphate (test samples) or with 50 ]il of
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0.125 M phosphate buffer, pH 7.5, containing 
5 mM KCN (tissue blanks). These were incubated 
for 10 minutes at 37°C. 100 pi of freshly prepared 
solution of INT (4 mg/ml) and PMS (2.5 mg/ml) 
in 0.05 M phosphate buffer, pH 7.5, was added 
to each tube, samples and blanks. The total reaction 
volume was adjusted to 250 pi with addition of 
distilled water. These were then mixed and incubated 
for 15 minutes at 37°C. The reaction was stopped 
by the addition of 50 pi of 10% TCA and 2.5 ml 
of 96% ethanol. The samples were centrifuged 
to remove any precipitate and the extinction 
measured at 500 nm.
Results were expressed as AOD/min/ml of tissue.
Activity was calculated as follows:
Activity Etest Eblank x dilution factor 
time of incubation 
(minutes)
2.6.4. URICASE.
This method is due to Beaufay and co-workers (1959).
Uricase catalyses the reaction:
Uric acid + --- > allantoin + CO^
Uric acid absorbs at 292.5 nm whereas allantoin 
does not. Therefore, the rate of reaction can 
be determined by following the change in absorbance 
at 292.5 nm.
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Reagents.
5 mM phosphate buffer (Nal^PO^I^O), pH 7.4.
0.03 M phosphate buffer, pH 7.4, containing 
- 43.75 x 10 M sodium urate, and 0.3% triton X-100 (v/v).
(substrate solution) . . ....  :L;:V -~T
0.3% triton X-100 (v/v) in 0.03 M phosphate buffer, pH 7.4. 
0.83 mM phosphate buffer, pH 7.4.
Method.
All reagents were equilibrated to 37°C.
Aliquots of samples were placed in test tubes, 
labelled S (sample) and B (blank) and allowed 
to equilibrate for 5 minutes. The samples were 
diluted with 0.83 mM phosphate buffer, pH 7.4, 
to give a protein solution of approximately 
1 mg/ml homogenate protein. 1 ml of substrate 
solution was added to test tubes labelled S and 
1 ml of 0.03 M phosphate buffer, pH 7.4, containing 
0.3% triton X-100 (v/v) was added to those labelled 
B. The solutions were then transferred to silica 
cuvettes and the change in absorbance was followed 
at 292.5 nm for at least 4 minutes or until 
a fall of 0 . 2 absorbance units was observed.
Activity of uricase was calculated as follows:
Activity = & A292 5/m:*-nute x 3 pnioles uric acid
, 9 9 destroyed/minute.
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2.7. SUCCINATE DEHYDROGENASE.
This was measured as a marker of mitochondrial 
function, using a method based on that of 
Pennington (1961).
Succinate dehydrogenase is assayed using 
2-(p-iodophenyl)-3-(p-nitrophenyl)-5-phenyltetrazolium 
chloride (INT) as an acceptor. Following reduction 
of INT, red water-insoluble formazan is extracted 
into ethylacetate and read at 490 nm.
Reagents.
0.3 M sodium succinate, pH 7.4.
0.3 M sodium malonate, pH 7.4.
0.3 M sodium phosphate (Na2 HP0 ^1 2 H2 0 ) buffer, pH 7.4.
INT solution (1.5 mg/ml in 0.3 M sodium phosphate 
buffer, pH 7.4).
Ethyl acetate (A.R. grade).
6 % (w/v) trichloroacetic acid.
Method.
Glass test tubes (15 ml capacity) were set 
up as follows:
test: 0.5 ml liver homogenate.
0.25 ml INT in 0.3 M phosphate buffer, pH 7.4.
0.25 ml 0.3 M sodium succinate, pH 7.4.
blank:0.5 ml liver homogenate
0.25 ml INT in 0.3 M phosphate buffer, pH 7.4.
0.2 5 ml 0.3 M sodium malonate, pH 7.4.
The tubes were mixed on a Whirlymix (Fisons Ltd., UK.) 
and incubated at 37°C for between 5 and 20 minutes,
-102-
until a red colour was visible. The reactions 
were stopped by addition of 1.5 ml of 6 % TCA.
4 ml of ethyl acetate was added to each tube, 
tubes were covered and shaken to extract the
red colour into the ethyl acetate. The tubes were 
then centrifuged for 5 minutes at 1500 g. The 
upper layer was carefully transferred into a glass 
cuvette and the absorbance measured at 490 nm.
Activity was calculated as yMoles INT reduced,
3using the molar extinction coefficient of 20.1 x 10 .
2.8. g-GALACTOSIDASE.
This was measured as a marker of lysosomal 
activity, using the method of Hinton and Norris (1972).
The release of p-nitrophenol by $-galactosidase 
is estimated by an automated procedure.
Reagents.
5 mM p-NP $-galactosidase.
0.3 M acetate, pH 5.0, containing 0.2% triton X-100 (v/v). 
1 N NaOH.
p-Nitrophenol standard solutions were made to give a 
range from 1 lamole/ml to 5 lomole/ml.
Method.
The autoanalyser manifold flow diagram is 
shown in Figure 2.3.
Sampling time was 1 minute and wash (^O) 
time was 36 seconds. Transmission was recorded 
at 402 nm (Vivatron colorimeter). The standard 
curve was used to calculate the amount of 
lag p-nitrophenol released/min/mg homogenate protein.
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FIGURE 2.3.
Reagents Flow rate
(ml/min)
sample 0.32
SMC
0.3M acetate 0. 
+ 0.2% triton X100
air
DMC
5 mM pNP 
5-galatosidase
DMC
wash (HO)
Both 
coils 
37 °C
IN NaOH
DMC
repump Waste
colorimeter
4 2 0 nm
Autoanalyser flow diagram for manifold used in the estimation 
of B-galactosidase activity.
SMC = single mixing coil 
DMC = double mixing coil 
1— J = pulse suppressor
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2.9. MICROSOMAL ENZYMES.
2.9.1. CYTOCHROME P„rft.   4 ^ U—
This method is based on that of Omura and Sato (1964).
Sodium dithionite when added to a microsomal
suspension reduces the cytochrome P4 5 Q. The subsequent
gassing of the sample with CO results in a CO-complex
of reduced cytochrome P.rrk, which has a maximal
4 5 U
spectral absorption at 450 nm.
Reagents.
Carbon monoxide (British Oxygen Co., London, UK.).
6 6 mM Tris-HCl buffer, pH 7.4.
Sodium dithionite (B.D.H., Poole, Dorset, UK.).
Method.
Aliquots of microsomal suspensions were diluted 
to about 2 mg protein/ml with 6 6 mM Tris-HCl buffer, 
pH 7.4. A few crystals of sodium dithionite (Na2 S2 0 )^ 
were added, mixed and the solution divided equally 
between two cuvettes (test and reference) and 
scanned between 400 and 500 nm to establish a 
baseline. The test cuvette was then removed and 
the contents gassed with carbon monoxide (CO) 
for 30 seconds, and the sample rescanned.
The amount of cytochrome P^^q present in 
the sample was calculated using the peak absorbance at 450 nm 
minus the absorbance at 490 nm (baseline), and using the 
millimolar extinction coefficient of 91.
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2.9.2. CYTOCHROME Br.
----------------------------  U , _
This method is due to Omura and Sato (1964).
The addition of a source of reducing 
equivalent, NADH, to the contents of the sample 
cuvette containing a catalytic amount of NADH- 
cytochrome reductase results in reduction of 
cytochrome b^ with an associated change in spectra 
between 4 09 nm and 424 nm.
Reagents.
60 mM Tris-HCl buffer, pH 7.4.
11.5 mM NADH.
Method.
Microsomal suspensions were diluted to about 
1 mg protein/ml with 6 6 mM Tris-HCl buffer, pH 7.4. 
This was divided equally between two cuvettes 
and a baseline recorded between 4 00 nm and 
440 nm. NADH was added to the sample cuvette, 
to give a final concentration of 0.45 mM NADH.
The sample cuvette was replaced, and both sample 
and reference cuvettes rescanned between 400 nm 
and 440 nm.
The concentration of cytochrome b_ was
5
calculated by measuring the change in absorbance 
between 424 nm and 409 nm, using a milliMolar 
extinction coefficient of 185 mM/cm.
-106-
2.9.3. ETHOXYCOUMARIN O-DE-ETHYLASE.
This method is that of Ullrich and Weber (1972).
7-ethoxycoumarin is metabolised by hepatic 
microsomes to a single major fluorescent product,
7-hydroxy couinar in (umbelliferone ) . The rate of 
reaction may be measured by monitoring the linear 
increase in fluorescence with time.
Reagents.
6 6 mM Tris-HCl buffer, pH 7.4.
1.0 mM 7-Ethoxy couinar in substrate solution.
1.0 mM 7-hydroxycoumarin standard solution (stack).
0.05 mM 7-hydroxycoumarin standard (working).
6.2 mM NADPH solution.
Method.
The fluorimeter (Perkin-Elmer LS-5, Perkin 
Elmer Ltd., Beaconsfield, Bucks., UK.), and circulating 
water bath were set at 37°C, and the cuvette compartment 
allowed to equilibrate for at least 15 minutes.
The fluorimeter conditions were set as follows: 
excitation wavelength = 370 nm, emission wavelength 
= 4 5 0 nm.
1 0 0 pi of microsomal suspension (containing 
about 20 mg protein/ml), 250 lil of 7-ethoxycoumarin 
substrate solution and 2.15 ml of 6 6 mM Tris-HCl 
buffer, pH 7.4, were mixed together in a fluorescence 
cuvette, which was placed in the cuvette holder 
of the fluorimeter, and allowed to equilibrate 
at 37°C for 15 minutes. The baseline was then 
recorded on a chart recorder. Then 2 0 pi of NADPH
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was added to the cuvette, mixed and the increasing 
fluoresence monitored for at least 3 minutes.
A standard for each sample was prepared;
100 pi of microsomal suspension, 250 pi of 7-ethoxycoumarin 
substrate solution and 2.15 ml of 6 6 mM Tris-HCl 
buffer, pH 7.4,were mixed and allowed to equilibrate 
at 37°C. In place of NADPH successive aliquots - -
(typically 5 pi, 0.25 nmol) of the working 7-hydroxy- 
coumarin standard solution were added and the 
deflection monitored.
The activity of ethoxycoumarin O-de-ethylase 
was calculated as follows:
(1) The mean total deflection caused on the chart 
recorder by 1.0 nmol of added 7-hydroxycoumarin 
was measured.
(2) The deflection produced by test samples during 
a defined period of time was measured, and a value 
of deflection/minute calculated.
(2)= ethoxycoumarin O-de-ethylase activity.
(1 ) (nmol of product formed/incubate/min.).
If the microsomal protein content of the 
samples is known, enzyme activity can be calculated 
as nmol of product formed/mg microsomal protein/minute.
2.9.4. GLUCOSE-6 -PHOSPHATASE.
Glucose-6 -phosphate is metabolised by glucose-6 - 
phosphatase to yield glucose and inorganic phosphate.
The inorganic phosphate so released may be estimated
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by any standard procedure. This method for estimation 
of glucose-6 -phosphatase activity is based on 
Hinton et al (1970), as modified by Prospero and 
Hinton (1973).
Reagents.
0.3 M 3,3-dimethylglutaric acid buffer, pH 6 .5, 
containing 0.025 M EDTA and 0.03 Na(+)tartrate.
3.5 mM D-glucose-6 -phosphate, monosodium salt.
0.37 M trichloroacetic acid (TCA).
Method.
Liver homogenate (0.1 mg protein/ml),
3,3-dimethylglutaric acid buffer pH 6.5 (130 mM),
EDTA (10 mM) and sodium tartrate (13 mM)'were 
mixed in small test tubes on an ice bath. 
D-glucose-6 -phosphate (350 pM) was rapidly added 
to all these tubes which were incubated for 2 0 
minutes in a shaking water bath ( 1 2 0 cycles/min.).
A tissue blank was set up for each sample, 
in which substrate was replaced by distilled water, 
and reagent blanks were also set up in which distilled 
water replaced both tissue and substrate. The 
reaction was stopped by addition of ice-cold TCA 
(0.22 M) to all tubes, the temperature was maintained 
at 4°C for at least 15 minutes. Protein was centrifuged 
out (2000g for 5 minutes), and the inorganic phosphate 
of the supernatant was estimated by the method 
of Lowry and Lopez (1946), adapted to the auto­
analyser by Marzban and Hinton (1970).
The phosphate was estimated by reaction with 
ammonium molybdate followed by reduction of the
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resulting phosphomolybdate complex with ascorbic 
acid to yield 'molybdenum blue'. The absorbance 
of this complex was measured at 721 nm.
Estimation of inorganic phosphate using the autoanalyser. 
Reagents.
0 .6 % (w/v) ammonium molybdate containing 0 .5 % (w/v) 
perchloric acid.
0 .2 % (w/v) ascorbic acid.
4.0% (w/v) trichloroacetic acid (sample wash).
6 .0 % (w/v) trichloroacetic acid.
0.1 M potassium dihydrogen phosphate (stock solution). 
Method.
The autoanalyser flow diagram is shown in 
Figure 2.4.
Sampling time was 48 seconds, and wash time 
was 36 seconds.
Working standards of 0.25, 0.5, 0.75, 1.0,
1.5 and 2.0 pmoles/2.5 ml were prepared from the 
stock solution of 0.1 M potassium dihydrogen phosphate, 
by dilution initially to 2 . 0 ml followed by addition 
of 3 ml of trichloroacetic acid (6 %, w/v). The 
absorbance of the standards and samples was read 
at 721 nm, and the phosphate content of the samples 
was estimated from the standard curve.
The glucose-6 -phosphatase activity in the liver 
may be calculated as follows:
glucose-6 -phosphatase activity = (Exp-TB) - (SB-RB) x D 
(pmol/min/g liver) inc. time (min.) x 0.5
-110-
FIGURE 2.4.
Reagents Flow rate 
(ml/min)
6air
8
sample
DMCmolybdate 1.2
0.2%
ascorbate
0.42
Wash 
(4% TCA)
SMC
WasteRepump
one 
coil 
37 °C
colorimeter 
721 nm
Autoanalyser diagram for manifold used for the estimation 
of inorganic phosphate.
SMC = single mixing coil 
DMC = double mixing coil
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where: Exp is the amount of phosphate in the 
experimental tube (pmol).
TB is the amount of phosphate in the 
tissue blank (pmol).
SB is the amount of phosphate in the
substrate blank (|imol)  .......
RB isthe amount of phosphate in the 
reagent blank (pmol).
D is the dilution factor for the liver 
homogenate used in the assay.
2.9.5. LAURATE HYDROXYLASE.
This method is that of Prough et al (1978). The assay 
measures total hydroxylated products ( 1 1 and■1 2 -hydroxy- 
laurate), separated from the parent compound by chromatography.
Reagents.
140.5 mM [1- C]-lauric acid (500 pCi/mmol) in 
0.1 M Tris-HCl buffer, pH 7.5.
10 mM isocitric acid, >1600 U/l isocitrate dehydrogenase 
(porcine heart) and 2.0 mM NADP in 0.1 M Tris-HCl 
buffer, pH 7.5, containing 10 mM MgCl2.
1 0 % (v/v) H2 S0 4.
Method.
Tris-HCl buffer, pH 7.5 (75mM); [1-^C]- 
lauric acid (0.1 mM, 100 nCi/incubate), MgCl2 
(7 mM), isocitrate (5 mM), isocitrate dehydrogenase 
(>800 U/l) and NADP (1.0 mM) were mixed together 
in a Soverill test tube and preincubated for 3 
minutes at 37°C. Microsomal suspension (about 
0.75 mg protein/ml) was added in the final incubation 
volume of 2 . 0 ml and the reaction continued for
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a further 5 minutes. The reaction was terminated
by addition of E^SO^ (2 .8 6 % v/v) and the mixture
extracted 3 times with diethyl ether (3 x 5 ml).
The ether layers were combined and washed twice
with water (2 x 5 ml). After evaporation to dryness
the residue was taken up in 1 0 0 pi of methanol
and aliquots subjected to thin layer chromatography
on Silica Gel G-coated aluminium plates ( Merck
GmbH, Darmstadt, West Germany), developed in
hexane:ether:glacial acetic acid (70:28.5:1.5 v/v).
14The positions of unmetabolised [1- c]-lauric
acid and labelled hydroxyalted products were determined
by autoradiography. The relevant zones of the
plates were cut into small pieces, placed in counting
vials and 4.0 ml of Picofluor-36 (Packard Instruments
Co. Inc., Caversham, Berks., UK.) were added.
* 14In addition, 0.1 ml aliquots of [1- C]-lauric
acid were added to counting vials containing 4.0
ml of Picofluor-36. Counting was carried out
on a PL-Prias counter (Packard Instruments Co.
Inc., Caversham, Berks., UK.).
Blanks, in which no co-factors were present, 
were also taken through the procedure.
Laurate hydroxylase activity can be calculated 
as follows:
% recovery = total counts x 1 0 0  
input counts*
% metabolism = metabolite count x 1 0 0  
total count
activity = % metabolism x 2 0 0 nmoles laurate metabolised/ 
1 0 0 incubate
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If the protein concentration of each sample 
is known then the results can be expressed as 
nmoles laurate metabolised/mg protein.
2.10. SERUM PARAMETERS.
2.10.1. TOTAL CHOLESTEROL.
This method is an adaptation of the method 
for total cholesterol determination from Henry 
(1974), in which both free and esterified cholesterol 
react with a combined reagent of ethyl- acetate, 
sulphuric acid and ferric perchlorate. The resultant 
purple colour is measured photometrically at 610 
nm.
Reagents.
(concentrated).
Ethyl acetate.
Ferric perchlorate.
Cholesterol reagent: 52 0 mg of ferric perchlorate 
were dissolved in 600 ml of ethylacetate, to which 
4 00 ml of concentrated H^SO^ was added. Note: it 
is essential to carry out this procedure in a 
fume cupboard. The sulphuric acid must be added 
in small amounts to the ethylacetate and ferric 
perchlorate solution, which should be kept on 
ice. The reaction temperature should be carefully 
monitored, and not allowed to go over 40°C. 
Cholesterol standard: 200 mg cholesterol/100 ml 
of glacial acetic acid.
Method.
5.0 ml of cholesterol reagent was added to
test tubes, to which either 50 \il of cholesterol 
standard or 50 pi of test serum or plasma (or 
nothing for blanks) was added, mixed thoroughly, 
and placed in a boiling water bath for exactly
1.5. minutes and then immersed in tap water (20°C 
or cooler) for 5 minutes. The contents of the 
tubes were then mixed by inversion and the absorbances 
of test (A^ ) and standard (Ag) samples read against the 
blank at 610 nm.
The amount of' cholesterol was calculated 
as follows:
mg cholesterol/ 1 0 0  ml of serum = (At) x 0 . 1 x 1 0 0
2.10.2. TRIGLYCERIDE.
This was estimated using a kit for triglycerides 
(Boehringer Mannheim, Cat. no. 126012. Triglycerides 
fully enzymatic (Neutral fat)) (Boehringer Mannheim 
GmbH Diagnostica, Lewes, East Sussex, UK.).
This method is an enzymatic triglyceride 
assay, rather than a colorimetric assay, after 
enzymatic hydrolysis. The test principle is as 
follows:
0.05
triglycerides lipase/esterase } glycerol and fatty acids
glycerol + ATP GK ■^glycerol-3-phosphate + ADP
ADP+PEP PK ■^pyruvate + ATP
pyruvate + NADH + H.+ LDH *L-lactate + NAD
+
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Reagents: as provided in the kit.
2.10
Method: can be followed from Method in the kit.
The absorbance of the test samples is measured 
at 340 nm, against an air or distilled water blank, 
and the amount of triglyceride determined by the 
following calculation:
AA x 711 = mg triglyceride/100 ml serum
where A A = AOT3 - A , ASB sample RB
where A = absorbance of the sample blank.
oi3
A = absorbance of the reagent blank.
K13
A n = absorbance of the sample, sample c
Note: The results obtained (see section 3.24 
showed very considerable variation between samples. 
The cause of this variation was investigated by 
a colleague (Connelly, J., Unpublished results).
It was found that the kit used, although reliable 
with human serum, was not suitable for use with 
rat serum, and is not recommended to anyone reading 
this thesis.
,3. CROSSED IMMUNOELECTROPHORESIS.
This method is based on that of Axelsen and 
co-workers (1973).
Crossed immunoelectrophoresis combines electrophoretic 
separation of proteins in an agarose gel with 
a subsequent antibody-antigen reaction performed 
in a second dimension electrophoretically. This 
technique allows the detection of substances of
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similar electrophoretic mobility by specific 
precipitation reactions between antigen and homologous 
antibodies. The technique is of prime importance 
in detecting antigens in complex physiological 
mixtures e.g. antigens of the immunoglobulins.
The constituents of a protein mixture can be defined 
by both their electrophoretic mobilities and their antigen 
specificities. :: -
Reagents.
Barbitone-acetate buffer, pH 8 .6 :
11.3 g diethylbarbituric acid.
8 8 . 8 g diethylbarbiturate sodium 
65 g sodium acetate.
Tank buffer: 3 litres of barbitone-acetate buffer 
were diluted with 2 litres of distilled 'water, 
and added equally to each side of the tank.
1% Agarose in barbitone-acetate (Agarose A37,
Indubiose Pharmindustrie, Clichy, France).
Bromophenol blue: a small spatula tip of dye was 
dissolved in 1 0 0 ml of distilled water.
Coomassie Brilliant Blue stain: 450 ml of 96% 
ethanol, 450 ml of distilled water, 100 ml of 
glacial acetic acid were added together, to which 
5 g of Coomassie Brilliant Blue R was added, mixed, 
and left to stand overnight, and then filtered.
Destainer: 450 ml of industrial methylated spirit (or 
96% ethanol) was mixed with 450 ml of distilled water 
and 1 0 0 ml of glacial acetic acid.
0.9% (w/v) NaCl.
Anti-rat sera was obtained from Dako-Immunoglobulins, 
Mercia-Brocades, West Byfleet, Surrey, UK. It was 
rabbit to rat anti-serum.
dissolved in 1 0 litres 
of distilled water.
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Method.
The electrophoresis tank was filled with tank 
buffer and.the plates prepared. 10 ml of hot agarose (1% 
w/v) was spread evenly over each plate and allowed 
to set. Holes were cut 1.5 cm from each of the 
lower corners of the plate as shown below.
serum- bromophenol blue 
The plates were placed in the tanks and the 
tank set up:
cooling  --- —
platten Y"~
electrode — "
__ ___ —  -electrophoresis plate 
<r-------- wicks
buffer
electrode
The cooling water was turned on. Once the 
plates were in postition in the tank one drop of 
bromophenol blue was added to the right-hand well 
of each plate, and 1 vil of serum to the left well.
The lid was placed on the tank, and the leads from 
the power pack connected so that the samples were 
close to the negative electrode. The power pack 
was switched on to give 200 V per plate. Electrophoresis 
continued until the bromophenol tracker dye reached 
the far end of the plate, then the plates were 
removed (N.B. having switched off the power pack) 
and the gel removed as shown below:
cut here
sample well"
o
■n? 0
-bromophenol blue spot 
 scrape off all this agarose
i-bromophenol blue well
0.5 cm
Anti-serum was pipetted into a test tube warmed 
to 50°C. Sufficient agarose solution was added 
to make up the volume to 1 0 ml, mixed by inversion, 
poured onto the plate and allowed to set. The plate 
was placed in the tank so that the sample strip 
was next to the negative electrode, the plate was 
then connected to the tank with clean wicks. The 
power pack was switched on and adjusted to give 
a constant voltage of 45 Volts. Electrophoresis 
was continued for at least 16 hours. The plates 
were then removed (N.B. having switched off the 
power pack), washed in 0.9% NaCl solution, pressed 
and subsequently stained with Coomassie Brilliant 
Blue stain.
2.10.4. SEPARATION OF SERUM LIPOPROTEINS (VLDL, LDL 
& HDL), BY ELECTROPHORESIS IN AGAROSE GEL.
This method is based on that of Axelsen and 
co-workers (1973).
The degree of separation of macromolecules in 
gelc- electrophoresis depends upon their charge 
and their size relative to the pore size in the 
gel. Separation can be optimised by changing the 
pH of the electrophoresis buffer.
Reagents.
These are the same as those described for crossed 
immunoelectrophoresis (see section 2 .1 0 .3. ), in 
addition to which a saturated solution of Sudan 
Black B stain in 60% alcohol is required.
1 0 % (v/v) acetic acid.
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Method.
Plates were prepared by cutting 4 slots, 1 mm 
wide, 2.5 cm from the edge of the plate and equally 
spaced across the plate. 25 \il of serum was placed 
into each slot. The electrophoresis tanks were set up 
as described in 2.10.3. The plates were run for 45 
minutes at 150 V. After the first 15 minutes the 
apparatus was switched off, the slits were filled 
with molten agar, and the apparatus switched on 
again. At the end of the run the plates were placed 
in 10% (v/v) acetic acid solution (15 minutes) to 
fix the proteins. The plates were washed in distilled 
water (15 minutes) and then pressed, dried, and 
stained in a saturated solution of Sudan Black B 
stain in 60% (v/v) alcohol (10 minutes). Unbound 
stain was removed by washing in 50% (v/v) alcohol 
(30 minutes)
2.11. MEASUREMENTS IN BILE.
2.11.1. BILIRUBIN.
Bilirubin (total and direct) in bile was measured 
at 600 nm, using a Sigma kit (Cat. no. 605 (colorimetric)). 
(Sigma Chemical Co. Ltd., Poole, Dorset, UK.).
Direct (conjugated) bilirubin couples with 
sulphanilic acid (p-diazobenzene sulphonic acid) 
forming a blue colour at alkaline pH. Indirect 
(unconjugated) bilirubin is diazolised only in 
the presence of an "accelerating" agent, caffeine- 
benzoate-acetate mixture. Thus, the blue azobilirubin 
produced in the mixtures containing the "accelerating" 
agent contains both direct and indirect fractions 
and reflects the total bilirubin concentration.The
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final colour is measured at 600 nm and the final 
bilirubin concentration is calculated using the 
azobilirubin molar extinction coefficient.
2.11
Reagents: As provided in the Sigma kit.
Method: This is clearly set out in the instructions 
of the Sigma kit.
Serum TOTAL or DIRECT Bilrubin (mg/100 ml) 
was calculated as follows:
A x5 8 4 x 3 , 3 X--5QQ = A x 13.2
73,000
Where:
A = Absorbance of test.
584 = molecular weight of bilirubin.
3.3 = reaction mixture (ml).
500 = conversion of volume of serum used to 100 ml
73,000 = molar extinction coefficient of alkaline 
azobilirubin at 600 nm.
2. GAMMA-GLUTAMYL TRANSPEPTIDASE (yGT).
This was measured using either the method of 
Rosalki and co-workers (1972) or using Sigma kit 
no. 416 (kinetic colorimetric).
yGT catalyses the transfer of the glutamyl 
group from L-glutamyl-p-nitroanilide to glycylglycine 
as follows:
vGTL-Y-glutamyl-p-mtroanilide + glyclglycine — L-——  ^
p-nitroaniline + glutamylglycylglycine.
The rate of p-nitroaniline formation measured
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at 405 nm is proportional to yGT activity.
As there was no difference in the results between 
the two methods and the use of the kit is faster 
and easier than the manual method, the method employing 
Sigma kit no. 416 was used.
Reagents: As provided in Sigma kit no. 416.
Method: This is clearly set out in the kit.
The calculation of yGT activity is explained 
in the kit.
j
2.11.3. LACTATE DEHYDROGENASE.
This was carried out using the method of Bergmeyer 
and Bernt, 1974, as described in section 2.12.8, 
except that 16.7 \il of bile was used in place of 
medium or cell supernatant.
2.11.4. 51 NUCLEOTIDASE.
This method is due to Hinton and co-workers, 1970, 
as modified by Prospero et al, 1973.
Adenosine 5'monophosphate is broken down to give 
adenosine and phosphate, by 5'nucleotidase. The 
inorganic phosphate so released is estimated by a 
standard procedure (see 2.9.4). Non-specific phosphatases 
active against adenosine monophosphate may contribute
to the activity observed. 5 1 nucleotidase depends
. . .  2+.for its activity on the presence of Mg ions.
Na(+)tartrate is included to help reduce the attack 
of non-specific phosphatases.
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Reagents.
0.4 M Tris-HCl buffer, pH 7.7, containing 12.5 mM 
MgC^-G^O and 25 mM Na ( + ) tartrate.
0.05 M Adenosine 5'-monphosphate (substrate).
6 % (v/v) trichloroacetic acid (TCA).
Inhibitory anti-serum. (This is prepared by immunising 
rabbits with rat liver plasma membrane, or purified 
liver or rat bile, or biliary 5'-nucleotidase and 
separating a globulin fraction from the serum).
Method.
Experimental tubes were set up as follows:
A) 0.4 ml tissue, 0.1 ml 'antiserum, 0.4 ml buffer, 0.1 ml substrate
B)0.4 ml tissue, 0.1 ml water, 0.4 ml buffer, 0.1 ml substrate.
C)0.4 ml water, 0.1 ml antiserum, 0.4 ml buffer, 0.1 mlsubstrate.
D)0.4 ml water, 0.1 ml antiserum, 0.4 ml buffer,0.1ml substrate.
E)0.4 ml tissue, 0.2 ml water, 0.4ml buffer.
F)0.5 ml water, 0.4 ml buffer, 0.1 ml substrate.
G)0.6 ml water, 0.4 ml buffer.
H)0.4 ml tissue, 0.1 ml antiserum, 0.4 ml buffer, 0.1 ml water.
' The test tubes were placed in a rack in an ice-bath.
0.4 ml of tissue (suitably diluted) was added to the 
appropriate tubes, 0.4 ml buffer was added. All tubes 
were mixed. 0 . 1 ml substrate solution was added to the 
appropriate tubes, which were mixed well, and then 
incubated at 37°C for between 20 minutes and 2 hours.
The reaction was stopped by addition of 1.5 ml of 
6 % (v/v) TCA solution. The samples were cooled to 
4°C, and maintained at 4°C for at least 15 minutes.
They were then centrifuged at 2000 r.p.m. for 5 
minutes. The released phosphate was then estimated, 
as described in 2.9.4.
Dorset, UK.), which was added to control cultures also.
The cells were examined for any signs of toxicity- 
such as, blebbing, rounding up and detachment from the 
flasks.
2.12.2. HOMOGENISATION, PROTEIN AND D.N.A. ESTIMATION.
2.12.2.i. HOMOGENISATION OF CULTURED HEPATOCYTES.
At the end of the treatment period, the flasks 
were placed on ice and the culture medium removed.
The flasks were then washed twice with 1 ml of ice- 
cold S.E.T. buffer, pH 7.4, and then scraped with a 
rubber policeman into 1 ml of S.E.T. buffer, pH 7.4.
The cells were either homogenised with the use of 
a hand homogeniser (7 return strokes) or by sonication 
(2 x 10 seconds) (Ultrasonics Ltd., Dawe Instruments Ltd., 
Shipley, West Yorks., UK.).
S.E.T. buffer: 0.25 M sucrose containing 5 mM EDTA 
and 5 mM Tris. The pH was adjusted to 7.4.
2.12.2!ii. PROTEIN ESTIMATION.
Protein in whole hepatocyte homogenate was estimated 
by the method of Lowry and his co-workers, 1951.
Reagents.
0.05 M NaOH.
. 2% (w/v) Na2 C03 in 0.05 M NaOH.T 
1 % (w/v) potassium tartrate 7 
5% (w/v) CuS04 .5H2 0. J
These are the constituents of the "Lowry buffer", 
the solution should be made up on the day of use, 
in a ratio of 1 0 0 :1 :1 , of the above solutions, respectively. 
Folin-Ciocalteu reagent (Fisons Scientific Apparatus,
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Loughborough, Leics., UK.), diluted 1 in 4 on the 
day of use.
500 pg Bovine Serum Albumin/ ml (Stock solution).
Method.
30 nl of sample was added to duplicate test tubes, 
to which 470 pil of 0.05 M NaOH solution was added.
0.5 ml blank and standards (25, 50, 100, 150, 200 and 
250 pg B.S.A./ml) were added to tubes in duplicate.
5 ml of "Lowry buffer" was added to each test tube, 
mixed immediately and allowed to stand for 15 minutes, 
at room temperature. 0.5 ml of Folin-Ciocalteu1s (diluted) 
reagent was added to each tube, mixed immediately 
and allowed to stand for at least 30 minutes, after 
which time the absorbance, at 700 nm, was read against 
distilled water. The absorbance must be read within 
2 hours, at the most, of adding the Folin-Ciocalteu1s 
reagent, as after this time the colour begins to fade.
The use of the standard curve allows the amount of 
protein present in each sample to be calculated 
as mg protein/ml.
2.12.2.iii. DNA ESTIMATION.
This was estimated by the same procedure as 
that described in Section 2.5.3., except that initially 
0.3 ml of cell homogenate was precipitated with 0.3 ml 
of ice-cold 1 0 % (v/v) perchloric acid.
2.12.3. PEROXISOMAL ENZYMES.
Cyanide-insensitive palmitoyl-CoA oxidase and 
a-glycerophosphate dehydrogenase activities were 
assayed using hepatocyte homogenate as described in 
Sections 2.6.2. and 2.6.3. respectively.
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2.12.4. "GLUTATHIONE" ASSAY.
This method is due to Saville (1958), and it 
determines the amount of non-protein thiols.
Thiols and other molecules possessing -SH groups 
are converted to their S-nitroso derivatives which 
yield an equivalent of nitrous acid on mercuric ion- 
assisted hydrolysis. This nitrous acid is finally used 
in the formation of a brilliant azo dye from sulphanilamide 
and N-l-naphthylethylenediamine, the optical density of 
which is read at 546 nm.
Reagents.
Solution A: 1 volume of 0.01 M NaNC>2 and 9 volumes of 
0.3 M H2 S04.
Solution B: 0.5% (v/v) ammonium sulphamate (aqueous)
Solution C: 1 volume of 1% (v/v) HgCl2 (aqueous) and 
4 volumes of 3.4% (w/v) sulphanilamide 
in 0.4 M HC1.
Solution D: 0.1% (w/v) N-1-naphthylethylenediamine-HCl 
(NNED) in 0.4 M HC1.
GSH standard solution: 100 pig GSH/ml in 6.5% (w/v) 
trichloroacetic acid solution (TCA).
6.5% (w/v) TCA solution.
Method.
The medium was removed from the flasks, and the cells 
were washed 3 times with PBS'A' solution (Flow Laboratories, 
Irvine, Scotland, UK.). 0.5 ml of 6.5% (w/v) TCA was 
added into the flasks, the cells were scraped from the 
flasks with a rubber policeman, and the TCA solution 
and the cells placed in a centrifuge tube. A further 
0.5 ml of 6.5% (w/v) TCA was added and the remaining
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cells scraped off and added to the centrifuge tube.
After allowing the samples to stand for at least 
15 minutes, the samples were centrifuged at 1000 g 
for 20 minutes. The assay was set up using 0.1 ml 
6.5% TCA for the blanks, 0.1 ml of supernatant for 
the samples and 0.1 ml of 10, 20, 30, 40 and 50 ug/ml 
GSH standards for a standard curve. To each of these 0.5 ml 
of solution A was added, followed by mixing and incubation 
at room temperature for 5 minutes, then 0.2 ml of 
solution B was added, mixed and incubated for 5 minutes.
1.0 ml of solution C and 0.8 ml of solution .D: were added, 
mixed and incubated for 10 minutes. The optical density 
of the samples was read at 546 nm.
Calculation of the concentration of glutathione 
in the samples was carried out as follows:
From the standard curve the concentration of 
glutathione (as vig/ml) in the samples can be calculated. 
Multiplication by 3.26 converts this to the concentration 
of glutathione in nmoles/ml. If the protein concentration 
of the samples is known (mg protein/ml) glutathione 
concentration can be calculated as nmoles of GSH/mg protein.
2.12.5. GLUTATHIONE PEROXIDASE.
This method is that of Thompson and co-workers 
(1982).
Glutathione peroxidase catalyses the following reaction:
ROOHj GSH »NADP
^Glutathione ^^Glutathione 
( peroxidase ^/reductase
H2OVN .^— ^GSSG —  ^-NADPH
The activity of glutathione peroxidase is determined
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by following the rate of NADPH oxidation, at 340 nm, 
with t-butylhydroperoxide as a substrate, in the 
presence of glutathione reductase and sodium azide.
Sodium azide is added in order to inhibit catalase 
activity.
Reagents.
20 mM phosphate buffer, containing 6 mM EDTA, pH 7.3.
20 mM phosphate buffer, containing 6 mM EDTA, 2 pmoles
GSH, 0.5 units GSH reductase (Sigma Chemical Co.,
Poole, Dorset, UK.), 1 pmol NaN^ and 0.1 pmol NADPH, pH 7.3. 
30 mM t-butylhydroperoxide (Koch Light and Co., Slough, 
Berks., England.
Method.
An aliquot of 0.5 ml cell homogenate was added to 
a cuvette containing 0.9 ml of 2 0 mM phosphate buffer, 
containing 6 mM EDTA, 2 pmol GSH, 0.5 units GSH reductase,
1 ]imol NaN^, and 0.1 pinole NADPH, pH 7.3. This was mixed
by inversion and incubated for 10 to 15 minutes at 25°C.
The reaction was started by addition of 10 pi of 30 mM
t-butylhydroperoxide. After mixing the reaction was 
followed for 4 minutes, at 340 nm.
The linear rate of NADPH oxidation, between 2 and
4 minutes of the reaction time, was calculated, assuming
6a molar extinction coefficient of 6 . 2 2 x 1 0 , from 
which the rate of non-enzymic oxidation of NADPH was 
subtracted.
1 enzyme unit of activity is equivalent to 
1 pmol NADPH oxidised/minute. The results may be expressed 
as Units/mg protein, if the protein values are known.
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2.12.6. HYDROGEN PEROXIDE.
This method is due to Hildebrant and co-workers (1973).
It is a. chemical assay of H^O^ production, and
depends on the formation of Fe(SCN)^ from ammonium
ferrous sulphate and potassium thiocyanate (KSCN)
2+ 3+upon the oxidation of Fe to Fe . An intense colour 
develops that can be measured at 480 nm.
Reagents.
5 % (w/v) trichloroacetic acid.
0.08 M sodium azide.
10 mM ammonium ferrous sulphate.
2.5 M KSCN.
34 pM H202.
6 6 mM Tris-HCl buffer, pH 7.4.
Method.
Cell homogenates were prepared in 2 ml of 6 6 mM 
Tris-HCl buffer, pH 7.4. A 0.5 ml aliquot of cell 
homogenate was added to 1.0 ml of 5% TCA solution,
1.25 pi of 0.08 M sodium azide was also added. For blanks 
0.5 ml of 6 6 mM Tris-HCl buffer, pH 7.4, was added in 
place of the cell homogenates, and for the standard 
in addition to the 0.5 ml of buffer, 1 yl of 34 pM 
H2°2 WaS ac^ ec^ * T^e samples were centrifuged for 5 
minutes at 1,000 g. A 1 ml aliquot of supernatant 
was taken into a clean test, tube, to which 0 . 1 ml of 
10 mM ammonium ferrous sulphate was added, and 
exactly 2 minutes later, 0.05 ml of 2.5 M KSCN was 
added. The absorbance was read after 10 minutes, at 
480 nm.
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The concenctration of in each sample was
calculated by comparison with the standard (pmoles/ml). 
If the protein concentration of the sample is known 
then the results can be expressed as pmoles of H2 C>2 
produced/mg protein.
2.12.7. GLUCOSE-6 -PHOSPHATASE.
This method is based on that of Nordlie and 
Arion (1966).
Glucose-6 -phosphatase catalyses the reaction
Glucose-6 -phosphate + H2 0— >glucose + P^ .
The inorganic phosphate so released may be 
estimated by any standard procedure.
Reagents.
0.2 M Tris-Maleate buffer, pH 6.5.
0.2 M NaOH, this is used to adjust the pH of the 
Tris-Maleate buffer to pH 6.7.
10% (w/v) trichloroacetic acid (TCA).
Phosphate standard, 3.23 x 10  ^M KH2 PO^.
Method.
Cell homogenates were prepared using the method 
described in Section 2.12.2., except that the homogenate 
was finally resuspended in 3 ml of Tris-Maleate buffer, 
pH 6.7. The assay was set up so that sample tubes 
contained 0.5 ml of cell homogenate, 0.2 ml distilled 
water, 0.6 ml of Tris-Maleate buffer, pH 6.7, and 
0 . 2 ml glucose-6 -phosphate, and tissue blanks contained
0.5 ml of cell homogenate, 0.8 ml of Tris-Maleate 
buffer, pH 6.7 and 0.2 ml of distilled water. All 
the tubes were mixed, and incubated at 37°C, for 30 
minutes, after which time the reaction was stopped 
by the addition of 1 ml of 10% TCA. The tubes were 
placed in an ice-tray, to lower the temperature to 
4°C, and maintained at this temperature for at least 
15 minutes. The samples can be frozen at this point 
and the assay for inorganic phosphate carried out at 
a later time. Inorganic phosphate may be assayed as 
described in Section 2.9.4.
The activity of glucose-6 -phosphatase was 
calculated for each sample, by comparison with the 
phosphate standard, and as the protein concentration 
of the samples was known, activity-was expressed 
nmoles phosphate produced/mg protein/minute.
2.12.8. LACTATE DEHYDROGENASE.
This method is that of Bergmeyer (1974).
Pyruvate + NADH + H+ —  LDH ^ Lactate + _NAD+.
The equilibrium is far on the side of lactate 
and NAD+. The lactate dehydrogenase activity is 
indicated by the rate of oxidation of NADH. The change 
in extinction at 340 nm is measured.
Reagents.
50 mM phosphate buffer, pH 7.5, containing 0.63 mM pyruvate.
11.3 mM 3-NADH.
0.9% (w/v) NaCl solution, containing 0.1% (v/v) triton X-100 
and 0.1% (w/v) bovine serum albumin (B.S.A.).
PBS'A' solution (Flow Laboratories, Irvine, Scotland, UK.).
Method.
At the termination of the experiment the medium 
was removed from the Falcon flasks, and the cells were 
washed 3 times with PBS'A' solution. Cells were harvested 
into 4 mis of 0.9% NaCl solution, containing 0.1% 
triton X-100 and 0.1% B.S.A., and incubated, at room 
temperature, for 10 minutes. The cells were then 
centrifuged at 3,500 r.p.m. (Digifuge, V. A. Howe 
and Co. Ltd., London, UK.) for 15 minutes, and the 
supernatant kept. The lactate dehydrogenase activity 
was assayed by the addition of 16.7 pi of medium or 
of cell supernatant (diluted 1 in 4 with buffer) to 
a cuvette containing 1 ml 50 mM phosphate buffer, 
pH 7.5, containing 0.63 mM pyruvate. The reaction was 
started by the addition of 16.7 ]il of 11.3 mM 3-NADH.
The change in extinction at 340 nm was measured.
The activity (units/litre) was calculated as follows:
(AE/minute - blanks) x total reaction volume x dilution factor 
volume of diluted sample x extinction coefficient of NADH
assuming a molar extinction coefficient of NADH, at pH 7.5 
is .
% leakage into the medium was calculated as
% leakage = activity in medium_____  '_____ x 100
activity in medium + activity in cells
2.12.9. MEASUREMENT OF FATTY ACID UTILISATION IN ISOLATED 
HEPATOCYTES.
This method is based on that of Capuzzi and co­
workers (1983).
- 1 3 3 - y
Primary isolates of hepatocytes are incubated in
the presence of radiolabelled fatty acid; labelled lipids
are then isolated by extraction, and counted to give
a measure of the utilisation of lipid. Fatty acid
oxidation is measured by incubating primary isolates
of hepatocytes in the presence of labelled lipid and
14measuring the production of CC>2 •
Reagents.
14[1- C] palmitic acid (specific activity 58.2 mCi/mmole) 
(Amersham Intl. Ltd., Amersham, Bucks, UK.).
Fraction V fatty acid poor bovine serum albumin (B.S.A.) 
(Sigma Chemical Co., Poole, Dorset, UK.).
140.22 mM [1- C] palmitate-(BSA) (5% w/v) in 0.9% NaCl
solution. Note: it is important to warm 0.9% NaCl
solution, then add BSA (5% w/v), and when this has
14dissolved add 0.22 mM [1- C] palmitic acid.
1.0 mM palmitic acid-BSA (5% w/v) in 0.9% NaCl solution, 
this should be prepared in the order described above.
HCO^ -free Hanks solution, pH 7.4, containing 1.25 mM CaCl^• 
Isopropanol:heptane solution (4:1 v/v).
50% et.hanolic NaOH solution.
Method.
Male Wistar Albino rats, weighing between 2 00
and 250 g, of the University of Surrey strain were
used in these experiments. In some cases these animals
were starved for 18 to 24 hours prior to isolation of
hepatocytes. Hepatocytes were isolated as described
in Section 2.4. and resuspended in HCO^-free Hanks
solution, pH 7.4, containing 1.25 mM CaCl0, at a
6density of 2 x 10 cells/ml. Dispersed hepatocytes 
were incubated at 37°C, under air, in 50 ml
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Erlenmeyer flasks, in a shaking water bath.
Triplicate aliquots of hepatocytes were incubated 
with various levels of MEHP, MnOP, MnHP (0-0.25 mM) 
or with 1.0 mM clofibrate (acting as a positive control) 
for 30 minutes at 37°C, in a shaking water bath. Then 
50 pi of 0.22 mM[l-^^C] palmitate-BSA (5% w/v) was 
added and 100 pi of -1.0 mM palmitate-BSA (5% w/v) 
was also added, and the hepatocytes incubated for a 
further 30 minutes at 37°C, in a shaking water bath.
The reaction was stopped by placing the flasks on 
crushed ice.
Isolation of labelled lipid.
The contents of each flask were individually 
transferred to 12 ml conical centrifuge tubes, and 
centrifuged at 100 g for 1 minute (Beckman TJ-6, 
Beckman-Riic Ltd., High Wycombe, Bucks., UK.). The 
supernatant was removed and kept for assessing export 
of fatty acids. The cell pellets were vigourously 
shaken, by whirlimixing, with 5 ml of isopropanol:heptane 
(4:1 v/v). After separation into 2 layers by the addition 
of 3 ml of heptane and 2 ml of distilled water, the 
upper phase was transferred to clean test tubes and washed 
twice with 50% ethanolic NaOH solution. The neutral 
lipids, mainly triglycerides and cholesterol esters, 
were recovered in the upper phase. Samples of the 
upper phase were transferred to glass scintillation 
vials and dried under nitrogen. Once dried, 4 ml of 
Picofluor-36 (Packard Instruments Co. Inc., Caversham, 
Berks., UK.) was added to each vial and counted on a 
Prias-PL counter (Packard Instruments Co. Inc.).
Export of fatty acids was assayed by taking 
2 ml of the supernatant (as described above) to which
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2 ml of normal human plasma was added as a carrier, these 
were mixed, and centrifuged at 35,000 r.p.m. (Prepspin 50, 
M.S.E., Crawley, Surrey, UK.) for more than 15 hours.
A 1 ml aliquot of chylomicrons was taken and added to 
4 ml of Picofluor-36, in glass scintillation vials, 
mixed and counted on a Prias PL counter.
. 14
Isolation of CO^.
For studies of fatty acid oxidation, 10 ml
Erlenmeyer flasks with centre wells containing filter
paper soaked in a CC^ trapping agent, 100 ul of
ethanolamine:ethylene glycol monoethyl ether:toluene
(1:8:10);. After pre-incubation of 1 ml aliquots of cell
suspensions, in triplicate, with the test compound for
1430 minutes and incubation with [1- C]-palmitate-BSA
for 30 minutes, at 37°C, in a shaking water bath, 0.25 ml
of 12% (v/v) perchloric acid was added, in order to 
14release the C09 from cell suspensions. The liberated 
14CC>2 was trapped during a subsequent 30 minute incubation 
at 37°C, in a shaking water bath. The filter papers 
were then removed and placed in 4 ml of Picofluor-36 
(Packard Instruments Co. Inc.) in plastic scintillation 
vials and counted on a Prias PL counter (Packard Instruments 
Co. Inc., Caversham, Berks., UK.).
2.13. HISTOLOGICAL PROCEDURES■
2.13.1. PREPARATION OF SAMPLES.
This method is taken from that of Culling, 1974.
Pieces of tissue taken at post-mortem were placed 
in 10% neutral buffered formalin (N.B.F.), and allowed 
to remain in fixative for at least 2 weeks. Tissue for 
haematoxylin and eosin staining or periodic-acid-Schiff
treatment was dehydrated in increasing concentrations 
of ethanol, cleared in toluene and impregnated with 
paraffin wax. Sections (7 urn in thickness) were cut, 
taken onto glass slides, and allowed to dry at 37°C.
2.13.2. STAINING WITH HAEMATOXYLIN AND EOSIN.
Sections were brought to water, stained in Ehrlich1s 
acid Haematoxylin (15 minutes) and blued in tap water 
(5 minutes). Following differentiation with acid alcohol 
(5 seconds), they were returned to tap water and counter­
stained with 1% (v/v) aqueous eosin (2. minutes). The 
sections were rinsed in tap water (30 seconds), dehydrated 
in 85% (v/v) ethanol (30 seconds) and 100% ethanol 
(2 x 30 seconds), cleared in xylene and mounted in D.P.X. 
(British Drug Houses Ltd., Poole, Dorset, UK.).
2.13.3. PERIODIC ACID-SCHIFF (PAS) STAIN FOR GLYCOGEN.
This method is due to Culling, 1974.
The sections were brought to water and oxidised in 
1% (v/v) aqueous periodic acid (5 to 10 minutes). After 
washing in tap water (5 minutes) and rinsing in distilled 
water, sections were treated with Schiff reagent (10 to 
30 minutes), washed again in tap water (10 minutes), 
dehydrated in 100% ethanol twice (30 seconds), cleared 
in xylene twice (2 x 30 seconds) and mounted in D.P.X. 
PAS-positive substances stain red.
Further sections were treated with diastase, and 
were stained to check for the specificity of the reaction 
for glycogen. PAS-positive substances stain bright pink, 
whilst other tissue constituents are clear.
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2.13.4 OIL RED 'O' STAIN FOR LIPIDS.
This method is after Culling,. 1974.
Reagents.
Stock Oil Red 'O', 0.5% (w/v) in isopropanol.
Diluted Oil Red 'O' for use: stock O.R.O. (6 ml added to 
distilled water (4 ml), allowed to stand for 10 minutes 
and then filtered).
Method.
Tissue dehydrated, cleared and embedded in paraffin 
wax in the normal manner cannot be used, since the organic 
solvents employed remove lipids. Accordingly, blocks of 
liver fixed in neutral buffered formalin were frozen 
and sections were cut (7 yin in thickness) on a freezing 
microtome. The sections were washed in water and placed 
in the diluted O.R.O. solution for 10 to 15 minutes.
After differentiation in 60% (v/v) ethanol, the sections 
were washed in water, counter-stained with Harris's 
haematoxylin, blued in tap water and mounted in glycerin 
jelly. Lipids stain bright red and nuclei blue.
For staining of cultured hepatocytes, the medium was 
removed and the flasks washed, three times, with PBS'A1 
buffer (Flow Laboratories, Irvine, Scotland, UK.). The 
hepatocytes were fixed in neutral buffered formalin, for 
at least 10 minutes, after which time the method described 
above was followed- the solutions being poured into the 
flasks.
2.13.5. ELECTRON MICROSCOPY.
Samples for examination by the electron microscope
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were prepared using a method which has become standard 
at the Robens Institute ( Price, 1984).
Reagents.
Glutaraldehyde (E.M. Grade).
0.2 M cacodylate buffer, pH 7.4.
Osmic acid (4% w/v stock solution).
Glutaraldehyde (4% w/v) in 0.1 M cacodylate buffer, pH 7.4. 
Buffered osmic acid: equal volumes of osmic acid stock 
solution and cacodylate buffer are mixed together, on 
the day of use.
Note: weighing of cacodylate must be carried out wearing 
gloves and a mask, and if possible, carried out in a 
fume cupboard. Preparation of osmic acid solution MUST 
be carried out in a fume cupboard, and ALWAYS wearing 
gloves, a mask and safety spectacles; in addition, this 
procedure must never be carried out if you are alone in 
the laboratory.
Absolute alcohol.
Propylene oxide.
Epon 812 (Taab Laboratories Equipment Ltd., Reading,
Berks., UK.).
Method.
Pieces of liver obtained at post-mortem were cut 
into cubes of 0.5 to 1 mm in size and fixed in glutaraldehyde 
(4% w/v) in 0.1 M cacodylate buffer, pH 7.4, for 2 to 4 
hours at 4°C, washed in 0.1 M cacodylate buffer, pH 7.4, 
for 12 to 18 hours, at room temperature, and then counter­
fixed in buffered osmic acid (2% w/v) in 0.1 M cacodylate 
buffer, pH 7.4, for 2 hours. The fixed material was then 
dehydrated by immersing it in progressively increasing 
concentrations of ethanol (25, 50, 75, 90 and 100%, v/v;
2 x 10 minutes changes at each concentration). The tissue
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was then immersed in a propylene oxide:absolute alcohol 
(1:1) solution, propylene oxide (2 changes) and finally 
in a propylene oxiderEpon 812 (1:1) resin mixture (20 i 
minutes). Plastic capsules were filled with Epon 812 resin 
and 2 to 3 blocks of tissue were placed in each capsule.
The resin was polymerised for 48 hours at 60°C, and sections 
were subsequently cut, using a Reichert Orn U3 Ultra- 
micrtome, for examination under the electron microscope 
(Jeol 100B, Japan).
For preparation of cultured hepatocytes for 
examination by the electron microscope, the above method 
was employed, with the following adaptations. At the 
termination of the experiment, the medium was removed, 
and the flasks rinsed three times with ice-cold PBS'A1 
buffer. Fixation was acheived as described above, the 
solutions being placed in the flasks. After dehydration, 
as propylene oxide cannot be used at this stage because 
it destroys the plastic culture flasks, the flasks were 
rinsed three times with Epon 812, £o ensure removal of 
any remaining alcohol, and then filled to a depth of 
approximately 8 mm with Epon 812, and placed at 60°C 
for 48 hours.
2.14. ASSAY OF THE MUTAGENICITY OF DEHP & MEHP.
The Ames test was carried out according to standard 
operating procedures employed in the Genetic Toxicology 
Laboratory, Robens Institute. The mutagenicity of DEHP 
and MEHP was assessed using S. typhimurium strains TA 98 
and TA 100, in the presence and absence of S-9 mix.
In addition, the mutagenic activities of DEHP and MEHP 
were assayed in S. typhimurium TA .100, with and without 
pre-incubation.
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2.15. MEASUREMENT OF CAT ALAS E COMPOUND I IN PERFUSED LIVERS.
A preliminary study was carried out at the University 
of Dusseldorf in collaboration with Professor Sies.
In this study male Wistar Albino rats were treated with 
DEHP in the diet (1,000 mg/kg/day for 7days). The measurement 
of catalase compound I was carried out according to Sies et al. 
(1982). In addition the levels of oxidised glutathione in the bile 
from control animals and animals treated with DEHP were 
assayed.
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3.1. COMPARISON OF THE SHORT TERM EFFECTS OF DI-2-ETHYLHEXYL
PHTHALATE, DI-N-HEXYLPHTHALATE AND PI—N-OCTYLPHTHALATE 
IN RATS.
Introduction.
A study in which the changes in the livers of rats 
treated with di-2-ethylhexylphthalate (DEHP) were compared 
to those in the livers of rats treated with di-n-octyl- 
phthalate (DnOP) and di-n-hexylphthalate (DnHP) was 
carried out at the Robens Institute, by Alan H. Mann, 
as part of tHe M.Sc. degree in Toxicology. DnHP and 
DnOP are the straight chain analogues of DEHP.
Groups of rats were fed diets containing 20,000 
p.p.m. of one of these compounds. Subgroups were killed 
3, 10 and 21 days after commencement of‘treatment; the 
livers were examined by histological, cytological and 
biochemical methods.
Results.
A summary of the results is presented in Table 3.1.1. 
The results showed considerable differences between 
the effects of DEHP and its straight chain analogues,
DnOP and DnHP. (For details of the results refer to 
Mann, 1981 or Mann et al3 1984 ).
After the study was finished I undertook the 
assay of the peroxisome-associated enzymes, cyanide- 
insensitive palmitoyl-CoA oxidase and a-glycerophosphate 
dehydrogenase, in order to have a complete profile of the 
peroxisomal changes induced by these compounds. The 
results are shown in Table 3.1.2.
Both cyanide-insensitive palmitoyl-CoA oxidase and
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TABLE 3.1.1.
A Summary of changes in the livers of rats administered 
diets containing 20,000 p.p.m. of DEHP, DnOP or DnHP.
Treatment
Effect DEHP DnHP DnOP
Hepatomegaly +++a +(late) +(late)
General appearance of liver dark light, 'light,
Centrilobular loss of .greasy. .greasy
glycogen + + + +
Total glycogen loss 
after 21 days treatment
+ b —
Fall in glucose-6-phosphatase ++ +(late) +(late)
Centrilobular necrosis - H—h ++
Periportal fat accumulation + - -
Centrilobular fat accumulation - + +
Peroxisome proliferation (EM) +++ +(late) +(late)
Induction of peroxisomal 
enzymes
+++ +(late) +(late)
Smooth Endoplasmic Reticulum 
proliferation
++ + +
Loss of Rough Endoplasmic 
Reticulum
+ + +
Increased density of inner 
mitochondrial matrix
++ — —
Initial burst of mitosis ++ - -
Fall in non-protein SH +++ — —
a
The + —* +++ denotes the degree of change seen when compared 
to age-matched controls.
j .
Refers to absence of lesion.
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TABLE 3.1.2.
The effect of administration of diets containing 20,000 p.p.m. 
DEHP, DnHP or DnOP on cyanide-insensitive palmitoyl CoA 
oxidation and a-glycerophosphate dehydrogenase activities 
in rat liver.
3Cyanide-insensitive palmitoyl CoA oxidation.
Time of treatment. Control DEHP DnHP DnOP
3 days 0.95+0.08° 3.97+0.77** 1.23+0.29 0.90+0.2
10 days 1.21+0.12 14.0+ 0.96** 1.85+0.19** 2.48+0.2
21 days 0.77+0.09° 10.88+0.93** 1.15+0.22d 1.39+0.2
a-glycerophosphate dehydrogenase.
Time of treatment. Control DEHP DnHP DnOP
3 days 4 7 + 6  108j^ 14** 5 2 + 1 1  4 4 + 5
10 days 54 + 10 135 + 11** 3 4 + 4  4 4 + 1 0
21 days 4 1 + 6  102 + 15** 5 9 + 7  2 8 + 6
3Cyanide-insensitive palmitoyl CoA oxidase activity in the 
homogenate from livers of rats treated with diets containing
20,000 p.p.m. of DEHP, DnHP or DnOP. Results are presented 
as nMol NAD+ reduced/min/mg protein + standard error.
^Alpha-glycerophosphate dehydrogenase activity in the large 
particulate fraction from the livers of control rats treated witl 
diets containing 20,000 p.p.m.of DEHP, DnHP or DnOP. Results 
are presented as units/mg protein + standard error.
For both assays each control group consisted of 6 rats, and 
each experimental group of 4 rats, unless otherwise noted.
°Results from 5 animals only.
Results from 3 animals only.
is is
Significantly different from control at 1% level.-
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a-glycerophosphate dehyrogenase activities were rapidly 
and markedly induced by DEHP. There was some increase 
in cyanide-insensitive palmitoyl CoA oxidation in 
animals treated with DnHP and DnOP, but it was very 
small compared to that found in rats treated with 
DEHP. No change was observed in the activity of 
a-glycerophosphate dehydrogenase in these animals.
3.2. THE DOSE AND TIME RESPONSE RELATIONSHIPS OF THE EFFECTS 
OF DEHP IN MALE AND FEMALE RATS.
The dose and time response relationship to DEHP 
was carried out in order to show the development of 
changes which ultimately give rise to hepatocarcinomas, 
and to distinguish these from early effects which are 
unlikely to be associated with subsequent tumour 
development, on grounds of the dosage involved.
Longer term responses were also investigated.
The experiment was designed as follows:
9 0 male rats, weighing 210 g at the start of the 
experiment, were grouped, at random, into groups of 
6, for control groups, and groups of 4 animals for 
each treatment group. The animals were acclimatised 
for 3 days and then fed either control diet (Labsure, 
CRM), or diet containing sufficient DEHP to give dose 
levels of either 50, 200 or 1,000 mg/kg body weight/day. 
Groups of 6 control rats and 4 rats from each 
experimental group were killed after 3, 7, 14 and 28 
days and 9 months after commencement of feeding.
The entire experiment was repeated using female rats. 
Both male and female rats were Wistar Albino rats, 
of the Alderley Park strain.
Before each necropsy, in animals treated with DEHP
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for up to 28 days, the rats were injected with 
3H-thymidine (500 ]iCi/kg body weight.) in order to 
study DNA incorporation. At necropsy the livers were 
removed and pieces taken for electron microscopy, 
light microscopy and for biochemistry.
Electronic microscopic examination of liver sections 
was carried out, in order to assess changes following 
treatment with DEHP. Of the changes investigated, 
the following were noted and graded: peroxisome proliferation; 
S.E.R. proliferation; R.E.R. dilatation, disorganisation 
and degranulation; changes in the mitochondria included 
increased density of the internal matrix, and mitochondrial 
swelling; loss of structure of the bile canaliculi and 
the presence of myelin within the bile canaliculi were noted; 
in addition, the presence of lysosomes, intracellular 
myelin figures and autophagosomes were noted. E.M. 
confirmation of changes in lipid and glycogen were 
also assessed.
Light microscopic examination of the liver involved 
the examination of the overall morphology using 
haematoxylin and eosin staining. The distribution of 
lipid and changes in the glycogen distribution in 
the liver were examined using Oil Red 0 and Periodic 
Acid Schiff (PAS) stain, respectively. Use of PAS- 
diastase reagent allowed examination of the number of 
lipofuscin granules.
Biochemical examination of the livers included 
assessment of the following marker enzymes in particular: 
catalase, sedimentable catalase, cyanide- insensitive 
palmitoyl CoA oxidase and uricase, as markers of 
peroxisomal function; of the endoplasmic reticulum 
markers, the changes in glucose-6-phosphatase and 
in laurate hydroxylase activities and in the level
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of total cytochrome P ^ q were noted; succinate dehydrogenase 
and g-galactosidase activities were assayed after 
treatment with DEHP, as markers of mitochondrial and 
lysosomal activities, respectively.
Acknowledgement is due to Shirley Price, who 
carried out the electron microscopy for this study, 
and to Professor Grasso who provided expert advice 
on the interpretation of the light microscopy.
3.2.1. GENERAL FINDINGS.
The addition of DEHP to the diet had no adverse 
effect upon the food consumption of either male or 
female rats (Table 3.2.1.). The male rats treated with 
200 or 1,000 mg/kg body weight/day of DEHP had a higher 
food intake than the controls in the period of 1 to 9 
months of treatment. The average intakes of DEHP 
deviated by less than 10% from the nominal values 
(Table 3.2.2.). Administration of diets containing 
DEHP had no significant effect on the growth of male 
rats up to 28 days after treatment commenced. However, 
after 9 months of treatment the body weights of animals 
treated with 200 or 1,000 mg/kg body weight/day of 
DEHP were significantly decreased compared to controls, 
despite the increased food consumption. Female rats 
treated with 1,000 mg/kg body weight/day of DEHP were 
consistently lighter than controls after 7 days of 
treatment and at all subsequent time points (Table 3.2.3.). 
Treatment of female rats with 200 mg/kg body weight/day 
of DEHP resulted in a reduction of body weight after 
28 days, which appeared to recover after 9 months 
of treatment.
There was no evidence of changes in appearence or 
behaviour or any other signs of gross toxicity, in
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TABLE 3.2.1.
The effect of diets containing nominal doses of 50, 200 or 1,000 mg/kg/day of
DEHP on food consumption in rats.
MALE RATS
Food Consumed3
Control 50
Nominal-doses 
200
of DEHP
1,000
0t2 days 114.3 106.4 117.5 113.4
3-6 days 89.9 85.5 83.7 84.0
7-10 days 83.6 83 87.3 87.3
11-17 days 100.5 99.4 92.5 96.4
18-24 days ^ 81.4 72.5 79.2 81.6
25-31 days 75.7 74.4 70.5 69.0
1-9 months 50.4 52.3 56.1 64.3
FEMALE RATS
Food iConsumed3 Control 50
Nominal doses 
200
of DEHP
1,000
0-2 days 97.6: 84.8 86.8 80.3
3-6 days 114.2 101.4 104.5 102.6
7-10 days 86.9 99.0 85.7 78.4
11-17 days 91.6 84.6 83.3 93.1
18-24 days 87.8 67.7 79.2 62.2
25-31 days 78.3 73.3 73.5. 75.3
1-9 months 70.1 68.5 70.6 69.7
a Food consumption of male and female rats treated with nominal doses of 
50, 200, or 1,000 mg/kg/day of DEHP.
Results are presented as g diet consumed/kg body weight/day.
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TABLE 3.2.2.
Nominal and average actual amounts of DEHP ingested.
Nominal Actual (mg/kg/day)
Male animals
50 
200 
1,000
Female animals
50 52.5
200 217.5
1,000 1024.0
49.9
199.9
1018.0
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TABLE 3.2.3.
The effect of administration of diets containing nominal doses
of 50, 200 or 1,000 mg/kg body weight/day of DEHP on
body weights- in rats.
MALE RATS
Time of treatment Control Nominal doses of DEHP
50 200 1,000
% control
3 days 260 + 6.2 101 102 99
7 days •269 + 6.1 101 101 102
14 days 299 + 6.5 105 98 93
28 days 372 + 11.7 100 98 93
9 months 596 + 17.7 101 91* 85*
FEMALE RATS
Time of treatment Control Nominal doses of DEH
50 200 
% control
1,
3 days 178 ± 1-1 97 100 100
7 days 210 + 11.1 103 108 99
14 days 232 + 7.2 97 88* 93
28 days 252 + 7.5 105 96 88
9 months 285 + 6.7 106 106 88* (
*Significantly different from control at 5% level.
cl Body weight of male .and female rats treated with nominal 
doses of 50„ 200 or 1,000 mg/kg/day of DEHP. Control results 
are presented as mean (g) + standard error.
Each control group consisted of 6 rats and each experimental
group of 4 rats, unless otherwise noted.
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either male or female rats, following administration 
of diets containing DEHP.
At autopsy, male rats treated with 1,000 mg/kg 
body weight/day of DEHP showed marked hepatomegaly.
Liver weights were increased after 3 days of treatment, 
further increased after 7 days, and thereafter reached 
a plateau compared to control animals (Tables 3.2.4 and
3.2.5.). Treatment with 50 or 200 mg/kg body weight/day 
resulted in increases in liver weight after 14 and 28 
days and 9 months after commencement of treatment. Thus, 
in male rats there was a distinct dose-related 
hepatomegaly resulting from treatment with DEHP. In 
female rats treated with DEHP (Tables 3.2.4. and 3.2.5.) 
there was also a dose-related hepatomegaly, but it was 
much less marked than that observed in male rats.
Apart from hepatomegaly, no visible abnormalities 
were observed in the abdominal or thoracic organs of 
any animals after up to 9 months of treatment. There 
was no significant change in testis weights of animals 
treated with DEHP compared to controls, except at the 
top dose after 14 days of treatment. Taking the results 
overall it would appear that this is probably due to 
statistical variation, and that at doses of up to
1,000 mg/kg body weight/day, treatment with DEHP does 
not lead to testicular atrophy (Table 3.2.6.). The 
increase in testis weight (g/kg body weight) observed 
in animals treated with 200 or 1,000 mg/kg body weight/day 
of DEHP for 9 months is clearly due to the fall in body 
weight. The lack of testicular atrophy observed in the 
current study cannot be attributed to a strain difference 
as in an earlier study in our laboratory, using the 
same rat strain (Mann et al3 1984) there was marked 
testicular atrophy in rats treated with 2,000 mg/kg 
body weight/day of DEHP. Thus, testicular atrophy is
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TABLE 3.2.4.
The effect of administration of diets containing nominal doses
of 50, 2 00 or 1,000 mg/kg body weight/day of DEHP on
absolute liver weight.a
MALE RATS
Time of treatment Control Nominal doses of DEHP
50 200 1,000
% control
3 days 11,2 + 0.44 111 108 126*
7 days • 11.5 + 1.25 104 98 152*
14 days 12.1 + 0.49 122* 138* 169*
28 days 14.8 + 0.98 105 120 141*
9 months 17.6 + 0.66 123* 118* 140*
FEMALE RATS
Time of treatment Control Nominal doses of DEHP
50 200 
% control
1,
3 days 7.7 + 0.32 102 98 115
7 days 8.5. + 0.61 115 117 129*
14 days 9.1 + 0.35 106 100 127*
28 days 9.3 + 0.88 116 113 127
9 months 10.2. + 0.88 112 117* 131*
*Significantly different from control at 5% level.
g
Absolute liver weights of male and female rats treated with 
nominal doses of 50, 2 00 or 1,000 mg/kg/day of DEHP. Control 
results are presented as mean (g) + standard error.
Each control group consisted of 6 rats and each experimental
group of 4 rats, unless otherwise noted.
TABLE 3.2.5.
The effect of administration of diets containing nominal doses
of 50, 200 or 1,000 mg/kg body weight/day of DEHP on
relative liver weight.
MALE RATS
Time of treatment Control ■‘Nominal
50
'" ’• Q."o
doses of 
200 
control
DEHP
1,0(
3 days 0.043 + 0.001 110* 106 127*
7 days 0.041 + 0.002 103 96 148*
14 days 0.040 + 0.001 116* 141* 168*
28 days 0.040 + 0.002 106 123* 152*
9 months 0.029 + 0.001 122* 131* 164*
FEMALE RATS
Time of treatment Control Nominal doses of DEHP
50 200
; control
1,000
3 days 0.044 + 0.002 105 99 113*
7 days 0.041 + 0.003 112 107 129*
14 days 0.040 + 0.002 109 114 135*
28 days 0.037 + 0.003 111 119 147*
9 months 0.035 + 0.002 110 114 153*(3 )
*Significantly different from control at 5% level.
aRelative liver weights in control male and female rats treated 
with nominal doses of 50, 200 or 1,000 mg/kg/day of DEHP. 
Control results are presented as (g) liver weight/g of body 
weight + standard error.
Each control group consisted of 6 rats and each experimental
group of 4 rats, unless otherwise noted.
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TABLE 3.2.6.
The effect of administration of diets containing nominal doses
of 50, 200 or 1,000 mg/kg body weight/^ay of DEHP on
absolute and relative testis weight. '
MALE RATS TESTIS WEIGHT.
Time of treatment Control Nominal doses of DEHP
50 200 
% control
1,
3 days 5.75 + 0.22 99 96 106
7 days 6.13 + 0.21 97 91 100
14 days 7.25 + 0.28 102 98 89
28 days 5.55 + 0.38 89 98 92
9 months 3.68 + 0.07 107 105 100
RELATIVE TESTIS WEIGHT.
Time of treatment Control Nominal doses of DEHP
50 200 1,000
% control
3 days 22.2 + 1.0 97 94 108
7 days 23.3 + 0.9 96 91 98
14 days 24.2 + 0.7 97 100 89*
28 days 14.8 + 0.6 90 100 100
9 months 6.2 + 0.1 106 115* 118*
*Significantly different from control at 5% level.
a Testis weights in control rats and rats treated with nominal 
doses of 50, 200 or 1,000 mg/kg/day of DEHP. Control results 
are presented as (g) testis + standard error.
Relative testis weights in control rats and rats treated with 
nominal doses of 50, 200 and 1,000 mg/kg/day of DEHP. Control 
results are presented as (g) testis/kg body weight + standard 
error.
Each control group consisted of 6 rats and each experimental 
group of 4 rats, unless otherwise noted.
-154-
probably a dose-dependent effect, which is not observed 
at doses of 1,000 mg/kg body weight/day or below.
BIOCHEMICAL RESULTS.
3.2.2 LIVER BIOCHEMISTRY.
3.2.2.1.i. PROTEIN.
There were no significant changes in the protein 
content of liver homogenates of the 150,000 g-min. 
pellet or of the microsomal fraction at any time point 
in male or female rats treated with any dose of DEHP. 
Microsomal protein is shown as an example (Table 3.2.7.).
3.2.2.1.ii. DNA and DNA SYNTHESIS.
In male rats treated with DEHP there was a time
and dose-dependent decrease in the amount of DNA/g of
liver (Table 3.2.8.) indicative of hepatocyte hypertrophy.
3Incorporation of H-thymidine into DNA (Table 3.2.9.) 
was increased in a dose-dependent manner in male rats 
treated with DEHP. In animals treated for 3 days with
1,000 mg/kg body weight/day of DEHP the increase in 
synthesis was marked, becoming less pronounced after 
7 and 14 days of treatment and after 28 days the 
incorporation was below control levels (Figure 3.2.1.). 
Male rats treated with 2 00 mg/kg body weight/day 
showed a similar but less marked response, whilst 
treament at 50 mg/kg body weight/day of DEHP resulted 
in an increase in DNA synthesis, which peaked after 
7 days of treatment, and showed a significant decrease 
after 28 days. In order to establish whether the 
increase in DNA synthesis was due to increased cell 
repair or to increased cell division, mitotic counts 
were carried out on liver sections stained with
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TABLE 3.2.7.
The effect of administration of diets containing nominal doses
of 50, 200 or 1,000 mg/kg body wgight/day of DEHP on
microsomal protein in rat liver.
MALE RATS
Time of treatment Control Nominal doses of DEHP
50 200 
% control
1,
3 days 20.0 + 4.3 107 100 100
7 days 001—1 
CN + 1.4 108 129 106
14 days 19.4 + 1.7 107 108 97
28 days 19.0 + 1.6 78 96 92
9 months 24.8 + 1.0 94 96 98
FEMALE RATS
Time of treatment Control Nominal doses of DEHP
50 200 1,000
% control
3 days 15.8 + 1.0 99 100 114
7 days 20.1 + 1.1 96 82 84
14 days 20.6 + 1.1 87 95 98
28 days 18.5 + 0.4 99 102 91
9 months 23.8 + 0.7(4) 04 102 96(3)
*Significantly different from control at 5% level.
g
Protein recovered in the microsomal fraction separated from the 
livers of control rats and rats treated with 50, 200 and 1,000 
mg/kg/day of DEHP. Control results are presented as' mg mi 
mg microsomal protein/g of liver + standard error.
Each control group consisted of 6 rats and each experimental
group of 4 rats, unless otherwise noted.
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TABLE 3.2.8.
The effect of administration of diets containing nominal doses
of 50, 200 or 1,000 mg/kg body weight/day of DEHP on 
. a
DNA m  rat liver.
MALE RATS
Time of treatment Control ' - Nominal doses of DEHP
50 200 1,000
. : - ■ % control'
3 days 2.97 + 0.06 88* 91* 88*
7 days '3.32 + 0.27 95 118 79
14 days 3.04 + 0.13 94 86 78*
28 days 2.81 + 0.13 86 79* 75*
9 months N.A. N.A. N.A. N.A.
FEMALE RATS
Time of treatment Control Nominal doses of 
50 200
% control
DEHP
1,01
3 days 1.81 + 0.30 103 92 87
7 days 3.14 + 0.11 89 88* 98
14 days 2.65 + 0.25 98 111 88
2 8 days 2.88 +' 0.16 86 78* 86
9 months N.A. N.A. N.A. N.A.
*Significantly different from control at 5% level.
aDNA in homogenate from livers of control rats and rats treated 
with nominal doses of 50, 200 and 1,000 mg/kg/day of DEHP. 
Control results are presented as mg DNA/g liver + standard 
error.
Each control group consisted of 6 rats, each experimental 
group of 4 rats, unless otherwise noted.
N.A. .Not assayed at this time point.
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TABLE 3.2.9.
The effect of administration of diets containing nominal doses
of 50, 200 or 1,000 mg/kg body weight/day of DEHP on
DNA synthesis in rat liver.a
MALE RATS
Time of treatment Control Nominal doses of 
50 200
% control
DEHP
1,000
3 days 8.1 + 1.3 141 279* 484*(3)
7 days '5.7 + 1.0 181* 172* 226*
14 days 13.2 + 1.5 132 115 110
2 8 days 14.8 + 4.8 74* 86 91
9 months N.A. N.A. N.A. N.A.
FEMALE RATS
Time of treatment Control Nominal doses of DEHP 
50 200 1,000 
% control
3 days 9.4 + 0.9 101 239 405*
7 days 17.0 + 1.9 158 177* 137*
days 13.2 + 1.9 141 133 99
28 days 9.3 + 0.7 126 139 96
9 months N.A. N.A. N.A. N.A.
*Significantly different from control at 5% level.
aDNA synthesis in the homogenates of livers from control rats 
and rats treated with nominal doses of 50, 2 00 and 1,000 
i^g/kg/day of DEHP. Control results are presented as 
H-DNA/mg DNA + standard error.
Each control group consisted of 6 rats and each experimental 
group of 4 rats, unless otherwise noted.
N.A.Not assayed at this time point.
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FIGURE 3.2.1.
A graph of DNA synthesis (^H-DNA/ mg DNA) plotted against time
of treatment of male and female rats with various levels of DEHP.
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TABLE 3.2.10.
The effect of administration of diets containing 
a nominal dose of 2 00 mg/kg/day of DEHP on the number of 
mitotic figures in rat liver.a
MALE RATS
Time of treatment Control 200 mg/kg/day DEHP
3 days 5 26
7 days 0 1
14 days 0 0
2 8 days 0 0
9 months 
(1,000 mg/kg/day)
0 0
FEMALE RATS
Time of treatment Control 200 mg/kg/day DEHP
3 days 0 11
7 days 1 26
14 days 0 6
2 8 days 2 2
9 months 0 0
(1,000 mg/kg/day)
^Fhis report was based on a visual comparison of liver sections 
of 6 control animals and 4 experimental animals. Ten fields 
were scanned/liver section and the number of mitotic figures 
(metaphase). Magnification x 400.
haematoxylin and eosin, from control and treated rats. 
These results (Table 3.2.10.) clearly indicated that 
the increase in DNA synthesis was at least due 
predominantly to increased cell division, rather 
than to increased cell repair.
Treatment of female rats with DEHP resulted in 
a similar change in the rate of DNA synthesis, as 
observed biochemically and morphologically, but a 
much smaller change in the content of DNA/g of liver 
was observed in female rats compared to that found 
in male rats.
It can be concluded that treatment of male rats 
with DEHP resulted in a dose-related increase in mitosis, 
followed by a compensatory decrease in mitosis in the 
enlarged livers of treated rats, together with a 
slower and dose-dependent hypertrophy. Female rats, 
like male rats, showed the initial hyperplasia, but 
unlike male rats, did not show the subsequent hypertrophy 
in response to treatment with DEHP.
3.2.2.2. PEROXISOMAL ENZYMES.
3.2.2.2.i. CYANIDE-INSENSITIVE PALMITOYL-CoA OXIDASE.
Cyanide-insensitive palmitoyl CoA oxidase activity 
was markedly induced in all groups of animals treated 
with DEHP, except for female rats treated with 50 mg/ 
kg body weight/day of DEHP, in which the increase was 
not statistically significant (Table 3.2.11.). In 
all treated groups there was a pronounced increase 
after 3 days of treatment, slight further increases 
7 and 14 days after commencement of treatment, and 
in male rats, a slight fall after 2 8 days of treatment, 
with a further rise after 9 months of treatment. Female
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TABLE 3.2.11.
The effect of administration of diets containing nominal doses
of 50, 200 or 1,000 mg/kg body weight/day of DEHP on
palmitoyl CoA oxidase activity in rat liver.a
MALE RATS
Time of treatment Control Nominal doses of 
50 200
% control
DEHP
1,000
3 days 1.22 + 0.08 233* 279* 314*
7 days 0.62 + 0.18(3) 116 304* 1067*
14 days 0.87 + 0.13 170* 295* 654*
28 days 1.00 + 0.11 .155 220* 483*
9 months 1.54 + 0.49(3) 223* 238* 747*
FEMALE RATS
Time of treatment Control Nominal doses of DEHP 
'50 200 1, 000 
% control
3 days 0.46 + 0.11 154 187 348*
7 days 1.25 + 0.13 119 147* 333*
14 days 0.94 + 0.14 154 188* 501*
28 days 0.98 + 0.05 120 222* 549*
9 months 2.49 + 0.56(4) 123 220* 593*
*Significantly different from control at 5% level.
cl Palmitoyl CoA oxidase activity in the homogenate of livers of 
control rats and rats treated with 50, 2 00 and 1,000 mcf/kg/ 
day of DEHP. Control results are presented as nmol NAD /reduced/ 
min/mg protein + standard error.
Each control group consisted of 6 rats and each experimental
group of 4 rats, unless otherwise noted.
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rats showed a further induction up to 28 days, which 
was maintained after 9 months of treatment. In general, 
female rats showed lesser, but qualitatively similar, 
changes to males rats treated at the same dose levels.
3.2.2.2.ii. g-GLYCEROPHOSPHATE DEHYDROGENASE.
Changes in a-glycerophosphate dehydrogenase activity 
were parallel to those of cyanide-insensitive palmitoyl- 
CoA oxidase activity, although somewhat smaller (Table 3.2.12).
3.2.2.2.iii. CATALASE and SEDIMENTABLE CATALASE.
Changes in catalase activity were complex, see 
Tables 3.2.13., 3.2.14. and 3.2.15.. Total catalase 
activity was consistently enhanced in male rats treated 
with 1,000 mg/kg body weight/day of DEHP, with the greatest 
increase found 9 months after commencement of treatment.
Changes in total catalase in male rats treated with 
50 or 2 00 mg/kg body weight/day of DEHP indicated a 
small, although statistically insignificant, induction 
of total catalase. The effect of DEHP treatment in 
female rats on total catalase was much less marked 
than in male rats; only female rats treated with
1,000 mg/kg body weight/day of DEHP for 28 days showed 
an increase in total catalase.
In male rats treated with 50 mg/kg body weight/day 
of DEHP there was a marked increase in both the 
proportion of catalase activity and in the specific 
activity of catalase recovered in the 150,000 g-min. 
pellet. Similar, but less pronounced, changes were 
seen in animals treated with 2 0 0 mg/kg body weight/day 
of DEHP, but in animals treated with 1,000 mg/kg body 
weight of DEHP there was a reduction in the 
proportion of catalase activity sedimentable at
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TABLE 3.2.12.
The effect of administration of diets containing nominal doses
of 50, 200 or 1,000 mg/kg body weight/day of DEHP on
alpha-glycerophosphate dehydrogenase activity in rat liver?
MALE RATS
Time of treatment Control Nominal doses of DEHP
■ . ' ■ • ■ ■ ■ ■ ■ v .
50 2 0 0  
% control
1 , 0 0 0  _
3 days 0.067 + 0 . 0 1 2 129 135 182*
7 days 0.043 + 0.009 1 1 2 172* 232*
14 days 0.028 + 0.003 185* 348* 337*
28 days 0.039 + 0.009 246* 250 335*
9 months 0.054 + 0.001(4)273* 315* -
FEMALE RATS
Time of treatment Control Nominal doses of DEHP 
50 200 1,000 
% control
3 days 0.035 + 0 . 0 1 1 125 1 2 2 167
7 days 0.048 + 0.014 71 74 97
14 days 0.026 + 0.006 182 182 310*
28 days 0.056 + 0.007 131 2 2 2 * 310*
9 months 0.058 + 0.010(4)116 2 0 2 * 344*
*Significantly different from control at 5% level.
a Alpha-glycerophosphate dehydrogenase activity in the large 
particulate fraction separated from the livers of control 
rats and rats treated with nominal doses of 50, 200 and
1,000 mg/kg/day of DEHP. Control results are presented as 
units/mg protein + standard error.
Each control group consisted of 6 rats, each experimental
group of 4 rats unless otherwise noted.
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TABLE 3.2.13.
The effect of administration of diets containing nominal doses
of 50, 200 or 1,000 mg/kg body weight/day of DEHP on
a
total catalase activity in rat liver.
MALE RATS
Time of treatment Control Nominal doses of DEHP
50 2 00  
% control
1 ,
3 days 0.875 + 0.037 1 2 2 * 116* 141*
7 days 1.132 + 0.055 108 1 0 1 128*
14 days 2.191 + 0.123 94 113 1 2 2 *
28 days 1.820 + 0.084 105 106 1 2 2 *
9 months 0.730 + 0.037(4)140* 124 172
FEMALE RATS
Time of treatment Control Nominal doses of DEHP
50 200 1,000
% control
3 days 0.327 + 0.075 132 144 127
7 days 0.618 + 0.046 98 107 1 1 2
14 days 0.460 + 0.077 95 108 1 2 1
28 days 1 . 2 2 0 + 0.050 104 1 1 1 154*
9 months 1.350 + 0.289(4)101 118 156
*Significantly different from control at 5% level, 
a .
Total catalase activity in the homogenates of livers of 
control ratc and rats treated with nominal doses of 50,
200 and 1,000 mg/kg/day of DEHP. Results are presented as 
units/mg protein + standard error.
Each control group consisted of 6 rats and each experimental
group of 4 rats, unless otherwise noted.
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TABLE 3.2.14.
The effect of administration of diets containing nominal doses 
of 50, 200 or 1,000 mg/kg body weight/day of DEHP on 
% of total catalase activity in the large particulate fraction 
of rat liver.
MALE RATS
Time of treatment
3 days 
7 days 
14 days 
28 days 
9 months
Control Nominal doses of DEHP
50 200 1,000
% control
62.7+6.7 55.9+3.7 61.4+3.4 46.5+4.0
•45.6+3.9 64.5+5.2 64.4+3.6(3) 53.9+9.2
49.4+2.6 62.6+4.1 51.3+2.2* 40.1+3.0*
45.2+3.7 70.4+1.4 55.8+2.5* 41.9+1.5
31.0+3.6(4) 57.9+4.3* 56.7+5.6* 19.6+2.0*
FEMALE RATS
Time of treatment Control Nominal doses of DEHP 
50 200 1,000
% control
3 days 
7 days 
14 days 
2 8 days 
9 months
73.1+13.8 101.9+24.9 68.6+17.3 84.2+14.9
67.5+4.3 68.9+3.9 73.3+1.4 55.9+6.5
76.8+6.3 85.6+6.3 87.1+4.4 58.2+3.7
79.5+3.4 86.1+4.5 80.2+4.5 66.6+8.4
73.1+9.7(4) 91.5+12.5 101.0+5.8 56.7+12.7(3
*Significantly different from control at 5% level.
a Catalase activity in the large particulate fraction of the 
horaogenate of livers of control rats and rats treated with 
nominal doses of 50, 2 00 and 1,000 mg/kg/day of DEHP.
Results are presented as % activity in whole homogenate 
+ standard error.
Each control group consisted of 6 rats and each experimental
group of 4 rats, unless otherwise noted.
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TABLE 3.2.15.
The effect of administration of diets containing nominal doses 
of 50, 2 00 or 1,000 mg/kg body weight/day of DEHP on 
catalase activity in the particulate fraction of rat liver 
homogenate , expressed as units/mg protein.
MALE RATS .
Time of treatment Control Nominal doses of DEHP
50 200 1,000
- % control
3 days 0.96 + 0 . 1 0 128 136* 129
7 days 1.08 0 . 0 6 141* 126* 118
14 days 1.82 + 0.06 123* 118* 103
28 days 1.63 + 0.16 147* 117 106
9 months 0.81 + 0 . 1 1 207* 185* 90
FEMALE RATS
Time of treatment Control Nominal doses of DI 
50 2 0 0 1 ,0 0.( 
% control
3 days 0.56 + 0.03 117 1 0 1 1 1 1
7 days 0.77 + 0.06 1 1 1 1 2 1 56
14 days 2.05 + 0 . 1 2 116 124* 1 1 1
28 days 2.47 + 0.17 103 103 1 2 1
9 months 1.78 + 0.37(4) 1 1 1 152 1 1 2
*Significantly different from control at 5% level, 
a
Catalase activity in the large particulate fraction, expressed 
as units/mg protein, of the homogenate livers of control rats 
and rats treated with nominal doses od 50, 200 or 1,000 
mg/kg/day of DEHP.
Each control group consisted of 6 rats, each experimental
group of 4 rats, unless otherwise noted.
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150.000 g-min., although the overall increase in 
catalase meant that there was no actual reduction 
in the specific activity of this fraction. Female
rats treated with DEHP showed similar, but less marked, 
changes to those observed in male rats treated with 
DEHP. . .. , . ...............-
3 . 2.2.2. iv. URICASE. ; 'I
The activity of uricase was unchanged at early 
time points and fell slightly after 28 days of treatment 
with 200 and 1,000 mg/kg body weight/day of DEHP in 
male rats. There was no significant change in uricase 
activity in female rats treated with DEHP at any 
dose level or time point. Uricase activity was not 
measured at the 9 month time point. (Table 3.2.16.).
3.2.2.3. SUCCINATE DEHYDROGENASE.
Succinate dehydrogenase was assayed as a marker 
of mitochondrial function. There was no significant 
change in the activity of succinate dehydrogenase 
in either male or female rats treated with up to
1.000 mg/kg body weight/day of DEHP, at any time 
point (Table 3.2.17.), although electron microscopic 
examination of the livers of animals treated with
DEHP indicated that there were changes in the appearence 
of the mitochondria (see section 3.2.4.).
3.2.2.4. 3-D-GALACTOSIDASE.
This enzyme was measured as a marker of lysosomal 
activity. There were no significant changes in the 
activities of 3-D-galactosidase in male rats treated 
with up to 1,000 mg/kg body weight/day of DEHP for 
up to 28 days. 9 months after commencement of treatment
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TABLE 3.2.16.
The effect of administration of diets containing nominal doses
of 50, 200 or 1,000 mg/kg body weight/day of DEHP on
uricase activity in rat liver.a
MALE RATS
Time of treatment Control Nominal doses of DEHP
50 200 1,000
% control
3 days 8.96 + 0.36 1 0 1 89 104
7 days 7.23 + 0.63 91 79 94
14 days 6.43 + 0.32 83* 83 99
28 days 3.32 + 0.09 105 74* 80*
9 months N. A. N. A. N. A. N. A.
FEMALE RATS
Time of treatment Control Nominal doses of D 
50 200 1,00 
% control
3 days •4.76 + 0.58 84 85 87
7 days 8.40 + 0.29 96 97 83*
14 days 4.93 + 0.29 1 0 1 104 109
28 days 6.46 + 0.38 98 97 103
9 months N. A. N. A. N. A. N. A.
*Significantly different from control at 5% level.
aUricase activity in the homogenates of livers of control rats 
and rats treated with nominal doses of 50, 200 or 1,000 mg/ 
kg/day of DEHP. Control results are presented as 
ymoles/min/g protein + S.E.M.
Each control group consisted of 6 rats, each experimental 
group of 4 rats, unless otherwise noted.
N A Not assayed at this time point.
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TABLE 3.2.17.
The effect of administration of diets containing nominal doses
of 50, 200 or 1,000 mg/kg body weight/day of DEHP on
succinate dehydrogenase activity in rat liver?
MALE RATS
Time of treatment Control Nominal doses of DEHP
50 200 1,000
% control
3 days 3.76 + 0.23 8 8 95 94
7 days 2.98 + 0.19 113 107 1 0 0
14 days 3.36 + 0.27 80 63* 72*
28 days 5.47 + 0.55 82 99 113
9 months 7.44 + 0.64(4) 92 94 1 0 2
FEMALE RATS
Time of treatment Control Nominal doses of DEHP
50 200 1,000
% control
3 days 2.94 + 0.25 1 1 1 87 80
7 days 3.77 + 0.19 89 77 105
14 days 1 . 1 1 + 0 . 2 2 129 162 109
28 days 1.84 + 0.17 117 103 1 2 0
9 months 3.51 + 0.80(4) 1 2 1 128(3) 94(3)
*Significantly different from control at 5% level.
a Succinate dehydrogenase activity in the homogenates of livers 
from control rats ams rats treated with nominal doses of 50,
2 00 or 1,000 mg/kg/day of DEHP. Control results are presented 
as ymoles/min/g protein + standard error.
Each control group consisted of 6 rats, each experimental
group of 4 rats, unless otherwise noted.
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p-galactosidase activity was markedly induced in both 
male and female rats treated with 1 , 0 0 0  mg/kg body 
weight/day of DEHP. In female rats there was also 
a significant induction of g-galactosidase activity 
after 7 and 14 days of treatment with 2 00 mg/kg body 
weight/day of DEHP, but there were no significant 
alterations in animals treated with either 50 or
1.000 mg/kg body weight/day of DEHP up to 28 days 
after commencement of treatment.(Table 3.2.18.).
3.2.2.5. ENZYMES ASSOCIATED WITH THE ENDOPLASMIC RETICULUM.
Five enzymes associated with the endoplasmic 
reticulum were assayed in this study. Glucose-6 -phosphatase 
activity was assayed in whole liver homogenates, and 
the other enzymes, namely total cytochrome total
cytochrome b^, lauric acid hydroxylase and ethoxycoumarin 
de-ethylase were assayed in separated microsomes. Liver 
homogenates and microsomes were prepared as described 
in section 2.5.1.
3.2.2.5.i. GLUCQSE-6 -PHOSPHATASE.
Loss of activity of this enzyme is often taken as 
indicative of hepatotoxicity. Glucose-6-phosphatase 
activity fell sharply in male rats treated with
1.000 and 200 mg/kg body weight/day of DEHP and in 
female rats treated with 1 , 0 0 0 mg/kg body weight/day 
of DEHP. Activity remained depressed up to 9 months 
after commencement of treatment (Table 3.2.19.).
Female rats treated with 2 00 mg/kg body weight/day
of DEHP showed a marked loss of glucose-6 -phosphatase 
activity-after 2 8 days of treatment but the fall at 
earlier time points was much less pronounced. In 
male rats treated with 50 mg/kg body weight/day of DEHP 
there was little change in glucose-6-phosphatase activity
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TABLE 3.2.18.
The effect of administration of diets containing nominal doses
of 50, 2 00 or 1,000 mg/kg body weight/day of DEHP on
0-galactosidase activity in rat liver?
MALE RATS
Time of treatment Control - Nominal doses of DEHP -.
- r- ' • r ..
50 2 0 0  
% control’
1 , 0 0 0
3 days 2.73 + 0.13 96 98 89*
7 days 2.71 + 0.16 93 1 1 1 93
14 days 3.01 + 0.08 103 1 0 1 1 0 2
2 8 days 2.28 + 0 . 2 2 108 90 113
9 months 1.40 + 0.25 119(3) 115(3) 189*(3)
FEMALE RATS
Time of treatment Control Nominal doses of 
50 200
% control
: DEHP 
1 , 0 0 0
3 days 3.46 + 0.45 93 106 84
7 days 2.81 + 0 . 2 0 1 0 1 125* 96
14 days 2.75 + 0.23 1 0 0 134* 113
28 days 2.51 + 0.14 1 1 1 139 116
9 months 2.43 + 0.21(4) 126 133*( 3 ) 187*(3)
*Significantly different from control at 5% le ve 1 .
a 3~galactosidase activity in the homogenate of livers of control 
rats and rats treated with 50, 200 or 1,000 mg/kg/day of DEHP. 
Control results are presented as ymoles pnp released/minute/ 
mg protein + standard error.
Each control group consisted of 5 rats, each experimental
group of 4 rats, unless otherwise noted.
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TABLE 3.2.19.
The effect of administration of diets containing nominal doses
of 50, 200 or 1,000 mg/kg body weight/day of DEHP on
glucose-6-phosphatase in rat liver.
MALE RATS
Time of treatment Control Nominal doses of DEHP
50 2 0 0  
% control 1 ' 1
3 days 38.4 + 2.7 85 8 6 70*
7 days 33.9 + 1 . 1 90 80* 63*
14 days 37.9 + 2 . 0 84 75* 52*
28 days 38.6 + 2 . 8 98 79 48*
9 months 27.3 + 2.4(4) 93 87* 56*
FEMALE RATS
Time of treatment Control Nominal doses of DEHP
50 2 0 0  
% control
1
3 days 28.6 + 2 . 0 1 1 2 99 72*
7 days 17.7 + 1.3 109 91 81
14 days 26.6 + 1.9 8 6 8 8 69*
28 days 30.2 + 2 . 0 73* 6 6 * 50*
9 months 39.2 + 3.7(4) 70 76 63*
*Significantly different from control at 5% level.
aGlucose-6 -phosphatase activity in the homogenate of livers of 
control rats and rats treated with nominal doses of 50, 2 00 
or 1,000 mg/kg/day of DEHP. Control results are presented as 
ymoles/min/mg protein + standard error.
Each control group consisted of 6 rats, each experimental
group of 4 rats, unless otherwise noted.
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at any time point, but in female rats treated at a 
dose level of 50 mg/kg body weight/day of DEHP there 
was a significant reduction in glucose-6 -phosphatase 
activity after 2 8 days of treatment, and although it 
was not statistically significant, it appeared to 
remain depressed after 9 months of treatment. . .
3 . 2 . 2 . 5 . ii. TOTAL CYTOCHROME P ^ rt.
-------------------------------    450—  --------
The response of cytochrome P4 5 Q to DEHP was complex, 
(see Table 3.2.20.) In male and female rats treated with
1,000 mg/kg body weight/day of DEHP there was a biphasic 
response during the first 28 days of treatment. Cytochrome 
P^5q levels were significantly elevated after 3 and 7 
days of treatment, fell to near control levels after 
14 days of treatment and showed a further increase after 
28 days. After 9 months of treatment, there was a 
fall to control levels in female rats and to below 
control levels in male. rats. In male rats treated with 
200 mg/kg body weight/day of DEHP there was an induction 
of total cytochrome P ^ q levels after 3 days of treatment, 
at 7 days levels had fallen back to those of control 
animals and remained unchanged thereafter. At a dose 
of 5 0 mg/kg body weight/day of DEHP there was no change 
in total cytochrome P^^q levels at any time point 
in male rats. In female rats treated with 50 or 200 
mg/kg body weight/day of DEHP there was a significant 
induction of cytochrome P^,.^levels after 7 days of 
treatment, by 14 days of treatment levels of total 
cytochrome P ^ q were the same as those of controls, 
and remained the same up to 9 months after commencement 
of treatment.
3 . 2 . 2.5.iii. CYTOCHROME Bn.  --------------
Unlike total cytochrome ’P.rn levels, there was
4DU
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TABLE 3.2.20.
The effect of administration of diets containing nominal doses
of 50, 200 or 1,000 mg/kg body weight/day of DEHP on
cytochrome levels in rat liver.
MALE RATS
Time of treatment Control Nominal doses of DEHP
50 200 1,000
% control
3 days 0.85 +
IT
)
OO
1 2 0 124* 143*
7 days 0. 92 + 0.09 1 1 1 107 161*
14 days 1 . 2 ‘8 + 0.04 93 104 105
28 days 1.05 + 0 . 1 0 128 136 165
9 months 0.97 + 0.11(4) 80 77 81
FEMALE RATS
Time of treatment Control Nominal doses of DEHP 
50 200 1,00 
% control
3 days 1.03 + 0.09 163 119 117
7 days 0.74 + 0.05 1 2 1 * 170* 162*
14 days 0.79 + 0.05 1 1 1 1 0 1 107*
28 days 0.84 + 0.04 1 1 1 104 128*
9 months 0.70 + 0.04(4) 1 1 1 108 104(3)
*Significantly different from control at 5% le ve 1 .
aTotal cytochrome P45Q levels in microsomes separated from the 
livers of control rats and rats treated with nominal doses of 
50, 200 or 1,000 mg/kg/day of DEHP. Control results are presen 
presented as nmoles/mg microsomal protein + standard error.
Each control group consisted of 6 rats, each experimental
group of 4 rats, unless otherwise noted.
-175-
no consistent pattern of changes in the levels of 
total cytochrome fc>5 at any dose level or time point 
in either male or female rats. (Table 3.2.21.).
3.2.2.5.iv. LAURIC ACID HYDROXYLASE.
Laurie acid hydroxylase activity was immediately 
and markedly induced in a dose-dependent fashion in male 
rats treated with DEHP. Although the induction was 
dose-dependent, it was not time-dependent, for there 
was no significant change in activity between 3 and 
28 days after treatment commenced, and the induction 
remained marked after 9 months of treatment. Female 
rats showed a similar pattern of response to DEHP; 
however, the activity in control rats and the degree 
of induction in rats treated with DEHP was less than 
in male rats. The time-course of the induction was 
slower in female rats, in that after 3 days of treatment 
a significant increase was observed only in animals 
treated with 1,000 mg/kg body weight/day of DEHP, by 
7 days of treatment significant increases were observed 
in animals treated with 2 0 0 as well as in animals 
treated with 1,000 mg/kg body weight/day of DEHP, but 
a significant induction was not seen in female rats 
treated with 50 mg/kg body weight/day of DEHP until 
after 28 days of treatment. In contrast, treatment of 
male rats at the same dose level resulted in an 
immediate induction of lauric acid hydroxylase activity. 
(Table 3.2.22.)
3.2.2.5.V. ETHOXYCOUMARIN O-DE-ETHYLASE.
The activity of ethoxycoumarin O-de-ethylase was 
not altered in male or female rats treated with DEHP 
for 3 or 7 days, but was elevated in both male and 
female rats treated with 2 0 0 or 1 , 0 0 0  mg/kg body weight/day
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TABLE 3.2.21.
The effect of administration of diets containing nominal doses 
of 50, 200 or 1,000 mg/kg body weight/day of DEHP on
3.cytochrome b^ levels in rat liver.
MALE RATS
Time of treatment Control ’ ‘ Nominal doses of DEHP ' "
..
50 2 0 0  
% control
If c
3 days 0.502 + 0.035 114 93 92
7 days 0.554 + 0.088 67 51* 6 8
14 days 0.360 + 0.043 139 98 115
28 days 0.521 + 0.030 1 2 2 133* 1 2 0
9 months 0.589 + 0.016(4) 85 130(3) 104
FEMALE RATS
Time of treatment Control Nominal doses of DEHP
50 200 1,000
% control
3 days 0.522 + 0.034 1 1 1 133 105
7 days 0. 540 + 0.072 92 148 118
14 days 0.537 + 0.043 96 1 2 1 108
28 days 0.512 + 0.056 113 1 1 0 125
9 months 0.622 + 0.054(4) 83 115 90(3)
*Significantly different from control at 5% level.
a Total cytochrome b^ levels were assayed in microsomes separated 
from the livers of control rats and rats treated with nominal 
doses of 50, 200 or 1,000 mg/kg/day of DEHP. Control results 
are presented as nmoles/mg microsomal protein + standard error.
Each control group consisted of 6 rats, each experimental
group of 4 rats, unless otherwise noted.
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TABLE 3.2.22.
The effect of administration of diets containing nominal doses
of 50, 200 or 1,000 mg/kg body weight/day of DEHP on
laurate hydroxylase activity in rat liver.
MALE RATS
Time of treatment Control Nominal doses of DEHP
50 200 1,000
% control
3 days 4.76 + 0.80 238* 213* 416*
7 days 4.64 + 0.78 197* 263*(3) 394*
14 days 4.23 + 0.43 219* 322*(3) 431*
28 days 3.58 + 0.51 2 2 1 * 4 0 3 * (3 ) 527*
9 months 4.92 + 0.34(4) 412* 517* 680*
FEMALE RATS
Time of treatment Control Nominal doses of DEHP
50 200 1,000
% control
3 days 2.14 + 0.17 147* 165 388*
7 days 1.98 + 0.31 168 170* 292*
14 days 1.77 + 0.13 133 191* 292*
28 days 2 . 0 2 + 0 . 2 2 195* 196* 330*
9 months 5.16 + 0.46(3) 141*(3) 104 336*(3)
*Significantly different from control at 5% level.
aLaurate hydroxylase activity in microsomes separated from 
livers of control rats and rats treated with nominal doses 
of 50, 200 or 1,000 mg/kg/day of DEHP. Control results are 
presented as units/mg microsomal protein + standard error.
Each control group consisted of 6 rats, each experimental
group of 4 rats unless noted otherwise.
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TABLE 3.2.23.
The effect of administration of diets containing nominal doses
of 50, 200 or 1,000 mg/kg body weight/day of DEHP on
ethoxycoumarin de-ethylase activity in rat liver.a
MALE RATS
Time of treatment Control Nominal doses of DEHP
50 200 1,000
% control
3 days 0.062 + 0.003 106 105 109
7 days 0.071 + 0.005 79 78 1 0 2
14 days 0.044 + 0.004 93 1 0 2 1 0 0
2 8 days 0.057 + 0.003 1 1 1 126* 1 2 1 *
9 months N. A. N. A. N. A. N. A.
FEMALE RATS
Time of treatment Control Nominal doses of 
50 200
% control
DEHP 
lr 0
3 days 0.058 + 0.008 104 116 1 2 1
7 days 0.058 + 0.005 92 148 118
14 days 0.028 + 0 . 0 0 2 157* 133* 177*
28 days 0.036 + 0.003 139* 169* 2 1 0 *
9 months N. A. N. A. N. A. N. A.
*Significantly different from control at 5% level.
aEthoxycoumarin de-ethylase activity in microsomes separated 
from the livers of control rats ans rats treated with nominal 
doses of 50, 200 or 1,000 mg/kg/day of DEHP. Control results 
are presented as units/mg microsomal protein + standard error.
Each control group consisted of 6 rats, each experimental 
group of 4 rats unless noted otherwise.
N.A. Not assayed at this time point.
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of DEHP for 28 days (Table 3.2.23.). This enzyme 
activity was not measured in rats killed after 
9 months of treatment.
3. 2. 2.6. CYTOSOL COMPONENTS.
The assay of succinate dehydrogenase activity by 
direct coupling to a tetrazolium dye included a blank, 
since colour was produced even in the presence of an 
enzyme inhibitor. The colour of this blank was due 
to the chemical reduction of the tetrazolium salt by 
low molecular weight constituents of the cytosol.
(R. H. Hinton, Unpublished experiments). We observed 
that the amount of these low molecular weight-reducing 
agents falls in rats treated with several hypolipidaemic 
drugs. In the present study, the amount of low 
molecular weight reducing activity in the cytosol fell 
in both male and female rats treated with DEHP 
(Table 3.2.24. ) .
3.2.3. SERUM BIOCHEMISTRY.
3.2.3.i. SERUM LIPIDS and LIPOPROTEINS.
In male rats there was a marked animal-to-animal 
variation in serum triglyceride levels. The assay 
method used had been optimised for measurement of 
triglyceride in human serum, not in rat serum, and 
this may account for the marked variation; therefore, 
any interpretation of these results must be treated 
with caution. There was a marked fall in animals 
treated for 3 days with 1,000 mg/kg body weight/day 
of DEHP,- which was maintained in animals treated for- 
7 and 14 days, with an apparent recovery towards control 
levels after treatment for 28 days (Table 3.2.25.).
After 9 months of treatment there appeared to be a
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TABLE 3.2.24.
The effect of administration of diets containing nominal doses
of 50, 200 or 1,000 mg/kg body weight/day of DEHP on
non-enzmic reducing agents in rat liver.
MALE RATS
' Time of treatment Control' " - Nominal doses of DEHP
50 200 1,000
' " ’ - % control- ."
3 days 10.3 + 1.2 143 117 70
7 days ■ 7.1 + 1.2 126 92 136
14 days 7.4 + 0.3 96 88* 76*
28 days 4.6 + 1.1 154 85 60
9 months 10.3 + 0.9 88 70* 66*
FEMALE RATS
Time of treatment Control Nominal doses of DEH
50 200 
% control
lr
3 days 5.9 + 0.5 128 90 80
7 days 3.4 + 1.5 82 114 92
days 4.9 + 0.4 66* 84 61*
28 days 5.2 + 0.3 96 91 71*
9 months 2.1 + 0.7(4) 120 95 2 2 (3 ;
*Significantly different from control at 5% level.
Non-enzymic dye reduction in the homogenate of livers of control 
rats and rats treated with nominal doses of 50, 200 or 1,000 
mg/kg/day of DEHP, Control results are presented as 
Vimoles INT reduced/g of liver + standard error.
Each control group consisted of 6 rats, each experimental
group of 4 rats, unless otherwise noted.
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TABLE 3.2.25.
The effect of administration of diets containing nominal doses
of 50, 200 or 1,000 mg/kg body weight/day of DEHP on
serum triglyceride of rats.
MALE RATS
Time of treatment Control Nominal doses of DEHP
50 200 
% control
1,
3 days 77.-1 + 8.5 99 76 53*
7 days 61.6 + 8.5 104 107 49*
14 days 87.7 + 13.7 69 63 36*
28 days 115.5 + 15.7 88 65 62
9 months 47.6 + 18.6(4) 232 215 145
FEMALE RATS
Time of treatment Control Nominal doses of DEHP
50 200
; control
1,000
3 days 40.3 + 5.1 119 93 106
7 days 53.3 + 4.8 120 93 115*(3)
14 days 67.9 + 15.9 87
/
90 71
28 days 36.7 + 7.6 200* 109 144
9 months
*Significantly different from control at 5% level.
^Triglyceride was assayed in serum from control rats and rats 
treated with nominal doses of 50, 200 or 1,000 mg/kg/day of 
DEHP. Control results are presented as mg triglyceride/100 ml 
of serum + standard error.
Each control group consisted of 6 rats, each experimental
group of 4 rats, unless otherwise noted.
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rise in triglyceride levels in male rats; however, 
this was not statistically significant because of the 
wide scatter of results. At a dose level of 200 mg/kg 
body weight/day of DEHP there was a reduction in serum 
triglyceride, although this was not statistically 
significant. Animals treated with 50 mg/kg body weight/ 
day of DEHP showed no consistent change in serum 
triglyceride. Female rats treated with up to
1,000 mg/kg body weight/day of DEHP showed no change 
in serum triglyceride at any time point.
In male rats changes in serum cholesterol 
paralleled those in serum triglyceride, but were 
less marked in magnitude. Treatment of female rats 
with DEHP did not cause a fall in serum cholesterol 
(Table 3.2.26.), except at the top dose after 9 months 
of treatment when serum cholesterol fell* to 75% of 
control levels.
In male rats treated with 200 or 1,000 mg/kg 
body weight/day of DEHP there was depression of the 
levels of very low density lipoproteins (VLDL),
(Table 3.2.27.), and high density lipoproteins (HDL) 
(Table 3.2.28.). There was little change in low 
density lipoprotein (LDL), (Table 3.2.29.) at any 
time point or dose level of DEHP, except for a fall 
after 9 months of treatment with 2 00 or 1,000 mg/kg 
body weight DEHP. There was little change in serum 
LDL or VLDL, but a marked reduction in female rats 
treated for 14 and 2 8 days with 1,000 mg/kg body weight/ 
day of DEHP. After 9 months of treatment there was a 
marked increase in serum LDL and VLDL together with 
a marked fall in serum HDL. In male and female rats 
there was little change in total lipoprotein levels 
(Table 3.2.30.). After 9 months of treatment, however, 
there was a fall in total lipoprotein levels in all
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TABLE 3.2.26.
The effect of administration of diets containing nominal doses
of 50, 200 or 1,000 mg/kg body weight/day of DEHP on
serum cholesterol levels in rats.a
MALE RATS
Time of treatment Control Nominal doses of DEHP
50 200 
% control
1,000
3 days 1.13 + 0.07 86 87 70*
7 days 0. 94 + 0.06 105 106 92
14 days 1.22 + 0.05 94 77* 82
28 days 1.35 + 0.06 87 82*(3) 83*
9 months 2.93 + 0.42 131 85 12 8
FEMALE RATS
Time of treatment Control Nominal doses of 
50 200
% control
DEHP
1,001
3 days 3.73 + 0.16 115 95 106
7 days 4.64 + 0.14 101 98 91
14 days 2.24 + 0.13 112 98 78
28 days 1.70 + 0.98 107 94 95
9 months 3.91 + 0.26 115 121 75*(3)
*Significantly different from control at 5% level.
a Cholesterol levels were assayed in serum from control rats and 
rats treated with nominal doses of 50, 200 or 1,000 mg/kg/day 
of DEHP. Control results are presented as grams of cholesterol/ 
litre of serum + standard error.
Each control group consisted of 6 rats, each experimental
group of 4 rats, unless otherwise noted.
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TABLE 3.2.27.
The effect of administration of diets containing nominal doses
of 50, 200 or 1,000 mg/kg body weight/day of DEHP on
very low density lipoprotein in serum from rats.
MALE RATS
Time of treatment Control Nominal doses of DEHP
50 200 
% control
1,000
3 days 1757 + 146 82 81 66*
7 days 14 42 + 33 83(3) 103(3) 107(3)
14 days 1760 + 211 83 68* 63
28 days 1328 + 128 88 81 82
9 months 940 + 175 83 75 84
FEMALE RATS
Time of treatment Control Nominal doses of DEHP
50 200 1,000
% control
3 days 1092 + 69 89 96 86
7 days 1145 + 43 99 91 84
14 days 1057 + 145 109 89 79
28 days 452 + 63 173 130 97
9 months 759 + 126 179 124 : 66
*Significantly different from control at 5% level, 
a
Very low density lipoprotein was measured in serum from 
control rats and rats treated with nominal doses of 50,
200 or 1,000 mg/kg/day of DEHP. Control results are presented 
as units + standard error. The units are arbitary being 
the peak of the appropriate lipoprotein after densitometric 
scanning of electrophoretograms of serum lipoproteins.
Each control group consisted of samples from 4 rats, and
each experimental group samples from 4 treated rats, unless
otherwise noted.
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TABLE 3.2.28.
The effect of administration of diets containing nominal doses
of 50, 200 or 1,000 mg/kg body weight/day of DEHP on
high density lipoproteins in serum from rats.a
MALE RATS
Time of treatment Control Nominal doses of DEHP
50 200 1,000
% control
3 days 1037 + 186 93 73 62
7 days •959 + 71 97(3) 121(3) 77(3)
14 days 534 + 67 195* 149 77
28 days 605 + 71 112 96 65
9 months 541 + 70 87 69 65
FEMALE RATS
Time of treatment Control Nominal doses of DEHP
50 200 
% control
1
3 days 613 + 84 123 108 110
7 days 676 + 44 117 92 87
14 days 591 + 74 103 81 65*
28 days 529 + 54 98 93 60*
9 months 567 + 107 89 93 48
*Significantly different from control at 5% level.
a
High density lipoproteins were assayed in serum from control 
rats and r it s treated with nominal doses of 50, 200 or 1,000 
mg/kg/day of DEHP. Control results are presented as units + 
standard error, as explained in Table 3.2.27.
Each control group consisted of samples from 4 rats, each
each experimental group of samples from 4 rats, unless
otherwise noted.
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TABLE 3.2.29.
The effect of administration of diets containing nominal doses
of 50, 200 or 1,000 mg/kg body weight/day of DEHP on
low density lipoproteins in serum from rats.a
MALE RATS
Time of treatment Control Nominal doses of DEHP
50 200 1,000
% control
3 days 674 + 137 100 106 121
7 days 546 + 71 86(3) 111(3) 145(3)
14 days 634 + 50 74 75 63*
28 days 311 + 58 123 129 124
9 months 452 + 148 110 63 60
FEMALE RATS
Time of treatment Control Nominal doses of DEHP
50 200 
% control
3 days 428 + 87 120 102 89
7 days 570 + 12 80 83 64*
14 days 373 + 14 130 89 88
28 days 450 + 73 123 80 107
9 months 274 + 22 174 174 103
*Significantly different from control at 5% level.
^Low density lipoprotein was assayed in serum from control rats 
and rats treated with nominal doses of 50, 200 or 1,000 mg/kg/da; 
of DEHP. Resul-us are presented as units + standard error, as 
explained in Table 3.2.27.
Each control group consisted of samples from 4 rats, and each
experimental group of samples from 4 treated rats, unless
noted otherwise.
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TABLE 3.2.30.
The effect of administration of diets containing nominal doses 
of 50, 200 or 1,000 mg/kg body weight/day of DEHP on
g
total lipoprotein in serum from rats.
MALE RATS
Time of treatment Control Nominal doses of DEHP
'  ii  ..
50 2 00 
% control .
1,000
3 days 3470 + 360 89 83 74
7 days 2947 + 134 88 110 104
14 days 2929 + 226 101 84 65
28 days 2245 + 233 99 92 83
9 months 1932 + 375 89 69 72
FEMALE RATS
Time of treatment Control Nominal doses of 
50 200
% control
DEHP
1,000
3 days 2040 + 80 110 105 97
7 days 2390 + 80 100 92 80*
14 days 2000 + 180 108 87 78
28 days 1470 + 160 126 98 84
9 months 1593 + 216 147 122 69
*Significantly different from control at 5% level.
a Total lipoprotein was assayed in the serum from control rats 
and rats treated with nominal doses of 50, 200 or 1,000 
mg/kg/day of DEHP. Total lipoprotein is estimated as the 
total area under the peak following densitometric scanning 
of electrophoretograms of serum lipoproteins.
Each control group consisted of samples from 4 rats, each
experimental group consisted of samples from 4 treated rats,
unless otherwise noted.
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groups of male rats treated with DEHP, and a fall in 
female rats treated with 1,000 mg/kg body weight/day 
of DEHP. There was a marked increase in the total 
lipoprotein levels of female rats treated with 50 mg/ 
kg body weight/day of DEHP, and a slightly smaller 
increase in female rats treated with 200 mg/kg.body 
weight/day of DEHP.
In general, the changes in plasma lipids and lipo­
proteins in female rats treated with 1,000 mg/kg body 
weight/day of DEHP were less than those in male rats 
treated with 200 or 1,000 mg/kg body weight/day of 
DEHP.
3.2.3.ii. SERUM PROTEINS.
Serum proteins were assayed by crossed immuno- 
electrophoresis on glass plates (Axelsen et al, 1973) 
against Dako anti-rat serum. The identification of 
serum proteins, quantitation and interpretation of 
results was largely carried out by Dr R. H. Hinton. The 
serum of two control and two experimental animals 
from each sub-group was examined after each time of 
treatment.
The following description merely summarises the 
changes in serum proteins observed after treatment 
of male and female rats with nominal doses of 50,
200 and 1,000 mg/kg body weight/day of DEHP. Figure 3,2.2 
illustrates a typical pattern obtained when control rat 
plasma proteins were fractionated by crossed immuno- 
electrophoresis. The pattern obtained was very 
reproducible between rats of the same age, strain 
and sex ( Hinton et al, 1984).
In male rats treated with 1,000 mg/kg body weight/
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day of DEHP there was:
(i) an immediate and sustained increase in protein 
P2,
(ii) a transient increase in protein a 1.8, which 
showed an increase in concentration after 3 days 
of treatment, but which returned to control 
levels after more prolonged treatment,
(iii) a fall in proteins al.2, a 1.3, aL.5, a 2.4 and 33,
(iv) the majority of proteins showed apparent random 
changes e.g. protein aL.6.
This pattern is typically reproduced after 
treatment with hypolipidaemic compounds, including 
clofibrate and fenofibrate, as well as DEHP, and is 
illustrated in Figure 3.2.3.
The changes observed were quite distinct from 
changes in plasma proteins which occur during the acute 
phase response to inflammatory agents. The fall in 
proteins al.2 and al.3 appeared to be characteristic of 
low grade chronic injury, as observed in cholestatic 
rats, in tumour bearing rats, and in rats treated 
with hypolipidaemic agents. Some changes, such as 
the fall in proteins al.5 and 33 appear to be associated 
with peroxisome proliferation.
No significant changes were found in the serum 
proteins of rats treated with 50 or 2 00 mg/kg body weight/ 
day of DEHP.
There were very few changes observed in the serum 
of female rats treated with DEHP. There was an increase 
in the concentration of protein P2 and an indication 
of an increase in protein al. 8 after 3 days of treatment, 
but unlike male rats, there were no significant changes in
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Figure 3.2.3. This illustrates some of the typical changes in seriim 
proteins, seen after treatment with DEHP.
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ranges in serum proteins in male rats treated with DEHP.
Results are presented as percentages of control values, and are based on 
analysis of two control and two animals from each experimental group at 
each time of treatment. The protein nomenclature is as indicated on Fig.3.
Nominal dose
of DEHP 50 200 1000 mg/kg/day
Time of Treatment
Protein P2
3 days 100 97+ 137+
7 days 78+ 102, 115
14 days 81 125 169
28 days 141 113 126
Protein a 1.2
3 days 85 77 89
7 days 75+ 98 9314 days 78 85 76
28 days 123 114 74
Protein a 1.3
3 days 100 90 103
7 days 83 90 - 90
14 days 100 93 93
28 days 108 115 85
Protein al.5
3 days 90 94 103
7 days 79 79 72
14 days 88 80 86
28 days 110 110 71
Protein a1.6
3 days 100 92 103
7 days 79 93 87
14 days 102 94 116
28 days 99 106 9?
protein al-8   " ~ ' "
3 days 88 86 135
7 days 66 94 108
14 days 91 95 118
28 days 90 124 86
Protein a 2.4
3 days 81 90 86
7 days 88 102 91
14 days 148 86 89
28 days 91 130 78
Protein 8-3
3 days 93 93 102
7 days 88 85 85
14 days 102 94 98
28 days 109 93 _76
= not measurable due to low titre of antibodies In 
the batch of anti-serum used for these exp
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Results are presented as percentages of control values and are based on 
analysis of two control sera and two experimental sera for each dose level 
at each time of -reatment. The protein nomenclature is as indicated on
Fig. 3.2.2.
Nominal dose
of DEHP 50 200 1000 mg/kg/day
Time of treat­
ment
Protein P2
3 days 1(J4 1J3 |19
7 days
Protein a1.2
Protein a 1.3
Protein a 1.5
Protein al.6
Protein a 1.8
Protein a 2.4
Protein 6 3
+  ■ —    +  . +
14 days
28 days 110 133 133
3 days 105 100 91
7 days 63 80 85
14 days 104 91 111
28 days 69 91 97
3 days 100 111 100
7 days 82 84 95
14 days 100 75 79
28 days 108 108 - 88
3 days 105 108 89
7 days 98 104 104
14 days 113 95 100
28 days 117 128 114
3 days 140 114 83
7 days 118 96 100
14 days 111 98 110
28 days 123 137 103
3 days 121 136 127
7 days 89 94 85
14 days 110 90 90
28 days 109 134 125
3 days 100 108 76
7 days 93 97 97
14 days 100 79 89
28 days 105 110 100
3 days 96 95 82
7 days 107 97 93
14 days 118 100 100
28 days 100,-194- 125 90
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proteins al.2 and al.3. Analysis of serum proteins 
suggested that the systemic response of female rats 
could be similar but considerably lower than that 
of male rats. See Tables 3.2.31. and 3.2.32.
3.2.4. ELECTRON MICROSCOPIC RESULTS.
Electron microscopic examination of sections 
of the livers from rats treated with DEHP, in this 
study, was mainly carried out by Shirley Price, and 
the results will be presented in full in her thesis.
The results are summarised in Table 3.2.33.
Marked peroxisome proliferation was observed 
after 3 days of treatment of male rats with 2 00 or
1.000 mg/kg body weight/day of DEHP, which was sustained 
9 months after commencement of treatment. Male rats 
treated with 50 mg/kg body weight/day of DEHP showed 
increased numbers of peroxisomes after 7 days of 
treatment, which remained 9 months after treatment began. 
Proliferation of peroxisomes was observed in female 
rats, but was much less marked than in male rats and 
developed over a longer time period. Treatment with
1.000 mg/kg body weight/day of DEHP resulted in 
peroxisome proliferation after 14 days of treatment; 
after 9 months of treatment peroxisome proliferation
was observed in all treatment groups, (see Figure 3.2.4.a & b).
Dose-dependent alterations in endoplasmic reticulum 
were observed in both male and female rats treated 
with DEHP. There was proliferation of smooth endoplasmic 
reticulum (S.E.R.) in male and female rats, and in 
male rats, particularly, a clear disorganisation of 
rough endoplasmic reticulum (R.E.R.). The density of 
the mitochondrial matrix was increased in male rats 
treated with all doses of DEHP. This was unchanged
-196-
Sections taken from livers fixed in 4% glutaraldehyde 
buffered with 0.1M sodium cacodylate buffer, pH 7.4, 
and counterfixed in 2% osmium tetroxide, buffered with 
0.1M sodium cacodylate, pH 7.4.
Figure 3.2.4.a.
Section from a rat fed CRM powdered diet.
Figure 3.2.4.b.
Section from a rat fed a diet containing DEHP (1,000 mg/kg/day) 
for 7 days, showing peroxisome proliferation.
Figure 3.2.5.
Section from a rat fed a diet containing DEHP (1,000 mg/kg/day) 
for 3 days, showing myelination in bile duct.
Figure 3.2.6.
Section from a rat fed a diet containing DEHP (1,000 mg/kg/day) 
for 2 8 days which shows lipofuscin granules.
ABBREVIATIONS.
N = nucleus
g = glycogen
Id = lipid droplet
mb = multivesicular body
p = peroxisome
po = peroxisome with uricase core
be = bile canaliculus
m = mitochondrion
rer= rough endoplasmic reticulum
Go = golgi apparatus
My = myelin
 represents 1- ym.
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FIGURE 3.2.5.
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in female rats, although there appeared to be an increase 
in the mitochondrial number. There was evidence of a 
transient alteration in the bile canaliculi, particularly 
in male rats, which appeared to be damaged and to 
contain myelin bodies after 3 days of treatment; thereafter, 
bile canaliculi had a near normal appearance. There was an 
increase in the number of lysosomes in both male and 
female rats treated with 1,000 mg/kg body weight/day of 
DEHP after 28 days of treatment. After 9 months of 
treatment increased numbers of lysosomes were also 
observed in animals treated with 2 00 mg/kg body weight/ . 
day of DEHP. (see Figures 3.2.5. and 3.2.6.).
3.2.5. LIGHT MICROSCOPIC RESULTS.
There was a dose dependent increase in the number 
of mitotic figures in rats administered'diets containing 
high doses of DEHP, as desribed briefly in section 3.2.2.1. 
and in Table 3.2.10. This effect was more pronounced 
in male rats than in female rats. After 7 days the number 
of mitotic figures in male rats was similar to controls 
but the number in female rats was still elevated. At 14 
days and subsequently there was no difference in mitotic 
figures between experimental and control animals. There 
was a dose-dependent hypertrophy, as well as the increase 
in mitotic figures. In male rats treated with 1,000 mg/ 
kg body weight/day the enlargement of hepatocytes was 
observed at all time points; this effect was only seen 
in male rats treated with 200 or 50 mg/kg body weight/ 
day 14 days after commencement of treatment. This effect 
was also seen in female rats but was much less pronounced.
In animals treated for up to 28 days with DEHP there 
was no evidence of any further effects in haematoxylin 
and eosin stained sections from the livers of these 
animals. After 9 months of treatment with DEHP there was
-202-
marked centrilobular eosinophilia, together with 
increased numbers of lipofuscin deposits, in liver 
sections stained with haematoxylin and eosin from 
male and female rats.
After 9 months of treatment with DEHP small 
necrotic foci, usually associated with blood vessels, 
were observed. These were also seen in control animals, 
and such foci are thought to represent a focal hepatitis 
of unknown aetiology (Carlton and Hunt, 1978). Bile duct 
proliferation is often observed in ageing animals, it 
was apparent in control rats killed after 9 months but 
was less apparent in treated animals.
Livers of male rats treated with 1,000 mg/kg body 
weight/day of DEHP showed centrilobular loss of glycogen 
after 7 days of treatment and at all subsequent time 
points. The results were less clear in female rats, 
although there was some evidence of centrilobular loss 
of glycogen in female rats treated with 1,000 mg/kg 
body weight/day of DEHP. There was no evidence of 
any difference in glycogen distribution between control 
rats and those treated with 50 or 2 00 mg/kg body weight/ 
day of DEHP, as seen by staining of liver sections with 
PAS.
Treatment with 1,000 mg/kg body weight/day of DEHP 
of both male and female rats, resulted in the increased 
appearance of small PAS positive-diastase resistant 
granules within hepatocytes aligned with the bile 
canaliculi, after 14 days of treatment. The granules 
were present thereafter. Subsequently such granules 
were observed in liver sections from animals treated 
with 2 00 mg/kg body weight/day of DEHP. Such granules 
have the staining properties of lipofuscin (Price et al, 
1982). (see Figure 3.2.7.).
-203-
Figure 3 .2.7.
Photograph of formalin-fixed, paraffin-embedded section 
stained with Periodic-Acid Schiffs reagent after diastase 
digest (Magnification x 960).
Section taken from the liver of a rat fed with a diet . 
containing DEHP (1,000 mg/kg/day) for 9 months. Small 
PAS-diastase resistnat granules are seen aligning 
peri-bile canalicular side of the hepatocytes. These 
granules have the staining properties of lipofuscin.
The same pattern is seen in female rats.
ABBREVIATIONS.
lg = PAS-positive diastase resistant granules
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Sections of livers from male rats treated with 
DEHP showed a time and dose-dependent periportal lipid 
accumulation. Treatment with 1,000 mg/kg body weight/ 
day of DEHP, for 3 days, resulted in a loss of stain 
around the centrilobular region, together with an 
apparent increase in lipid droplets around the 
portal triad (Figure 3.2.8.b. and 3.2.8.c.). Treatment 
with 200 mg/kg body weight/day of DEHP also resulted 
in periportal lipid accumulation, which increased 
slightly with time. There was little change in the 
distribution of lipid in animals treated with 50 mg/kg 
body weight/day of DEHP, but there was a slight increase 
in the amount of lipid present in these sections 
compared to controls (Figure 3.2.8.a.). In female rats 
treated with DEHP, as in male rats, there was a dose- 
dependent periportal accumulation of lipid after 3 
days of treatment with DEHP, which was sustained after 
28 days of treatment. There was little difference 
between the lipid distribution in animals treated for 
28 days and those treated for 9 months with DEHP. As 
in male rats, there was a marked animal-to-animal 
variation in the degree of response, and there was 
more lipid in the female control sections compared to 
male control sections.
The results of histological examination of liver 
sections from control rats and rats treated with DEHP 
are summarised in Table 3.2.34.
There was no evidence of testicular changes in male 
rats treated with DEHP, at any dose level or time point.
After 9 months of treatment with DEHP slight alterations 
were observed in the kidney and the thyroid. There was 
enlargement of the'droplets1 in the proximal tubule cells 
of the kidney. The changes observed in the thyroid were
-206-
Figure 3.2.8.
Photograph of frozen formalin-fixed liver section stained 
with Oil red 'O'.
Figure 3.2.8.a.
Section taken from the liver of a rat fed with a diet containing 
DEHP (50 mg/kg/day) for 3 days. There was" centrilobular loss, 
but an overall increase in the midzonal to periportal regions 
(Magnification x 230).
Figure 3.2.8.b.
Section taken from the liver of a rat fed with a diet containing 
DEHP (1,000 mg/kg/day) for 7 days. There is total loss of 
lipid from the centrilobular zone (Magnification x 230).
Figure 3.2.8.c.
Section taken from the liver of rat fed with a diet containing 
DEHP (1,000 mg/kg/day) for 7 days. This demonstrates periportal 
increase (Magnification x 230).
ABBREVIATIONS.
CV = central vein 
PV = portal vein
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Figure 3.2.9.
Photograph of formalin-fixed, paraffin embedded thyroid 
section stained with haematoxylin and eosin.
Section taken from the thyroid of a rat fed with CRM powdered
diet.(control).
Section taken from the thyroid of a rat fed with a diet
containing DEHP (1,000 mg/kg/day) for
(Magnification x 576).
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a) treated
b) control
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indicative of a hyperactive thyroid; that is, the 
follicular cells appeared more cuboidal in treated 
animals, and there was increased basophilia of the 
colloid which appeared to shrink away from the follicular 
cells. Such changes have also been observed in the 
thyroids of rats treated with hypolipidaemic drugs 
(Price et al, 1984 ).(see Figure 3.2.9. ).
Table 3.2.35. shows an overall summary of the 
results, including biochemical, light microscopic 
and electron microscopic results to give a complete 
profile of the most marked changes which occurred 
as a result of treatment of male and female rats 
with DEHP. This table also allows a rapid comparison 
of the effects produced in male and female rats 
treated with DEHP. It is clear that the response of 
female rats is qualitatively similar to "that of 
male rats, although it is generally lower in 
quantitative terms; alterations in female rats treated 
with 1,000 mg/kg body weight/day of DEHP being 
similar to alterations in male rats treated with 
200 mg/kg body weight/day of DEHP.
3.3. THE EFFECTS OF DEHP ON PARAMETERS OF BILIARY FUNCTION.
As electron microscopic examination of the livers 
of rats treated with DEHP revealed changes in bile 
canaliculi, as described in section 3.2.4., which can 
be seen in Figure 3.2.5., the composition of bile 
from control rats and rats treated with DEHP was 
examined.
A series of experiments were conducted in which 
male Wistar Albino rats (University of Surrey strain) 
were treated with 1,000 mg/kg body weight/day of DEHP 
for 3 and 15 days, after which time bile was collected
-213-
TABLE 3.2.35.
SUMMARY OF OVERALL RESULTS.
COMPARISON OF THE EFFECT OF DEHP ON MALE AND FEMALE RATS
MALE
Hyperplasia in liver +++
Hypertrophy in liver ++
Peroxisome proliferation e.m. +++
induction of enzymes +++
Smooth e.r. changes e.m.
Rough e.r. changes e.m.
Laurate hydroxylase 
Glucose-6-phosphatase loss
Mitochondrial changes e.m. ++
Bile canalicular changes e.m. ++
no change
+ changes only at lOOOmg/kg/day
++ changes at 200 and lOOOmg/kg/day
+++ changes at 50, 200 and lOOOmg/kg/day
+ +
+ +
+ + + 
+ +
FEMALE
+++
+
+
++ +
+ +
+
+ +
+
+
+
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by cannulation of the bile duct and the concentration 
of various components of the bile assayed.
Bile flow (ml/hour) was stimulated in animals 
treated with 1,000 mg/kg body weight/day of DEHP for 
3 days, although it was not quite statistically 
significantly different from controls (p = 0.20).
The results are presented in Table. 3.3.1. •and also ; ' . 
in Figure 3.3.1. In one animal there was an anomalously 
low bile flow, possibly as a result of obstruction of 
the cannula, which is indicated by the massive increase 
in lactate dehydrogenase in the bile compared to 
other animals, where lactate dehydrogenase activity 
in the bile increased slightly or decreased during 
the course of the experiment (Figure 3.3.2.). Clearly, 
damage to the liver had occurred; such damage could 
occur as a result of high back pressure,- which would 
build up with biliary obstruction. Therefore, the 
results from this animal have been neglected, as bile 
flow is obviously anomalous, which would alter the 
concentrations of enzymes in bile.
Treatment of animals with clofibrate (400 mg/kg 
body weight/day) for 3 days, as well as treatment with 
DEHP (1,000 mg/kg body weight/day), resulted in 
increased bile flow (1.14 ml/hour) compared to age- 
matched controls (0.76 ml/hour).
The choleretic effect of DEHP treatment was 
statistically significant in animals treated with
1,000 mg/kg body weight/day of DEHP for 15 days, compared 
to pooled control bile flow (Table 3.3.2. and Figure
3.3.3.). There was no difference between body weights 
of control and age-matched treated animals; thus, increased 
bile flow cannot be attributed to increased body weights 
in the treated animals compared to controls.
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y-glutamyltransferase activity was elevated after 
3 days of treatment with DEHP, and appeared to fall 
to below control levels after 15 days of treatment.
51-nucleotidase activity did not alter significantly 
from control values after 3 days of treatment with 
DEHP. There was a wide variation in the control 
levels of 5'-nucleotidase activity between experiments 
performed on two different days, which could account 
for the lack of difference between control and treated 
animals in 51-nucleotidase activities, after pooling 
of the control values. After 15 days of treatment, 
activity of 51-nucleotidase appeared depressed compared 
to controls.
There was no significant difference between the 
levels of total bilirubin in treated and control 
animals, although the amount of bilirubin present 
as direct (conjugated) bilirubin was increased in 
animals after 3 and 15 days of treatment with l,000mg/ 
kg body weight/day of DEHP compared to controls.
Lactate dehydrogenase activity was assayed, and 
found to be very variable in control animals; there 
was no significant difference between control and treated 
animals.
Bile proteins were also assayed. The samples in 
which proteins were assayed were those obtained in the 
first 15 minutes immediately after cannulation of the 
bile duct. The proteins present in the sample will be 
those that were present in the bile duct at the time 
of the cannulation (R.H. Hinton, personal communication).
The results after 3 and 15 days of treatment with DEHP 
indicate an increase in the levels of albumin in.. the 
bile, and decreases in the levels of secretory component,
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TABLE 3.3.1.
Summary of results of the administration of diet containing
sufficient DEHP to give a dose of 1,000 mg/kg body weight/day
of DEHP for 3 days on parameters of biliary function.
Control 1,000 mg/kg/day DEHP
Body weight .(g) 200 + 9 2 08 + 5
Bile flow 
(ml/hour)
0.77 + 0.15 1.23 + 0.13 (7)
Total bilirubin 
(Vimoles/litre)
20.6 + 8.7 (3) 49.6 + 6 . 6 (7)
Direct bilirubin 
(vunoles/litre)
15.2 + 3.3 (3) 41.2 + 6 . 6 (7)
y-glutamyltransferase 
(units/litre)
14.1 + 2.5 18.3 + 1.5
51-nucleotidase 
(umoles/min/ml bile)
0.196 + 0.040 0.188 + 0.025
Lactate dehydrogenase 
(units/litre)
8.06 + 4.45 (3) 3.71 + 2.19 (3)
Albumin 46.2 + 7.7 60.2 + 10.4
Secretory component 199.4 + 38.1 194.0 + 23.7
Haptoglobin 31.5 + 11.7 15.1 + 5.2
IgA
(Proteins were measured 
in arbitary units)
22.5 + 11.0 10.4 + 2.8
Results are presented as mean + standard error.
Bile proteins were assayed in bile collected in 15 minutes 
directly after cannulation, enzymes were assayed in bile collected 
between 15 and 45 minutes after cannulation.
There were 5 control animals and 8 treated animals unless 
indicated otherwise.
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TABLE 3.2.2.
Summary of results of the administration of diet containing
sufficient DEHP to give a dose of 1,000 mg/kg body weight/day
of DEHP for 15 days on parameters of biliary function.
Body weight (g)
Bile flow 
(ml/hour)
Total bilirubin 
(ymoles/litre)
Direct bilirubin 
(ymoles/litre)
y-glutamyltransferase 
(units/litre)
51-nucleotidase 
(pmoles/min/ml bile)
Lactate dehydrogenase 
(units/litre)
Albumin
Secretory component
Haptoglobin
IgA
(proteins were measured 
in arbitary units).
Control 
278 + 8 
1 .0 1 + 0.10
68.7 + 4.5
41.6 + 8.1
15.7 + 0.7
0.200 + 0.010
2.85 + 0.41
41.3 + 12.3 
302.2 + 7.8
23.0 + 7.0
40.1 + 0.5
1.000 mg/kg/day DEHP 
268 + 6 
1.69+0.18
55.6 + 4.4
40.0 + 5.0
12.5 + 1.6 
0.118 + 0.024 
12.40 + 3.52
38.8 + 14.3
238.8 + 35.4
25.5 + 12.6 
15.9+3.4
Results are presented as mean + standard error.
Bile proteins were assayed in bile collected in 15 minutes 
directly after cannulation, enzymes were assayed in bile collected 
between 15 and 45 minutes after cannulation.
There were 2 control animals and 4 treated animals unless 
indicated otherwise.
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haptoglobin and IgA. The results suggest that there is 
a leakage, into the bile, of albumin, and that there is 
a decrease in the active transport of proteins into 
the bile, as indicated by the fall in IgA after 3 and 
15 days of treatment with DEHP, there is a fall in 
haptoglobin after 3 days of treatment, which recovers 
after 15 days of treatment and there is a fall in 
secretory component after 15 days of treatment with DEHP.
In summary, the results indicate that damage to 
the bile ducts occurred rapidly after treatment with 
DEHP, as indicated by the increase in y-glutamyltransferase 
activity, and although, this was followed by a marked 
choleresis there was no increase in the amount of 
enzymes in the bile. By 15 days after commencement of 
treatment with 1,000 mg/kg body weight/day of DEHP the 
damage to the bile ducts appeared to have recovered.
These results confirm, biochemically, the transient 
nature of the damage to the bile canaliculi, which 
was observed by electron microscopic examination of 
livers of animals treated with DEHP. The results from 
this study are summarised in Tables 3.3.1. and 3.3.2.
3,4, COMPARISON OF THE SHORT TERM EFFECTS OF DEHP, FENOFIBRATE 
AND CLOFIBRATE IN MATURE RATS.
An experiment was carried out in which mature rats 
were treated with either fenofibrate ( 2 0 0 mg/kg body weight/ 
day), clofibrate (400 mg/kg body weight/day) or di-2-ethyl- 
hexylphthalate (1 , 0 0 0  mg/kg body weight/day) and the 
changes observed compared to those in the immature rats, 
used in the previous experiments. This was done in order 
to assess whether ageing influenced the response to 
hypolipidaemic agents.
Mature rats, unlike immature rats used in previous
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studies did not take readily to the experimental diets.
Food consumption was less than that of control rats 
and this resulted in a slight loss of body weight 
(Table 3.4.1.). Furthermore, the total amount of drugs 
ingested did not reach the nominal dose. There were no 
significant changes in absolute liver weight; however, 
on a relative weight basis (g liver/g body weight) 
hepatomegaly was apparent. After 3 and 13 days of treatment 
with fenofibrate (140-190 mg/kg bodyweight/day) significant 
changes in relative liver weight were observed, treatment 
with clofibrate (101-183 mg/kg body weight/day) or 
DEHP (446-781 mg/kg body weight/day) resulted in 
significant increases in relative liver weight after 13 
days of treatment. There were no effects on the absolute 
or relative weights of the kidneys, spleen or testes 
with any of the compounds, at either time point. This 
indicates that the increase in relative iiver weights 
were not simply a reflection of the loss of body fat.
The health of the animals did not appear to be affected 
by the decreased food consumption.
Morphological studies.
Examination of sections of liver stained with 
haematoxylin and eosin showed no significant difference 
between treated and control animals after 3 days of 
treament. After 13 days of treatment slight centrilobular 
eosinophilia was observed in treated animals. There was 
no increase in the number of mitotic figures in any 
treatment group. There was a marked loss of glycogen, 
from the centrilobular areas principally, in all treatment 
groups, it was most marked after 13 days of treatment 
(Table 3.4.2.). Such a loss of glycogen is observed 
after fasting of rats and this response is probably 
associated with the decreased food intake and not, in 
fact, treatment-related. Periportal accumulation of fat
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TABLE 3.4.1.
The effect of the administration of diets containing 
fenofibrate (140-190 mg/kg/day), clofibrate (101-183 mg/kg/day) 
and DEHP (446-781 mg/kg/day) on food consumption, body weights 
and liver weights in mature rats.
control fenofibrate clofibrate DEHP
Time
Food consumption - ■ •
0 - 3 days 21.46 20.56 10.00 15.40
3-13 days 24.61 16.80 11.46 16.50
Additive consumed*3
0-3 days “ 191 101 446
3-13 days ~ 140 183 781
Body weight
3 days 771+19 93(3) 85(3)* 97
13 days 775+31 87 73 8 8
dAbsolute liver 
weight
3 days 20.06+1.96 127 73 110
13 days 20.72+1.22 106 74 111
0
Relative liver 
weight
3 days 0.026+0.003 136* 85 114
13 days 0.029+0.001 121* 101 126*
cLFood consumption is presented as g food consumed/rat/day.
33Additive consumed is presented as mg additive cbnsumed/kg body 
weight/day.
cBody weight is presented as weight(g) + standard error .for 
control group, the results from treated groups are presented 
as % control.
Absolute liver weight is presented as weight (g) + standard error, 
for control groups and as % control for treated groups.
0
Relative liver weight is presented as the liver weight as a % 
of body weight + standard error for control groups, and-, as 
% of control for treated groups.
-225-
TABLE 3.4.2.
The effect of administration of diets containing fenofibrate 
(140-190 mg/kg/day), clofibrate (101-183 mg/kg/day) and DEHP 
(446-781 mg/kg/day) on centrilobular loss of glycogen after 13 
days of treatment in mature rats.
Dose N + + ++ +++
Concrol (4)a 4 0 0 0 0
fenofibrate (3) 
(140-190 mg/kg/day)
0 1 0 0 2
clofibrate (3) 
(101-183 mg/kg/day)
0 0 0 0 3
DEHP (3) 
(44 6-781 mg/kg/day)
0 0 0 2 1
( ) refers to the nmber of animals per treatment group.
the number in the table refers to the animals in each group 
showing centrilobular loss of glycogen.
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was apparent after 3 days of treatment, and was more 
marked after 13 days of treatment (Table 3.4.3.).
Electron microscopic examination of the livers of 
rats treated with fenofibrate, clofibrate or DEHP was 
carried out by my colleague, Shirley Price. The following 
is a summary of her observations.
After 3 days of treatment there was a marked increase 
in the number of peroxisomes, many of which lacked the "core" 
seen in peroxisomes in control animals. Mitochondrial 
changes were observed, there was an increased density of 
the inner mitochondrial matrix and swelling of the mitochondria 
with loss of the internal structure. There was proliferation 
of smooth endoplasmic reticulum (SER), together with 
disorganisation, degranulation and dilatation of rough 
endoplasmic reticulum (RER). There was an increase in the 
number of lipid droplets in treated animals, in particular 
those treated with DEHP, compared to controls.
After 13 days of treatment, the changes described 
above were seen, except that there were fewer lipid droplets, 
in the treated animals. The degree of change was compound- 
related, in that fenofibrate resulted in the greatest degree 
of alteration, followed by clofibrate and DEHP.
Biochemical studies.
Changes in enzyme activities in mature rats treated with 
fenofibrate, clofibrate or DEHP are presented in Table 3.4.4. 
The peroxisome-associated enzyme, cyanide-insensitive 
palmitoyl CoA oxidase was significantly induced after 3 
days of treatment with fenofibrate, and in all treatment 
groups after 13 days of treatment. Total catalase was 
significantly induced in animals treated with DEHP and 
fenofibrate, treatment with clofibrate resulted in an
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TABLE 3.4.3.
The effect of administration of diets containing fenofibrate 
(140-190 mg/kg/day), clofibrate (101-183 mg/kg/day) and DEHP 
(446-781 mg/kg/day) on periportal -accumulation of fat in mature 
rats.
Time of 
treatment
Dose N £ ' '+ .. + - ++ +++
3 days / xacontrol (4) 3 1 0 0 0
fenofibrate (3) 
(140-190 mg/kg/day)
0 2 1 0 0
clofibrate (3) 
(191-183 mg/kg/day)
0 0 0 2 1
DEHP (3) 
(446-781 mg/kg/day)
0 0 1 2 0
13 days control (4) 0 1 2 1 1
fenofibrate (3) 
(140-190 mg/kg/day)
0 0 0 0 3
clofibrate (3) 
(101-183 mg/kg/day)
0 0 0 3 0
DEHP (3) 
(446-781 mg/kg/day)
0 1 2 0 0
a( ) refers to the number of animals per treatment group.
The number in the table refers to the animals in each group 
showing periportal fat accumulation.
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apparent increase which was not statistically significant. 
Changes in the distribution of catalase activity were less 
clear-cut. The specific activity of catalase in the 
particulate fraction was decreased after 13 days of 
treatment in animals treated with fenofibrate or clofibrate, 
although the decrease was only .statistically significant 
in animals treated with fenofibrate. Treatment with DEHP 
did not result in a significant change.
Three endoplasmic reticulum-associated enzymes were 
assayed. Glucose-6 -phosphatase activity was depressed in 
all treatment groups after 13 days of treatment, although 
the effect in animals treated with clofibrate was very 
small. Such an effect is treatment-related and not due 
to decreased food intake compared to control animals, as 
in animals fasted for 48 hours there is no change in 
glucose-6 -phosphatase compared to controls (Connelly,
1984). A biphasic change in total cytochrome P4 5 Q was 
observed after treatment of animals with fenofibrate or 
DEHP, there was an initial increase after 3 days of 
treatment followed by a fall to or below control values 
after 13 days of treatment. The P4 5 Q isoenzyme, laurate 
hydroxylase, was induced in all treatment groups, 
compared to controls.
The activity of the lysosomal marker enzyme, 
B-D-galactosidase, was unaltered compared to controls.
This was consistent with the picture observed by electron 
microscopy.
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TABLE 3.4.4.
The effect of the administration of diets containing 
fenofibrate (140-190 mg/kg/day), clofibrate (101-183 mg/kg/day) 
and DEHP (446-781 mg/kg/day) on liver enzymes in mature rats.
% control
Time control fenofibrate clofibrate DEHP
Total catalase3  
activity 
3 days 
13 days
b
KCN-insensitive 
PCoA activity 
3 days 
13 days
Glucose - 6-phosphatasec 
activity
3 days 
13 days
d
1.53 + 0 . 1 2 113 89 1 0 0
1.53 + 0 . 1 2 113 89 1 0 0
1.71 + 0 . 1 0 128* 1 1 2 1 2 1 *
0.60 + 0.03 282 305* 1 2 1
0.54 + 0.06 712* 256* 424*
27.4 + 2.4 77 1 0 2 83
31.4 + 0.7 62* 92 67
1 .1 0 + 0.03 118 85 118
0.70 + 0 . 0 1 150 130 145
2.79 + 0.26 267* 132* 216*
4.70 + 0.43 312* 292* 266*
3.31 + 0.49 87 97 87
3.78 + 0.25 81 79 98
Cytochrome P^g 
activity 
3 days 
13 days
e
Laurate hydroxylase 
activity 
3 days 
13 days
f
3-D-Galactosidase 
activity 
3 days 
13 days
9. •Total catalase in homogenates of livers of control rats and rats 
treated as described above. Control results are presented as 
^units/mg protein + standard error.
KCN-insenstive palmitoyl CoA oxidase activity in the homogenates 
of livers of control rats and rats treated as described above. 
Control results are presented as nmoles NAD reduced/minute/mg 
protein + standard error.
Glucose-6 -phosphatase in homogenates of livers of control rats and 
rats treated as described above. Control results are presented as 
^ymoles/min/mg protein + standard error.
Total cytochrome P^g levels in microsomes separated from livers 
of control rats and rats treated as described above. Control results 
are presented as nmoles/mg microsomal protein + standard error.
0
Laurate hydroxylase activity m  microsomes separated from livers 
of control rats and rats treated as described above. Control results 
are presented as units/mg microsomal protein + standard error.
3~D_Galactosidase activity in the homogenates of livers of control 
rats and rats treated as described above. Control results are 
presented as pmoles PNP released/minute/mg protein + standard error.
3.5, STUDIES EMPLOYING HEPATOCYTES, EITHER IN CULTURE OR AS
PRIMARY ISOLATES.
Studies using cultured hepatocytes were carried out 
in an attempt to elucidate the biochemical events underlying 
peroxisome proliferation and the possible link between 
this response and the development in the long term of 
hepatocarcinomas. The use of cultured hepatocytes provided 
a precise environment and a rapid means of testing the 
biochemical events underlying peroxisome proliferation.
First, studies were carried out to test whether the 
characteristic hepatic response of peroxisome proliferation 
and the induction of peroxisome-associated enzymes produced 
by DEHP, as described earlier, could be reproduced in 
cultured rat hepatocytes. Subsequently, using this system, 
the responses to treatment with straight chain analogues of 
DEHP, DnOP and DnHP, were also investigated. The responses 
observed in vivo and in vitro were compared in order to assess 
the reproducibility of responses to in vitro treatment 
compared to those in vivo and to evaluate the validity of 
this as a model system.
Both the di and mono phthalate esters were used in 
the initial experiments. As a result of solubility problems 
and because it is well established that the phthalic acid 
diesters are hydrolysed in the gut prior to absorption 
into the body (Albro and Thomas, 1973) the corresponding 
mono-esters were used in the majority of subsequent 
experiments; that is, mono-(2-ethylhexyl)phthalate (MEHP), 
mono-n-octylphthalate (MnOP) and mono-n-hexylphthalate 
(MnHP) .
3.5.1. STUDIES IN CULTURED HEPATOCYTES.
The studies in which the response in cultured hepatocytes
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to treatment with DEHP, DnOP and DnHP was assayed were 
done in collaboration with Miss Angela Mitchell, at the 
Central Toxicology Laboratories, ICI, Macclesfield,
Cheshire, UK. All further experiments I carried out myself.
Peroxisomal enzymes. ..
Treatment of cultured hepatocytes, for 72 hours, with 
DEHP (0.1-5.0 mM) resulted in an increase in cyanide-insensitive 
palmitoyl CoA oxidation at doses of 0.1 and 1.0 mM DEHP, 
and induction of a-glycerophosphate dehydrogenase activity 
at each dose level (Table 3.5.1.). The treatment of hepatocytes 
with DnOP resulted in some induction of cyanide-insensitive 
palmitoyl CoA oxidase activity at a dose level of 0.1 mM, 
and of a-glycerophosphate dehydrogenase activity at all dose 
levels of up to 1.5 mM. Treatment with DnHP resulted in some 
induction of cyanide-insensitive palmitoyl CoA oxidase activity 
at all doses employed, together with induction of 
a-glycerophosphate dehydrogenase at dose levels of up to 
1 mM DnHP. The induction in activity of both cyanide- 
insensitive palmitoyl CoA oxidase and in a-glycerophosphate 
dehydrogenase was not nearly as marked after treatment with 
the staight chain phthalate esters as that found after 
treatment with DEHP, or its monester MEHP. This mirrors 
the situation observed in vivo (Mann et at, 1984).
In this study, the high doses of MEHP employed (>1 mM) 
resulted in toxicity. Cyanide-insensitive palmitoyl CoA 
oxidase activity was markedly induced at dose levels of 
0.1 and 0.5 mM MEHP, as was a-glycerophosphate activity.
In a further experiment on the effect of MEHP, 
treatment of cultured hepatocytes with MEHP, for 72 hours, 
resulted in a dose-dependent increase in cyanide-insensitive 
palmitoyl CoA oxidation. At the top dose of 0.5 mM MEHP, 
although statistically significantly induced, the activity
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THtSLiHi J . D . ± .
The effect of DEHP, DnOP, DnHP or MEHP on cyanide-insensitive 
palmitoyl-CoA oxidase activity and on a-glycerophosphate 
dehydrogenase activity in cultured rat hepatocytes.
Addition to a-glycerophosphate cyanide-insensitive
culture medium dehydrogenase activity PCoA oxidation
DMF
0.1 mM DEHP 
0.5 mM DEHP
1.0 mM DEHP
1.5 mM DEHP
2.0 mM DEHP
5.0 mM DEHP 
0.1 mM DnOP 
0.5 mM DnOP
1.0 mM DnOP
1.5 mM DnOP
2.0 mM DnOP
5.0 mM DnOP
DMF
0.1 mM DnHP 
0.5 mM DnHP
1.0 mM DnHP
1.5 mM DnHP
2.0 mM DnHP
5.0 mM DnHP
DMF
0.1 mM MEHP 
0.5 mM MEHP
Hepatocytes were prepared and cultured as described in Section
2.12.1. Additions were made to the medium as described in Section
2.12.1. Enzymes were assayed as described in Section 2.12.3.
^a-glycerophosphate dehydrogenase activity is presented as AO.D./min/ 
mg protein in whole hepatocyte homogenates.
cCyanide-insensitive palmitoyl CoA oxidase activity is presented 
as nmoles NAD reduced/minute/mg protein in whole hepatocyte 
homogenate.
Results are presented for the mean of 6 samples + standard error, 
unless otherwise noted.
*
Significantly different from control at the 5% level.
0.0276 + 0.002 1.29 + 0.21(5)
0.0687 + 0.003* 5.41 + 0.61*
0.0409 + 0.004* 1.87 + 0.17
0.0561 + 0.004* 2.85 + 0.49*
0.0374 + 0.002* 1.36 + 0.13
0.0432 + 0.004* 1.54 + 0.16
0.0407 + 0.004* 1.13 + 0.09
0.0486 + 0.004* 2.02 + 0.20*
0.0400 + 0.004* 1.00 + 0.09(5)
0.0452 + 0.003 *(5) 1.38 + 0.21(5)
0.0409 + 0.003* 1.61 + 0.11
0.0348 + 0.003 1.10 + 0.12(5)
0.0284 + 0.004
0.0245 + 0.004(4) 0.56 + 0.04
0.0551 + 0.007* 1.69 + 0.06*
0.0567 + 0.008* 1.36 + 0.20*
0.0482 + 0.006* 2.42 + 0.28*
0.0393 + 0.007 1.29 + 0.25*
0.0394 + 0.006 1.62 + 0.16*
0.0239 + 0.006(5) 1.32 + 0.19*
0.0267 + 0.003 1.09 + 0.13(5)
0.0652 + 0.005 4.15 + 0.69*(5)
0.0394 + 0.004 3.11 + 0.67*
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TABLE 3.5.2.
The effect of MEHP, MnOP and MnHP on cyanide-insensitive 
palmitoyl CoA oxidation in cultured rat hepatocytes.
3. “ bAddition to culture medium KCN -insensitive palmitoyl CoA
oxidation
DMF 1.03 + 0.02 (3)
0 . 0 1 mM MEHP 0.71 + 0.12 (3)
0.025 mM MEHP 1.65 + 0.31 (4)
0.05 mM MEHP 2.90 + 0.57*(4)
0 . 1 0 mM MEHP 5.85 + 0.27*(4 )
0.25 mM MEHP 10.27 + 0.30*(4)
0.50 mM MEHP 5.61 + 0.97 (3)
DMF 0.85 + 0.01 (3)
0 . 0 1 mM MnOP 1.35 + 0.17 (4)
0.025 mM MnOP 0.72 + 0.34 (3)
0.05 mM MnOP 0.35 + 0.19 (4)
0 . 1 0 mM MnOP 0.37 + 0.13* (3 )
0.25 mM MnOP 0.38 + 0.17 (4)
DMF 0.37 + 0 . 1 1 (4)
0 . 0 1 mM MnHP 0.44 + 0.13 (3)
0.025 mM MnHP 0.54 (2 )
0.05 mM MnHP 0 .80 + 0.03 (4)
0 . 1 0 mM MnHP 0.57 + 0.25 (3)
0.25 mM MnHP 0.46 + 0.23 (3)
0.50 mM MnHP 0.34 + 0 . 1 0 (4)
g
Hepatocytes were prepared and cultured as described in Section
2.12.1. Additions were made to the medium as described in Section
2.12.1. Cyanide insensitive palmitoyl CoA oxidation was assayed 
as described in Section 2.12.3.
Cyanide-insenitive palmitoyl CoA oxidation is presented as nmoles 
NAD+ reduced/minute/mg protein in whole hepatocyte homogenate.
Results are presented as mean + standard error for 3 or 4 culture 
dishes/treatment group, as indicated in parentheses.
*
Significantly different from control at the 5% level.
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of cyanide-insensitive palmitoyl CoA oxidase was only 
half that found in cultured hepatocytes treated with a 
dose of 0.25 mM MEHP (Figure 3.5 .1). A dose of 1.0 mM MEHP 
resulted in detachment of hepatocytes from the culture flasks; 
other signs of toxicity included blebbing and vacuolation of 
the cells after less than 24 hours of treatment. After 48 
hours of treatment all the cells had detached from the 
culture flasks and were no longer viable.
Cultured hepatocytes treated with MnOP and MnHP did 
not show an increase in cyanide-insensitive palmitoyl CoA 
oxidase activity, although at the lowest dose of MnOP 
there was a slight induction compared to controls (Table 
3.5.2. and Figure 3.5.2). After 72 hours of treatment with 
doses of 0.25 mM MnHP and MnOP cultured hepatocytes showed 
signs of toxicity, such as blebbing, vacuolation and 
detachment from the culture flasks. The leakage of lactate 
dehydrogenase into the medium was assayed, as a measure 
of toxicity. The results indicated that the leakage of 
lactate dehydrogenase into the medium was not significantly 
different from control cultures (Table 3.5.3). Thus, it was 
concluded that the lack of induction of peroxisomal 
3-oxidation of fatty acids in hepatocyte cultures treated 
with MnOP or MnHP, as compared to those treated with MEHP, 
was, probably, not attributable solely to the toxicity of 
these compounds (see Discussion).
Morphological studies in cultured hepatocytes.
As described earlier, treatment of male Wistar Albino 
rats (University of Surrey strain) with 2,000 mg/kg body 
weight/day of DEHP, DnOP or- DnHP resulted in lipid 
accumulation. Treatment with DEHP resulted in an accumulation 
of fine lipid droplets in the periportal region of the liver, 
whilst treatment with DnOP or DnHP caused an accumulation 
of lipid in the form of large droplets in the centrilobular
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TABLE 3.5.3.
The effect of MEHP, MnOP and MnHP on lactate dehydrogenase 
leakage into the medium in cultured hepatocytes.
£
Addition to 24 hours 48 hours 72 hours
culture medium
DMF 23.12 +3.38(12) 8.40 + 0.48(8) 12.58 + 1.76 (11)
0.05 mM MEHP 11.29 + 1.03 6.87 + 0.49 14.62 + 4.53
0.1 mM MEHP 22.09 +1.08(3) 12.91 + 2.73* 11.69 + 1.75
0.25 mM MEHP 32.01 + 0.77 17.82 + 5.37* 14.51 + 1.86
0.05 mM MnOP 11.26 + 1.25 16.94 + 3.44*(3) 11.71 + 2.74
0.1 mM MnOP 15.27+3.17 11.33+0.6* 12.95+6.48
0.25 mM MnOP 6.97 + 0.57* 13.36 + (1) 17.04 + 1.14(3)
0.05 mM MnHP 26.19 + 1.07 7.78 (2) 13.09 + 3.24(3)
0.1 mM MnHP 21.80 + 3.07 12.92 + 3.85 13.77 + 5.47(3)
0.25 mM MnHP 11.16 + 0.39 8.98 + 1.22 11.58 + 0.97
Compounds were added to the culture medium for 24, 48 or 72 
hours as described in Section 2.12.1. An equivalent volume of 
DMF (0.04% v/v) was added to control cultures. At the end of each 
treatment period cells were harvested and homogenised as 
described in Section 2.12.1.
Results are mean (% leakage into medium) + standard error for 
4 culture dishes for each treatment, unless otherwise noted.
*
Significantly different from control at the 5% level.
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region of the liver. A similar lipid accumulation was 
observed in cultured hepatocytes treated with MEHP, MnOP 
or MnHP; fine droplets of lipid accumulated at the periphery' 
of cultured hepatocytes treated with MEHP and larger, more 
central droplets were seen in hepatocytes which were treated 
with MnOP or MnHP {Figures 3.5.3a &b, 3.5.4a,b,c&d).
Electron microscopic examination of cultured 
hepatocytes treated with MEHP, MnOP or MnHP confirmed 
the biochemical results; peroxisome proliferation was 
observed in hepatocytes treated with 0.25 mM MEHP for 
24 hours, but not in hepatocytes treated with MnOP or 
MnHP. This was a limited investigation, in which no 
morphometric analysis was attempted, a visual examination 
only was carried out. There appeared to be little difference 
between the control cultures and those treated with MnOP 
or MnHP, apart from a possible mitochondrial proliferation. 
(Figures 3.5.5 a,b,c and d).
Further studies on the effects of MEHP on hepatocytes 
have concentrated on measurements related to the possible 
release of H^O^. There was no evidence of increased H^O^ 
production in cells treated with MEHP, no change in the 
activity of glutathione peroxidase, but there was, unexpectedly, 
an increase in glutathione levels in cultured hepatocytes 
treated for 72 hours with a dose of 0.25 mM MEHP (Table 3.5.4.).
The activity of glucose-6-phosphatase was investigated in 
cultured rat hepatocytes after treatment with MEHP. In vivo 
there is a marked fall in glucose-6-phosphatase activity 
after treatment with DEHP, as described earlier (Section
3.2.2.5.i.), the fall of which is taken as an indication 
of hepatotoxicity. In vitro there was no change in glucose-6- 
phosphatase activity resulting from treatment with MEHP 
(Table 3.5.5.).
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Photograph of frozen formal in-fixed, parffin embedded liver 
section stained with Oil Red 'O'. Magnification x .522.
Figure 3.5.3.a
Section taken from the liver of a rat fed with a diet containing 
DEHP (2,000 mg/kg/day) .for 10 days.
There is a centrilobular loss of lipid with a tendency for 
lipid to accumulate midzonal to periportal.
Figure 3.5.3.b.
Section taken from the liver of a rat fed with a diet containing 
DnOP (2,000 mg/kg/day) for 10 days.
Lipid has been lost from the portal region and accumulates in 
the centrilobular region.
A similar pattern is seen when rats are fed diets containing 
DnHP.
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Figure 3.5.4.
P h o to g rap h  o f fo rm a lin - f ix e d  c u ltu re d  h e p a to c y te s , s ta in e d  
w ith  O il R ed  'O '.  M a g n ific a tio n  x  576.
F ig u re  3 . 5 . 4 . a.
Section  ta k e n  fro m  c o n tro l c u ltu re d  r a t  h e p a to c y te s .
F ig u re  3 . 5 . 4 . b .
Section  ta k e n  fro m  c u ltu re d  r a t  h e p a to c y te s  tre a te d  w ith  
0 . 25  mM M E H P , fo r  24 h o u rs .
F ig u re  3.5.4.C.
Section  ta k e n  fro m  c u ltu re d  r a t  h e p a to c y te s  tre a te d  w ith  
0. 25  mM M nO P , fo r  24 h o u rs .
F ig u re  3 . 5 . 4 . d .
Section  ta k e n  fro m  c u ltu re d  r a t  h e p a to c y te s  tre a te d  w ith  
0 . 25  mM M n H P , fo r  24 h o u rs .
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Figure 3.5.4.b.
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Figure 3.5.4.C.
Figure 3.5.4.d.
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Sections taken from hepatocytes fixed in 4% glutaraldehyde 
buffered with 0.1 M sodium cacodylate buffer, pH 7.4, 
and counterfixed in 2% osmium tetroxide, buffered with 
0.1 M sodium cacodylate, pH 7.4.
Figure 3. 5.-5. a.
Section from control cultured hepatocytes.
Figure 3.5.5.b.
Section from cultured hepatocytes treated with 0.25 mM MEHP, 
for 24 hours.
Figure 3.5. 5*c.
Section from cultured hepatocytes treated with 0.25 mM MnOP, 
for 24 hours.
Figure 3 . 5 . 5.d.
Section from cultured hepatocytes treated with 0.25 mM MnHP, 
for 24 hours.
ABBREVIATIONS. ■
P = peroxisome 
  represents 1 ym
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FIGURE 3,5.5 .a.
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FIGURE 3.5.5.c.
FIGURE 3 . 5 . 5.d.
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TABLE 3.5.4.
The effect of MEHP on H2°2 release, levels of glutathione and on 
glutathione peroxidase activity in cultured rat hepatocytes.
Addition toa nmoles ^2^2 ° Glutathione0 Glutathione^
culture medium produced' peroxidase levels
activity
DMF 14.8 + 5.2 (4) 0.295 + 0.068(4) 79.91 + 9.56(8)
0.05 mM MEHP 15.0 +5.4 (7) 0.269 + 0.049(4) 107.60 +18.87(8
0.1 mM MEHP 16.2 + 3.1 (8 ) 0.312 + 0.017(4) 84.24 + 11.60(8
0.25 mM MEHP 13.3 + 2.08 (8 ) 0.318 + 0.042(4) 114.63 + 16.40(8
Compounds were added to the medium as described in Section 2.12.1 
An equivalent volume of DMF (0.04% v/v) was added to control 
cultures. At the end of the treatment period (72 hours) cells 
were harvested and homogenised as described in Section 2.12.1.
Results are presented as nmoles of ^2^2 Produced/mg protein +_ 
standard error.
Results are presented as units/mg protein + standard error.
Levies of glutathione in hepatocytes are presented as nmoles GSH/mg 
protein + standard error.
Results are mean + standard error for the number of treatment 
dishes indicated in parentheses.
-253-
TABLE 3.5.5.
The effect of MEHP upon glucose-6 -phosphatase activity in 
cultured rat hepatocytes.
ci bAddition to Glucose-6 -phosphatase activity
culture medium
DMF _  132.5 +4.11 (7)
0.05 mM MEHP 135.6 +24.4
0.1 mM MEHP 137.5 +5.7 (5)
0.25 mM MEHP 144.3 +5.5
g
Compounds were added to the medium as described in Section 
2.12.1. The cultured rat hepatocytes were treated for 72 hours, 
in total, after which cells were harvested, homogenised and 
assayed for glucose-6-phosphatase activity as described in 
Section 2.12.7.
b Results are presented as mean Cnmoles phosphate produced/minute/mg 
protein) + standard error.
Results are for 4 culture dishes, in duplicate, for each 
treatment, unless otherwise noted.
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TABLE 3.5.6.
3
The effect of MEHP upon [ H]-thymidine incorporation into 
cultured rat hepatocytes.
sl 3 dAddition to [ H]-thymidine incorporation , _
culture medium (c.p.m./mg protein)
DMFa 34.3+5.3
0.05 mM MEHPa 41.7+7.0
0.1 mM MEHPaa 27.8 + 2.8
0.2 5 mM MEHPa 27.4 + 4.3
DMFb 70.7+11.3
0.05 mM MEHP 92.7 + 25.3
0.10 mM. MEHP 81.4 + 14.0
0.25 mM MEHP 52.3+3.2
DMFC 59.7 + 10.0
0.05 mM MEHPC 67.7 + 8.5(3)
0.1 mM MEHPC 51.1 + 6.3
0.25 mM MEHPC 51.4 + 4.3
Compounds were added to the culture medium for 24 hours after which
3
time [ H]-thymidine was added. After 1 hour, the cells were arrested
3
harvested and assayed for [ H]-thymidine incorporation as described 
in Section 2.12.2.
bIn this case compounds were added to the culture medium for a
3
total of 4 8 hours, subsequently [ H]-thymidine incorporation was 
assayed.
Hepatocytes were allowed to recover from the isolation procedure
for 48 hours before being treated with various levels of MEHP for
3 ,24 hours, then [ H]-thymidine incorporation was assayed.
dResults are mean + standard error for 4 culture dishes for each 
treatment unless otherwise noted.
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A further difference observed between the in vitro and 
in vivo responses of hepatocytes to treatment with MEHP was 
the lack of DNA synthesis observed in vitro, both after 24 
and 48 hours of treatment with MEHP. In these cases the 
cells had been allowed to recover for 24 hours after the 
isolation procedure before treatment commenced. After 
allowing a recovery period of 48 hours and a subsequent 
treatment period of 24 hours, there was no evidence of 
increased DNA synthesis in hepatocytes treated with MEHP 
(Table 3.5.6.).
A summary of the comparison between in vivo and in vitro i 
responses to treatment with phthalic acid esters can be 
seen in Tables 3.5.7. and 3.5.8.
3.5.2. STUDIES USING PRIMARY ISOLATED HEPATOCYTES.
A STUDY OF THE ACUTE TOXICITY OF MEHP.
Marked toxicity of MEHP was observed in cultured 
hepatocytes treated with doses of 1.0 mM or above of 
MEHP within 24 hours of treatment (see Section 3.5.1.).
As the chemical structure of MEHP suggests that it could 
act as a detergent, at high doses, solubilising membranes 
and so causing marked toxicity , an experiment was carried 
out to determine whether detergent-related effects could 
be demonstrated in primary isolated hepatocytes.
Hepatocytes were isolated from a male Wistar Albino 
rat (University of Surrey strain) by the method described 
in Section 2.4., resuspended in complete L-15 medium and 
aliquots were incubated at 37°C, with various levels of 
MEHP or triton X-100. The viabilities of the cells were 
determined by trypan blue exclusion, at regular intervals 
after the addition of the compound to the medium. The results 
are summarised in Table 3.5.9. and Figure 3.5.6.
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FIGURE 3.5.6.
A graph of the % viabilities of primary isolates of rat 
hepatocytes plotted against the time of incubation (minutes) 
with MEHP or triton X-100.
% viability
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TABLE 3.5.9.
The effect of the addition to the incubation medium of 0.02% 
and 0.05% (v/v) MEHP, compared to that of 0.02% triton X-100 
on the viability of isolated rat hepatocytes.
Time after controlb Timea G.02%(v/v)b
aTime 0 .0 2 % (v/v!?
addition to ‘ MEHP ’ ' ' triton X-100g
medium
0 87.78 0 87.78 0 87.78
1 0 87.87 + 1.35 15 81.14 + 1.68 2 0 74.17 + 5.20
40 82.99 + 2.47 45 82.01 + 2.20 50 71.20 + 1.49*
70 83.78 + 1.80 75 79.26 + 3.19: 80 43.30 + 2.38*
1 0 0 82.42 + 1.03 105 74.42 + 3.25 1 1 0 1.67 + 1.67*
130 85.58 + 0.80 135 69.41 + 2.50*
160 83.35 + 0.98 165 77.99 + 4.98
190 83.55 + 2.47 195 77.14 (1)
Time after
Jcontrol b 0.0 5 %(v/v)b
addition to MEHP
medium
0 85.67 + 4.27 76.85 + 2.47
30 76.36 + 4.16 59.53 + 0.15*
60 81.38 + 1.28 30.15 + 5.23*
90 83.34 + 1.57 5.32 + 5.23*
1 2 0 83.49 + 2 . 8 6
.MEHP or triton X-100 were added to the incubation medium to 
give final concentrations of 0.02% and .0.05% .(v/v) MEHP and 
0.02% (v/v) triton X-100. Time after addition to the medium was 
measured in minutes.
Results are presented for triplicate samples(unless indicated 
otherwise) as mean % viability + standard error. % viability was 
measured by the trypan blue exclusion method.
*
Significantly different from control at the 5% level.
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Doses of 0.1% (v/v) MEHP and 0.1% (v/v) triton X-100 
resulted in immediate death of all the hepatocytes to which 
these doses were added. Addition of a dose of 0.05% (v/v) 
triton X-100 to the medium also resulted in an immediate 
failure of trypan blue exclusion. There was an immediate 
decrease in viability with the addition of a dose of 0.05%
(v/v) MEHP, and after 90 minutes the viability had fallen to 
5% only. Incubation with 0.02% (v/v) triton X-100 resulted 
in a fall in % viability which appeared to follow that of 
0.05% (v/v) MEHP, although the fall in % viability was
not as immediate as that evoked by 0.05% (v/v) MEHP. A dose 
of 0.02% (v/v) MEHP had little effect on the % viability 
within 3 hours after the addition of MEHP to the medium.
The doses of 0.02% (v/v) and 0.05% (v/v) MEHP are equivalent 
to doses of approximately 0.7 mM and 1.75 mM MEHP, respectively. 
Thus, at a dose of about 1.75 mM MEHP was showing detergent­
like activity, resulting in a marked fall in % viability in 
isolated hepatocytes, but at a dose of 0.7 mM MEHP there 
was only a slight fall in % viability compared to controls.
The appearence of the hepatocytes treated with 0.05% (v/v)
MEHP was similar to that of hepatocytes treated with 0.02%
(v/v) triton X-100, there was marked blebbing of the cell 
membrane, together with failure of trypan blue exclusion.
A STUDY OF THE IMMEDIATE EFFECTS OF PHTHALIC ACID ESTERS 
ON LIPID METABOLISM.
The effect of branched and straight chain phthalate 
esters upon lipid metabolism in hepatocytes isolated, from 
fed and fasted rats was investigated in an attempt to 
elucidate the biochemical mechanisms underlying the 
accumulation of lipid observed in rats treated with DEHP,
DnOP and DnHP.
Incubation of hepatocytes, isolated from fed rats, with 
MEHP or with clofibrate resulted in little increase in
-261-
14[1- C] palmitate incorporation into triglycerides and
cholesterol esters (Table 3.5.10). In contrast, in hepatocytes
14isolated from fasted rats, incorporation of [1- C] palmitate 
into triglycerides and cholesterol esters was stimulated 
in a dose-dependent manner, with a rise of almost 1 0 0 % 
in hepatocytes treated with 0.25 mM MEHP (Table 3.5.11.). 
Hepatocytes isolated at midday from rats fed ad libitum and 
incubated with MEHP showed a stimulation of [1-^C] palmitate 
incorporation into triglycerides and cholesterol esters 
which was half way between the response of hepatocytes 
isolated from fed and fasted rats treated with MEHP. The 
effects of 1 mM clofibrate were more marked than those of 
0.25 mM MEHP (Table 3.5.12.). This stimulation was markedly 
decreased when hepatocytes isolated at midday were incubated 
in L-15 medium, containing glutamine, compared to those 
incubated in HCO^ -free Hanks buffer, pH 7.4 (Table 3.5.13.).
The straight chain phthalate esters, MnHP and MnOP, 
caused greater increases in fatty acid incorporation into 
triglycerides and cholesterol esters in hepatocytes separated 
from fasted rats, compared to the equivalent doses of MEHP, 
and unlike MEHP, stimulated triglyceride and cholesterol 
ester synthesis in hepatocytes from fed rats.
Incubation with MEHP resulted in a dose-dependent
14 14stimulation of oxidation of [1- C] palmitate to C02
'(Table 3.5.14. ), which was more marked in hepatocytes
isolated from fasted rats than those isolated from fed rats.
Cells treated with 1 mM clofibrate showed more marked changes
than cells treated with 0.25 mM MEHP. Incubation with
MnOP or MnHP resulted in a marked stimulation of fatty
acid oxidation in hepatocytes isolated from fed rats, and an
equally marked inhibition in heptocytes isolated from fed
rats. (Tables 3.5.14. & 3.5.15.).
Incubation of hepatocytes isolated from fed and fasted
TABLE 3.5.10.
14The effect of MEHP, MnOP, MnHP or clofibrate on [1- C] palmitate 
incorporation into triglyceride and cholesterol esters in hepatocyte 
hepatocytes isolated from rats fed ad libitum.
a 1 4
Addition to [1- C] palmitic acid incorporation
7 ' •
medium. (c.p.m./lO cells)
DMF 149634+ 4938 149447+ 10082 134492+6439 12583+2231?
1 . 0 mM CPIB 84.31+12.53 84.60+2.41 136.76+16.81
0.05 mM MEHP 92.10+8.09 90.33+2.65
0 . 1 0 mM MEHP 82.10+0.58 97.73+5.95
0.25 mM MEHP 91.73+3.59 106.30+7.82
0.05 mM MnOP 183.27+13.89
0 . 1 0 mM MnOP 211.89+3.08
0.25 mM MnOP 223.12+15.88 248.61+7.27
0.05 mM MnHP 161.25+4.56
0 . 1 0 mM MnHP 147.36+32.24
0.25 mM MnHP 244.74+13.71
Treatment of primary isolates of hepatocytes was carried out 
as described in Section 2.12.9. Isolation of triglycerides and 
cholesterol esters was carried out as described in Section 2.12.9.
Each column of results represents a separate experiment. 
Results are presented as mean % control + standard error, 
for triplicate samples unless otherwise noted.
*
Significantly different from control at the 5% level.
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TABLE 3.5.11.
14The effect of MEHP, MnOP, MnHP or clofibrate on [1- C] palmitate 
incorporation into triglycerides and cholesterol esters in 
hepatocytes isolated from fasted rats.
Addition to medium3 [ l-^C ] palmitate incorporation13
(c.p.m./1 0 7 cells)
DMF 31720 + 3016 10147 + 2036
1 . 0 mM CPIB 348.79 + 24.82
0.05 mM MEHP 137.49 + 0.97
0 . 1 0 mM MEHP 153.09 + 11.50
0.25 mM MEHP 189.71 + 9.76 194.52 + 12.18
0.05 mM MnOP 144.44 + (2 )
0 . 1 0 mM MnOP 326.68 + 29.32
0.25 mM MnOP 608.14 + 24.57
0.05 mM MnHP 278.11 + 20.42 *
0 . 1 0 mM MnHP 457.81 + 54.11
0.25 mM MnHP 409.53 + 27.94
Treatment of primary isolates of hepatocytes and isolation of 
triglycerides and cholesterol esters was carried out as described 
in Section 2.12.9.
b Each column represents a separate experiment. Control results
7
are presented as mean c.p.m./lO cells + standard error. Results 
from treated groups are presented as % control + standard error, 
for triplicate samples unless otherwise noted.
*
Significantly different from control at the 5% level.
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TABLE 3.2.12.
14The effect of MEHP or clofibrate on [1- C] palmitic acid 
incorporation into triglyceride and cholesterol esters in 
hepatocytes isolated from rats fed ad libitum at 9-10 a.m. 
or at 2-3 p.m., compared to the effects in hepatocytes 
isolated from fasted rats.
Addition to 
medium
14 t b
[1- C] palmitate incorporation
7
(c.p.m./lO cells)
FED
DMF 149634+4939 58466+5446 81255+9926 10147+2036
1.0 mM CPIB 84.31+12.53 215.98+32.88 158.52+2.90 348.79+24:82
0.05 mM MEHP 92.10+8.09 114.23+3.05 98.21+9.96 137.49+0.97
0.10 mM MEHP 82.10+0.58 128.20+3.74 113.12+9.50 153.09+11.50
0.25 mM MEHP 91.73+3.59 144.73+3.30 151.01+8.41 194.52+12.18
clTreatment of primary isolates of hepatocytes and isolation of 
triglycerides and cholesterol esters was carried out as described 
in Section 2.12.9.
Each column represents a separate experiment. Control results
7
are presented as the average c.p.m./lO cells + standard error. 
Results from treated groups are presented as % control + standard 
error, for triplicate samples, unless noted otherwise.
*Significantly different from control at the 5% level
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TABLE 3.5.13.
14The effect of MEHP or clofibrate on [1- C] palmitate incorporation 
into triglyceride and cholesterol esters in hepatocytes isolated 
from a rat, fed ad libitumr at midday and incubated in either 
carbonate-free Hanks solution, pH 7.4, or in L-15 medium 
containing 2 mM glutamine.
Addition to 
medium3
14[1- C] palmitate incorporation 
(c.p.m./1 0 7 cells)1?
HCO^-free Hanks buffer, 
pH 7.4, + 1.25 mM CaCl0
L-15 medium 
containing glutamine
DMF(control 109654 + 4075 107354 + 3917
0.25 mM MEHP 176882 + 2891* 
(161% control)
118209 + 14758 
(1 1 0 % control)
1.0 mM CPIB 172568 + 759* 
(157% control)
138266 + 4009* 
(129% control)
Hepatocytes were treated and triglyceride and cholesterol 
esters were isolated as described in Section 2.12.9.
b 7Results are presented as mean (c.p.m./lO cells) + standard error,
for triplicate samples.
* Significantly different from control at the 5% level.
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TABLE 3.5.14.
The effect of MEHP, MnOP, MnHP or clofibrate on the oxidation of
14 14[1- C] palmitic acid to C02 in hepatocytes isolated from rats
fed ad libitum.
Addition to3 Oxidation of [1-^C] palmitic acid to‘"^CO. 
medium (c.p.m./lO cells + standard error)
DMF
1.0
0.05
0.10
0.25
0.05
0.10
0.25
0.05
0.10
0.25
mM CPIB 
mM MEHP 
mM MEHP 
mM MEHP 
mM MnOP 
mM MnOP 
mM MnOP 
mM MnHP 
mM MnHP 
mM MnHP
5856+712
90.52+6.45
80.09+2.16
52.54 (2)
38.28+2.99
45.16+1.63
28.31+1.09
30.05+0.21
5728+843
263.18+39.49
176.70+17.76 
104.12+9.93 
86.99+13.17 
72.45+4.40 
±31.53 (2) 
67.66+3.08 
56.60+2.73
7629+1810
139.79+3.05 
117.87+7.87 
147.43+21.73 
81.02 (2 ) 
50.50+1.26 
55.*33+8. 64 
38.59+6.45 
31.01+0.25
6866+372
253.78+28.71
113.63+4.05
126.55+3.82
135.87+5.02
Treatment of primary isolates of hepatocytes and trapping of 
14
CC>2 was carried out as described in Section 2.12.9.
b rEach column represents a separate experiment. Control results
7
are presented as the average c.p.m./lO cells + standard error. 
Results from treated groups are presented as control + standard 
error, for triplicate samples unless otherwise noted.
*
Significantly different from control at the 5% level.
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TABLE 3.5.15.
The effect of MEHP, MnOP, MnHP or clofibrate on the oxidation
14 14of [1- C] palmitic acid to CO2 in hepatocytes isolated from
fasted rats.
a 14 14Addition to Oxidation of [1- C] palmitic acid to C09.
7medium (c.p.m./lO cells + standard error)
DMF 14558 + 890
1 . 0 mM CPIB 234.72 +16.54
0.05 mM MEHP 116.14 + 17.50
0 . 1 0 mM MEHP 143.18 + 11.07
0.25 mM MEHP 146.25 (2 )
0.05 mM MnOP 105.87 + 12.99 128.66 + 6 . 1 0
0 . 1 0 mM MnOP 120.18 + 8.63 154.48 + 7.61
0.25 mM MnOP 132.13 (2 ) 190.93 +321.90
0.05 mM MnHP 117.23 + 6.52 139.60 (2 )
0 . 1 0 mM MnHP 108.58 + 3.29 134.50 + 1 1 . 2 1
0.25 mM MnHP 101.43 + 0.61 134.32 (2 )
£
Treatment of primary isolates of hepatocytes and trapping of 
14CO2 was carried out as described m  Section 2.12.9.
Each column represents a separate experiment. Control results
7
are presented as the average c.p.m./lO cells + standard error. 
Results from treated groups are presented as control + standard 
error, for triplicate samples unless noted otherwise.
•k
Significanly different from control, at the 5% level.
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TABLE 3.5.16.
The effect of MEHP, MnOP, MnHP and clofibrate on the incorporation 
. 14 _
of [1- C] palmitate into VLDL-like particles in hepatocytes 
isolated from fed and fasted rats.
Addition to 
medium
0.25 mM MEHP
14
[1- C] palmitate incorporation into VLDL-like 
particles.
FED FASTED
104% 93%
0.25 mM MnOP 166% 48%
0.2 5 mM MnHP 101% 70%
1.0 mM CPIB 75%
Treatment of primary isolates of hepatocytes and the isolation 
of labelled VLDL-like particles was carried out as described in 
Section 2.12.9.
Results are expressed as % control values, and are the mean of 
duplicate samples.
Significantly different from control at the 5% level.
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rats with MEHP resulted in a slight inhibition of the 
export of particles with the density of very low density 
lipoproteins (VLDL) in hepatocytes isolated from fasted rats, 
and no change in those isolated from fed rats. Incubation with 
MnOP,in contrast, resulted in a marked fall in export, in 
hepatocytes isolated from fasted rats, as did incubation 
with MnHP. However, in hepatocytes isolated from fed rats, 
incubation with MnOP resulted in an increase in the export 
of VLDL particles, whilst incubation with MnHP resulted in 
little change in export compared to controls.(table 3.5.16).
There was a marked variation in the degree of difference 
between experiments, carried out under the same conditions; 
Capuzzi et al, 1983, also observed differences in the degree 
of change between different batches of hepatocytes and 
attributed it to differences in enzymic activity in the 
isolated hepatocytes. This is possibly the explanation for 
the differences observed in the present study. However, 
this study has demonstrated another variable factor, namely, 
that the degree of change is dependent upon the nutritional 
status of the animal from which the hepatocytes were isolated. 
Although all perfusions were carried out at the same time 
to minimise the variation due to nutritional status, 
variations none the less could arise from differences in 
nutritional status.
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3.6. MUTAGENICITY OF DEHP AND MEHP.
The results indicate there is no increase in the 
number of mutant bacteria in plates treated with DEHP or MEHP 
(Table 3.6.1.). In addition, there was no increase in 
mutagenic activity with pre-incubation, in the presence and 
absence of S9 mix.(Table 3.6.2.).
3.7. H 2 O 2 production.
The production of catalase compound I was assayed in 
the livers of rats fed a diet containing sufficient DEHP to 
give a nominal dose of 1,000 mg/kg/day of DEHP. There was no 
evidence of an increase in catalase compound I production in 
these animals compared to controls.
In addition there was no evidence to suggest any increase 
in the levels of oxidised glutathione in the bile of rats treated 
with DEHP as compared to control fats.
Tabie 3.6.1.
The mutagenicity of DEHP and ME 
of revertants/plate, in the Ame 
strains TA98 and TA100, in the
Sample TA 98
(yg/plate) +S9 -S9
DEHP
10/000** 27.7+2.5 22.3+
5,000** 36.0 + 3.1 22.3 +
1,000* 28.3+0.7 18.5
300 28.3 +3.4 15.7 +
100 27.0 + 2.0 15.5
MEHP
5,000* TOXIC TOXIC
1,000 TOXIC TOXIC
300 26.0 + 1.0 18
100 24.5 (2) 23.7 +
' 30 25.5 (2) 16.0 +
0 25.5 (2) 24.5
DMSO 50yl 31.5 (2) 16
NF 1 yg 12 92.5
SA 0.1 yg 
. 2AA 1 yg 1520.5 (2)
The results are mean + S.E. for 
where otherwise noted.
** out of solution 
* slightly out of solution
1HP, as assessed by the number 
s test using S. typhirmrium 
presence and absence of S9 mix.
TA100 
+S9 -S9
3.4 34.7 + 2.5 40.7 + 4.5
5.5 31.7 + 0.3 38.3 + 7.3
(2 ) 30 (1 ) 31. 0 (2 )
2 . 1 37.7 + 2 . 2 36.7 + 5.7
(2 ) 37.0 + 2.7 45.7 + 3.2
TOXIC TOXIC
TOXIC TOXIC
(1) 41.5 (2) 37.7 + 1.8
1.9 37.5 (2) 35.5 (2)
0.6 42.3+ 6.5 45.7+2.7
(2) 42.7 + 1.8 48.0 (2)
(1) 48.7 + 0.6 47.0 +4.2
(2 )
81.3+6.2
460.7 +13.2
samples, except
Table 3.6.2.
The mutagenicity of DEHP and MEHP, using the Ames test, 
with S. typhirmrium TA 100, in the presence and absence of 
S9 mix, as assessed by the number of revertants/plate.
sample No + No
(yg/plate) preincubation preincubation preincubation
DEHP
5,000* 122.0 + 5.6 90.0 + 9.2 162.0 (2)
1,000* 100.7+6.3 92.0+8.5 162.5 (2)
300 101.6 + 6 . 6 98.3 + 6 . 8 153.0 (2)
100 107.3 + 4.0 108.3 + 6 . 8 165.5 (2)
30 106.7 +2.8 97.0+4.6 12 9.0 (2)
MEHP
1,000 109.0 + 2.7 70.5 (2) 120.0 (2)
300 98.0+6.1 82.7+1.2 124.5 (2)
100 106.0 + 3.3 96.3 + 9.7 139.5 (2)
30 96.7 + 3.9 78.7 + 8 . 8 127.5 (2)
10 101.7+0.9 89.7+8.1 149.5 (2)
0 113.7 + 6.2 122.0 + 8.7 147.5 (2)
DMSO 50 yl 117.0 + 12.1 97.0+2.6 133.5 (2)
2AA 1 yg 755.7 +5.5 763.0 + 46.4
SA 0.3 yg 328.0 (2)
The results are mean + S.E. for triplicate samples, 
unless otherwise noted.
* slightly out of solution.
CHAPTER FOUR 
DISCUSSION
4.1. INTRODUCTION.
The object of this project was to investigate the stages 
in the development of hepatocarcinomas in rats treated with 
DEHP, since it was felt that such knowledge, in rats, could 
yield insight into the underlying mechanisms. Such an 
understanding is crucial for assessment of the risk to man 
of DEHP and related compounds.
The report of Kluwe et at. (1982) which indicated that 
DEHP acts as a hepatocarcinogen in rats and mice prompted 
detailed investigation of the toxicity of DEHP and of other 
phthalate esters, both in the liver and other tissues. Many 
reports on these investigations have been published during 
the course of my studies of the effects of DEHP, and will be 
discussed together with my own results. The results in this 
thesis are particularly concerned with the early and sub­
chronic (up to 9 months) effects of DEHP, and concentrate on 
the development of hepatic changes resulting from treatment 
with DEHP. However, in order to interpret such results, 
it is important first to establish whether or not DEHP really 
is a carcinogen, and secondly, if it is, what type of 
carcinogen it is; that is, whether it is a genotoxic or 
non-genotoxic carcinogen. The sequence of changes seen in 
the livers of rats treated with DEHP will then be discussed, 
with a view to establishing a link between the effects 
observed in the short term and the development of hepatocellular 
carcinomas in the long term, after treatment,of rats, with 
DEHP.
4.2. THE HEPATOCARCINOGENICITY OF DEHP.
Early studies which have been criticised for limitations 
in design and reporting (see Introduction) (Wilbourn and
Montesano 1982) reported that DEHP was not carcinogenic in rats 
(Carpenter et at,, 1953 ; Harris et at., 1956 ). However a recent . 
study
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has been conducted in which statistically significant 
increases in hepatocellular carcinomas were observed in 
female rats (Fischer F-344) treated with 12,000 p.p.m. DEHP 
in the diet, in male mice (B6C3F1) receiving 6;000 p.p.m.
DEHP and in female mice treated with 6,000 and 3,000 p.p.m.
DEHP in the diet for 2 years (Kluwe et al. 1982, 19 83)
Although these investigations have been criticised because 
the maximum tolerated doses (M.T.D.) were exceeded, food 
consumption data were lacking and there were differences 
in the hepatic tumour rates in control populations (Northup 
et al. 1982) these deficiencies do not invalidate the findings 
totally and it must therefore be considered that DEHP is a 
potential risk to man.
Hepatocarcinogens have been divided into two classes - 
genotoxic and non-genotoxic hepatocarcinogens,(see Introduction), 
there is increasing evidence to suggest that’DEHP acts as a 
non-genotoxic hepatocarcinogen. Many reports have been 
published recently in which DEHP and its principal metabolites, 
MEHP and 2-d:hylhexanol (2-EH), fail to exert mutagenic 
activity, in a variety of sensitive bacterial mutagenic 
assays, although the results in mammalian mutagenic assays 
are less clear cut.
4.3. THE MUTAGENICITY OF THE PHTHALATE ESTERS.
As discussed in the Introduction and below, most studies 
of the mutagenic potential of DEHP, either bacterial or 
mammalian, have indicated that DEHP is non-mutagenic.
However, in contrast to other results, a recent publication 
(Tomita et al. 1982) reported that DEHP and MEHP showed 
mutagenic activities to S', typhimurium TA-100, with or without 
S-9 mix. As described in the Results section these results 
could not be reproduced , in our laboratory, using the 
conditions specified by Tomita et al. (1982); in addition, 
we observed that at the dose (5 mg/plate) of DEHP which 
Tomita et al. (1982) employed and claimed was mutagenic, DEHP 
came out of solution; DEHP also came out of solution at a
lower dose of 1 mg/plate . In our study, a dose of 
1 mg/plate of MEHP resulted in toxicity to the bacteria, 
as shown by the appearance of a very thin lawn. Tomita et al. 
(1982) stated that at a dose of 1.25 mg of MEHP/plate,
MEHP acted as a mutagen. No evidence is presented by Tomita 
et al. (1982) regarding the toxicity of MEHP or the solubility 
of either DEHP or MEHP. The significance of the results 
of the study by Tomita et al. (1982) must be questioned, 
in view of the fact that it could not be reproduced, and 
that results from many other studies indicate that DEHP 
is not mutagenic. DEHP was not mutagenic in the Ames 
test (Kirby et al. 1983; Kozumbo et al. 1982 ; Seed, 1982;
Zeiger et al. 1982). MEHP also failed to act as a mutagen 
in the Ames test, (Kirby et al. 1983, Kozumbo et al. 1982). 
2 -ethylhexanol was found to act as a weak mutagen at doses 
where significant cytotoxicity was observed (Seed, 1982), 
in contrast, Kirby et al. (1983) found no mutagenic activity 
of 2-EH in the Ames test. In conclusion it would appear/ 
that DEHP and its principal metabolites are not mutagenic 
in procaryotic test systems.
Neither DEHP, MEHP or 2-EH exerted mutagenic activity 
in L5178Y mouse lymphoma mutagenicity assay (Kirby et al.1983) 
nor in the CHO mutagenesis assay (Phillips et al. 1982).
In a rat bone marrow cytogenetics assay no activity was 
seen with DEHP, MEHP or 2-EH (Putman et al. 1983). MEHP, 
but not DEHP, was found to be clastogenic in CHO cells 
(Phillips et al. 1982), while both DEHP and MEHP were 
negative in the CHO sister chromatid exchange assays. It 
must be noted that results of sensitive cell culture systems 
must be interpreted with caution,where high doses are used, 
as such doses may cause severe toxicity, expecially as 
MEHP has detergent activity and can lyse both hepatocytes 
(see Results section) and red blood cells(Butterworth, 1984).
DEHP, MEHP AND 2-EH did not induce DNA repair in 
metabolically competant primary rat hepatocyte cultures
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(Hodgson et al. 1982, Kornbrust et al. 1984, Butterworth
et al. 1984). Kornbrust et al. 1984 reported that DNA
repair, as assessed by the autoradiograph measurement of
unscheduled DNA synthesis (UDS), was not observed in vitro>
-5 -2m  primary rat hepatocytes exposed to 10 to 10 M DEHP.
In a human hepatocyte DNA repair assay, no activity of 
DEHP or MEHP was seen. (Butterworth et al. 1984, as cited 
by Butterworth, 1984). Thus, in cell culture models, DEHP, 
MEHP and 2-EH do not directly interact with or alter the 
primary structure of DNA.
The mutagenicity of other phthalate esters has also 
been investigated. Kozumbo et al. (1982) reported that, 
in addition to DEHP and MEHP, the following phthalate 
esters showed no mutagenic activity in the Ames test, with 
S. typhimurium TA-100 or TA-98 either in the presence or 
absence of S9; DBP, butylbenzyphthalate, dimethyl 
isophthalate, and terephthalates. In contrast DMP and DEP 
caused a positive dose-related mutagenic response with 
S. typhimurium TA-100 in the absence of S9 liver enzymes. 
Further investigations revealed that the binding and 
mutagenicity of DMP inversely related the metabolism of 
DMP. Seed (1982) found that di-n-butylphthalate (DBP), 
as well as DMP and DEP, was mutagenic in an 8-azoguanine 
resistance assay in S. typhimurium3 whilst DEHP, DnOP, diallyl, 
diisobutyl and diisodecyl phthalate were not mutagenic.
Thus, it appears that there is a difference of response 
between long and short chain phthalate esters which is 
dependent upon chain length as the short chain phthalate 
esters act as weak mutagens, whilst the longer chain 
phthalate esters do not.
4.4. IS HYDROGEN PEROXIDE ACTING AS A MUTAGEN?
Although in vitro tests of the genotoxicity of DEHP 
have indicated that DEHP acts as a non-genotoxic 
hepatocarcinogen it is essential to examine the potential
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genotoxicity in the whole animal. In vivo additional 
factors come into play, e.g. the absorption, biodistribution, 
metabolism and elimination of the compound, all of which 
may influence its toxicity, as discussed in the Introduction. 
Further reactive intermediates may be generated in 
organelles other than the endoplasmic reticulum.
The effects of DEHP itself and its principal metabolites, 
MEHP and 2-EH on DNA have been studied in order to examine 
whether covalent interaction with DNA is involved in the 
hepatocarcinogenesis by DEHP. Some studies have 
concentrated on the possible effects of H202 in vivoj the 
basis of such studies is the working hypothesis postulated by 
Warren et al. 1982. Reddy and Lalwani (1984) suggested 
that DEHP and related compounds formed a novel class of 
carcinogens (Reddy et al. 1980). As such compounds are not 
directly genotoxic, it was proposed that peroxisome 
proliferation itself initiates neoplastic transformation 
by increasing intra-cellular rates of DNA damaging reactive 
oxygen species. In this model, DEHP would act as a 
complete carcinogen without directly altering DNA as the 
sustained increase in hepatic peroxisomes and the associated 
increases in peroxisomal H202-generating oxidases produced 
by hypolipidaemic agents lead to an excessive generation 
of H202 - which could react with superoxide radicals (02) 
or ferrous iron to form hydroxyl radicals (OH*). OH* and 
H202 produce degradation, strand breakage and cross-linking 
of DNA (Massie et al. 1972, Cadet and Teoule 1978). H202
also induces unscheduled DNA synthesis in vitro in mammalian 
cells (Stitch et al. 1978).
To test this, the author carried out a preliminary 
study in collaboration with Professor Sies, in Germany.
The levels of catalase compound I, that is, the catalase - 
H202 complex, were measured in perfused livers from rats 
treated with sufficient DEHP in the diet, to give a nominal 
dose of 1,000 mg/kg/day. There was little evidence of 
increased catalase compound I levels in treated animals
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compared to controls. In addition, there was no evidence 
of any change in the levels of oxidised glutathione in 
the bile from animals treated with DEHP. Once glutathione 
is oxidised, it is transported to the bile; and 
measurement of glutathione levels in the bile reflects 
the redox state in the liver. Increased levels of oxidised 
glutathione would be expected if the levels of H202 in 
the liver were increased as might be expected to result 
from treatment with DEHP.
This is the only direct evidence relating to the 
production of H202 in this study and it suggests that 
treatment of rats with DEHP did not lead to increased 
production of H202. The results from other studies indicate 
that DEHP, even under conditions to maximise H202-mediated 
effects, does not interfere with hepatic DNA.
Using the in vivo hepatocyte DNA repair assay 
(Mirsalis and Butterworth, 1980; Butterworth et al. 1982) 
examined the ability of DEHP to induce DNA damage or 
repair. DEHP was administered to rats, from which primary 
cell cultures were prepared and incubated with 3H-thymidine, 
and DNA repair as unscheduled DNA synthesis (UDS) was 
quantitated using autoradiography. DNA damage was 
measured by alkaline elution of cellular DNA from the 
same culture (Bermudez etal. 1982). In this study, rats 
were treated as follows - Female rats were treated with 
12,000 p.p.m. DEHP in the diet for 30 days, in addition 
some of these animals were given 500 mg/kg DEHP by gavage,
2 hours before sacrifice; male rats were treated with 
500 mg/kg DEHP by gavage 2, 12, 24 or 4 8 hours before 
sacrifice and male rats were treated with 150 mg/kg DEHP 
by gavage for 14 days. None of these treatments induced 
DNA damage or repair.
Kornbrust et al. 1984, reported that DNA repair was
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not observed in yiw after treatment with 5 g/kg body weight 
of DEHP, administered by gavage, 2, 15 or 24 hours prior to 
isolation of hepatocytes. These authors also reported 
peroxisome proliferation in the livers of male Sprague- 
Dawley rats. Additional administration of a single gavage 
dose of 5 g/kg body weight of DEHP to animals fed 2% DEHP 
in the diet for 4 or 8 weeks, did not induce any detectable 
DNA repair in hepatocytes isolated 15 hours following the 
single dose of DEHP, by gavage; neither was it induced in 
animals fed 2% DEHP in the diet for 4 weeks and also pre­
treated with 3-amino-l,2,4-triazole in order to inhibit 
endogenous catalase activity and to maximise H202-mediated 
effects. Also, there was no difference in lipid peroxidation 
between the 9000 x g supernatants of livers from animals 
treated with a single dose of DEHP (5 g DEHP/kg body weight) 
or with 2% DEHP in the diet for 6 weeks and a single dose of 
5 g/kg body weight and from controls. This suggests that 
DEHP does not elicit DNA damage or lipid peroxidation in 
the liver consequent to peroxisome proliferation. Also, non- 
cytotoxic doses of DEHP did not result in a positive response 
in the Chinese hamster V-79 metabolic co-operation assay 
for tumour promoters. Von Daniken et al. (1984) reported that 
there was no covalent binding of DNA in vivo after treatment 
of female rats and mice with radiolabelled DEHP and DEHA 
by oral gavage 16 hours prior to sacrifice with or without 
pre-treatment for 4 weeks with unlabelled 1% DEHP or DEHA 
in the diet. There were no significant strand breaks in DNA, 
as detected by alkaline elution assay in animals treated 
with DEHP (Butterworth et al., 1984).
A recent report suggests that peroxisomes purified 
from hepatocytes isolated from rats given the potent hypo- 
lipidaemic drug Wy-14,643 and incubated with 15 pM palmitate 
could nick SV-40 DNA ^ (Fahl et al., 1984). These authors concluded 
that as no effects were seen when DNA was incubated with 
control liver peroxisomes the DNA damage was from the hydrogen
peroxide generated from the induced peroxisomes. However, 
as hypolipidaemic agents induce lysosomal activity (Price,
1984) the DNA damaging effect could also result from a 
peroxisomal preparation contaminated with lysosomes.
In conclusion, it is unlikely that covalent interaction 
with DNA is the hepatocarcinogenic mechanism of DEHP, and its 
principal metabolites MEHP and 2-EH. In addition, there is 
no direct evidence to suggest that treatment with DEHP in vivo 
results in the increased production of H202, which, in turn, 
causes damage to DNA.
In all these studies the period of administration of DEHP 
may not have been sufficiently long to induce DNA damage.
In studies carried out by one of Professor Bridges' students 
(E. Irrissari, unpublished results) regression of hepatic 
nodules occurs after cessation of treatment in rats treated 
with 400 mg/kg/day of clofibrate for 24 months. (See 
Introduction- as the short term effects of DEHP and clofibrate 
are similar, it is likely that the long term effects will 
be also). The development of hepatocellular carcinomas appears 
to require prolonged, continuous treatment with peroxisome 
proliferating-type carcinogens, and so it is possible that 
the development of liver damage may only be evident 
after extended treatment, or certainly longer than the treatment 
regimens employed in the above studies.
Thus it appears that DEHP itself is not directly genotoxic 
and there is much evidence to suggest that indirect 
genotoxicity, mediated by H202 , does not occur as a result of 
treatment with DEHP. Further evidence supporting these 
conclusions has been recently published. Butterworth (1984) 
cites a study by Morton (1979) in which male Sprague-Dawley 
rats were treated with diets containing 500 to 5,000 p.p.m.
DEHP, which resulted in the induction of carnitine palmitoyl­
transferase, carnitine acetyltransferase B-oxidation activities.
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In F-344 rats similar increases were observed (Butterworth 
et at., 1984). These findings suggest that at the lower doses 
employed in the NTP study (Kluwe et al., 1982 ), i.e. at doses of 
3 & 6,000 p.p.m., should have resulted in significant peroxisome 
proliferation, and yet there was no evidence of increased 
incidence of hepatocellular carcinomas at this dose in either 
male or female rats. Also, DEHP is more effective in inducing 
peroxisomal enzymes in male than in female Sprague-Dawley ^  
rats (Osumi and Hashimoto, 1978) and in the presentrstudy, 
in Wistar Albino rats, and yet it was the female rats and 
not the male rats that exhibited the increased rates of 
hepatocellular carcinomas (Kluwe et aZ., 1982).
There is, however, much indirect evidence which suggests 
that proliferation of peroxisomes is, indeed, associated 
with increased H202 production. There are increased amounts 
of lipofuscin in livers of rats treated with DEHP, as 
compared to age-matched controls, and evidence of peroxidised 
lipids, in the present study. This will be discussed in 
Section 4.6.
4.5. PROMOTIONAL ACTIVITY OF DEHP.
A promoter is generally considered to be a compound, 
or a surgical procedure such as partial hepatectomy, which 
potentiates the production of a tumour or tumours, but 
is not in itself carcinogenic. As DEHP has been shown to 
act as a hepatocarcinogen (Kluwe et al., 1982 ), in rats 
and mice, it cannot, strictly, be termed a promoter.
Several investigations of the promotional activity of 
DEHP have been conducted, as promotional activity may be 
associated with the formation of liver tumours in rats and mice 
treated with DEHP. The results from these studies are not 
clear-cut.
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Schulte-Hermann et al. (1983) reported that non-mutagenic 
carcinogens may produce tumours by promotion of spontaneous 
neoplastic cells in rat liver. If pre-neoplastic lesions 
develop in control animals long term bioassays for carcino­
genicity will not discriminate between initiating and promoting 
compounds. On the basis of this hypothesis, and in view of the 
high doses required for an effect, in the study carried out 
by Kluwe et al. (1982) in which high incidences of hepatocarcinoma 
were observed in control male and female F-344 rats, DEHP 
could have been acting as a promoter, and not as a complete 
carcinogen.
Popp et al. (1984) reported a: lack of promoting activity 
in female F-344 rats initiated with diethylnitrosamine (DEN), 
followed by 12,000 p.p.m. DEHP in the diet for 6 months. 
Furthermore, DEHP had no initiating activity in rats (Popp 
et al., 1984 ) or in B6C3F^ mice (Ward et al., 1983 ), which is 
consistent with the lack of direct genotoxicity of DEHP and 
its metabolites. However, DEHP, at a dose of 3,000 to 12,000 
p.p.m. in the diet, promoted focal hepatocellular lesions in 
mouse liver after only 2 8 days. This is in contrast to 
phenobarbital, which required 168 days of continual exposure 
for a promotive effect to be seen (Ward et al., 1983 and 1984 ).
Staubli et al. (1984) observed that the selection of an 
appropriate dose may be crucial for the demonstration of the 
enhancing effect of peroxisome proliferators upon hepato- 
carcinogenesis. Low doses (1,000 p.p.m.) of clofibrate promoted 
liver tumour formation in DEN-pretreated rats more vigourously 
than higher doses (10,000 p.p.m.) (Mochizuki et al., 1982 and
1983). Thus, the lack of promotional activity of DEHP in the 
rat could result from administration of an inappropriate dose 
for demonstration of this effect. The dose-response relationship 
of promotional activity of DEHP in the rat liver clearly needs 
investigating. On the other hand, promotional activity may 
be species-specific, which is consistent with the greater
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induction of hepatic cancer in the mouse compared to the rat 
(Kluwe et al., 1982).
4.6. THE DEVELOPMENT OF HEPATIC DAMAGE.
A further possible explanation of the hepatocarcino- 
genicity of DEHP is through the stimulation of continual cell 
turnover. This is a recognised sub-class of the non-genotoxic 
carcinogens, in which the compounds exert their effect by 
producing cytotoxicity which results in increased cell 
regeneration and, therefore, DNA synthesis. (See Introduction 
1.9.). Such a continual cell turnover may result in an 
increase in fixation of the spontaneous mutational events 
and/or in the selection of mutant cells with a high growth 
potential. In the present study there was an initial mitotic 
burst, after treatment of male and female rats, with DEHP, 
which was dose-dependent. In male rats this was followed 
by hypertrophy. Increased liver to body weight ratios 
were maintained throughout the study, i.e. up to 9 months 
of treatment. In suport of this observation, (Butterworth 
et al. 1984 ), reported a small but reproducible increase in 
the number of hepatocytes in the S-phase after treatment 
of F-344 rats with DEHP. Furthermore, other hypolipidaemic 
peroxisome proliferators also stimulate a hepatomegalic 
and mitogenic response ,in rodents (Moody et al. 1977 ;
Reddy et al. 1976, 1978). 2 other parameters, like the rate
of mitosis, showed a transient change. These were eC1-8
and the appearance of bile canaliculi on electron microscopy.
The changes in serum proteins are discussed in a paper
from our laboratory (Hinton et al. 1984), but bile canalicular
changes are discussed later.
Although there is no evidence to suggest that DEHP 
unlike DnOP and DnHP causes hepatocyte necrosis even at 
doses of up to 2,000 mg/kg body weight/day, (Mann et al.
1984), nonetheless continual cell turnover could result from
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the administration of DEHP to rats as a result of chronic 
low grade damage, to hepatocytes,as will become evident 
from the following discussion of the sequence of hepatic 
changes induced by DEHP.
The effects which were found, in the present study 
after 3 days of treatment with DEHP included a marked 
dose-dependent hepatomegaly, which was accompanied by a 
short-lasting burst of mitosis, a proliferation of 
peroxisomes which lacked the uricase core which has been 
observed in a number of other studies (Reddy et al.,1976,
Moody and Reddy, 1978; Lake et al. 1975, 1984). There was 
a marked induction of the peroxisome-associated enzymes, 
cyanide-insensitive palmitoyl-CoA oxidase and cjv-glycerophosphate 
dehydrogenase but not of uricase. Although the total 
specific activity of catalase in the liver was induced 
there were complex changes in the percentage of catalase 
associated with peroxisomes in liver homogenates.
The changes in particle-associated catalase will be 
considered in some detail. Treatment with 50 mg/kg/day of 
DEHP resulted in an increase in the amount and proportion of 
catalase sedimentable at 10,000 g for 15 minutes, but at high 
doses the percentage of catalase in peroxisomes was less than 
in control animals. A similar effect has been observed 
in animals treated with hypolipidaemic drugs (Leighton et al. 
1975, Price 1984). These findings suggest that as a 
consequence of DEHP administration an imbalance may occur 
between the increased production of H202 due to the 
increased turnover of the peroxisomal fatty acid oxidation 
system and the capacity of catalase to detoxify this H202.
(N.B. At high dose levels of DEHP there may be up to a 
10-fold increase in peroxisomal fatty acid oxidation and 
only a 2-fold increase in catalase activity). Under these 
conditions it is possible that catalase activity is insufficient 
to cope with the increased load of H202 and as a result damage
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the burst of mitosis will not result, as although the livers 
of these animals will be subjected to metabolic stress, as in 
immature rats, the hepatocytes, which in immature rats responded 
.by dividing will have undergone cell division as the animals 
matured. Thus the livers of mature and immature rats appear to 
respond to metabolic stress differently.
We believe that our observations can be rationalised by 
assuming that there are two levels of the early response of 
rat liver to DEHP (and to other peroxisome proliferating agents). 
At low or moderate doses, there is an initial stimulation of 
peroxisomal and microsomal enzymes, which is an adaptive response 
without adverse consequences. (N.B. a dose of 50 mg/kg/day of DEHP 
in the present study, resulted in induction of peroxisomal 
enzymes without any evidence of damage to the hepatocytes).
With excessively high doses of peroxisome stimulating agents, 
over-stimulation of the system occurs, resulting in the release 
of toxic intermediates, such as H202 from peroxisomes, and 
cytochrome P4 5 q* Although much of the escaping toxic intermediate 
will be detoxified by cellular defence enzymes (e.g. glutathione 
peroxidase) there remains sufficient toxic intermediate present 
to cause damage to the cells. This is seen in the loss of 
glycogen and glucose-6-phosphatase activity, and after longer 
treatment, in the accumulation of lipid-rich material in 
lysosomes. This sequence of events also occcurs after 
administration of hypolipidaemic drugs (Price et al., 1982;
Price, 1984). The escaping toxic intermediates may prompt 
continual cell turnover, as suggested at the start of this 
section; this will be discussed in more detail in 4.10.
Although a knowledge of the sequence of events may help 
us to understand the development of hepatocarcinogenesis it 
does not explain what the initial trigger is for peroxisome 
proliferation or for lipid accumulation after treatment with 
DEHP. Answers are needed to a number of questions:
to the peroxisomal membrane by hydrogen peroxide occurs, 
leading to increased fragility of the peroxisomes. There could 
also be damage to the catalase molecule itself, resulting in 
an increase in its rate of loss to the cytosol (Masters and 
Holmes, 1977).
Thus, treatment with DEHP, at high doses, will result 
in an induction of total catalase activity in the liver, with 
a fall in the catalase activity associated with peroxisomes. 
Treatment with lower doses will .result in induction of total 
catalase activity in the liver, without the fall in the catalase 
activity associated with peroxisomes. This provides an 
explanation for the apparent contradiction of the effect of 
DEHP on catalase as described in the Introduction, where an 
increase in the total specific activity of catalase was 
observed by several authors (Reddy et al. , 1976; Moody and 
Reddy, 1978; Osumi and Hashimoto, 1978, 1979), whilst a depression 
of the catalase activity in the peroxisome fraction of the liver 
was observed by others (Ganning et al., 1980; Ganning and Dallner, 
1981).
SER proliferated in response to treatment with DEHP.
There was no overall induction of cytochrome however
laurate hydoxylase, which catalyses the w and w-l oxidation 
of fatty acids was induced in a dose but not time-dependent 
fashion. Laurate hydroxylase is induced after treatment of rats 
with clofibrate (Gibson et al., 1982; Orton and Parker, 1982 ).
Okita and Chance (1984) reported that DEHP, like clofibrate, 
induces the cytochrome „ P^5q mediated co-hydroxylation of fatty 
acids after treatment of male Sprague-Dawley rats with DEHP 
(2% in the diet) for 2 weeks. There was a 6-fold increase in 
laurate 12-hydroxylase activity, but no increase in 11-hydroxylase 
activity was reported. The assay used in the present study would 
not have distinguished the two iso-enzymes.
By 28 days of treatment with DEHP there was a dose-dependent
loss of glucose-6-phosphatase activity in livers from all 
treatment groups (which was statistically significant, except 
in male rats treated with 50 or 200 mg/kg body weight/day of 
DEHP). In addition, livers of male rats treated with 1,000 
mg/kg body weight/day of DEHP showed a centrilobular loss 
of glycogen, which developed after 7 days of treatment; this 
effect was seen in female rats also.
There was a time and dose-dependent periportal lipid 
accumulation, which was similar to that produced by clofibrate 
and other hypolipidaemic drugs. Rats treated with the lowest 
dose of DEHP showed an overall increase in lipid, whereas 
in male rats treated with 200 or 1,000 mg/kg body weight/day 
of DEHP there was a fat free zone around the central vein; 
this is the region in which peroxisomes are concentrated in 
both normal rats (Loud, 1968) and in rats treated with a 
hypolipidaemic agent (Moody and Reddy, 1978).
In addition, there is a fall in cytosolic reductants 
in rats treated with 1,000 mg/kg body weight/day of DEHP, 
which is thought to reflect a fall in hepatic glutathione 
levels. This effect is also seen after treatment with several 
hypolipidaemic drugs, e.g. clofibrate (Price, 1984).
These responses are indicative of subtle damage to the 
livers of animals treated With DEHP; these changes may precede 
the development of chronic damage which was evident in animals 
treated with DEHP for 9 months. Accumulation of PAS-diastase 
resistant granules was observed; these granules had the staining 
properties of lipofuscin, and their presence in the livers 
of rats treated with DEHP for 9 months suggests that mild 
liver damage had occurred. These changes were confirmed by 
electron microscopy which showed the presence of enlarged 
lysosomes in the livers of rats treated with DEHP.
These findings can be rationalised by proposing that DEHP
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causes damage to one or more cell organelle, as a consequence 
of which there is an increase in autophagy, resulting in an 
accumulation of enlarged lysosomes, which are filled with lipid- 
rich material which has the staining properties of lipofuscin 
(probably arising from organelle membranes). Accumulation of 
enlarged lysosomes is also observed after treatment of rats 
with clofibrate (Price et al., 1982;.Reddy et al., 1982). The 
increased lysosomal activity was also exemplified biochemically 
by an induction of the lysosomal enzyme, $-galactosidase, in 
male and female rats.
Lake et al. (1984c) investigated the earlier changes 
resulting from treatment of young male Sprague-Dawley rats 
with DEHP (1,000 mg/kg/day) and clofibrate (500 mg/kg/day) 
for 14 days and reported hepatomegaly, proliferation of 
peroxisomes, stimulation of palmitoyl CoA oxidation and 
carnitine acetyltransferase activity and increased microsomal 
cytochrome content, together with marked stimulation of
microsomal laurate hydroxylase activity. These findings support 
the observations in the present study. Treatment with DnOP 
(1,000 mg/kg/day) and MnOP (715 mg/kg/day) had little effect 
on these parameters. In addition, Lake et al. (1984c) observed 
that DEHP induced the hepatic peroxisome-associated 80,000 
M.W. polypeptide which is induced by clofibrate (Lalwani et al. , 
1981; Reddy and Kumar, 1977; Reddy et al., 1981).
An examination of the time and dose-response relationship 
of the changes induced by administration of DEHP shows a definite 
pattern, from which we have developed a working hypothesis, 
which a) provides a possible explanation of the development 
of hepatic changes described above, and b) relates the hepatic 
damage to the subsequent development of hepatocarcinomas, as 
a result of treatment with DEHP.
There is both indirect evidence (see Reddy and Lalwani,
1984) and direct evidence (Capuzzi et al., 1983) that clofibrate
interferes with lipid metabolism. We have shown that inter­
ference with lipid metabolism occurs in isolated hepatocytes 
incubated with various levels of MEHP. In vivo, we found that 
one of the most pronounced and immediate effects of DEHP (see 
Results, section 3.2.5.) was a change in the amount and 
distribution of lipid. It is reasonable to expect a link 
between the factor(s) responsible for the changes in lipid 
distribution and the factor(s) which triggers the induction 
of microsomal and peroxisomal fatty acid oxidising enzymes.
There is a parallel induction of microsomal P^q iso-enzyme 
and of peroxisomal fatty acid oxidation by many hypolipidaemic 
agents (Reddy and Lalwani, 1984; Lake et al., 1984b). This 
suggests that there may be a common receptor responsible for 
the initiation of both processes. A nafenopin binding protein 
has been discovered in rat liver cytosol (Lalwani et al., 1983); 
the binding to this protein, it was postulated, was responsible 
for the initiation of peroxisome proliferation- however, the 
of this protein was relativley low (0.53 pM for nafenopin) 
which suggests relatively non-specific binding.
The mitotic burst which occurs- immediately after treatment 
with DEHP commences is also seen with other hypolipidaemic 
drugs (Price, 1984 ) and trichloroacetic acid (Elcombe et al. ,
1984) and with microsomal enzyme inducers, such as phenobarbitone 
(Schulte-Hermann et al., 1974) , which do not affect peroxisomes, 
but may also initiate changes in lipid. Interestingly, in mature 
rats treated with DEHP there was no mitotic burst immediately 
after commencement of treatment although the lipid changes 
and induction of peroxisomal and microsomal fat metabolising 
enzymes occurred. As the burst'of mitosis produced by these 
compounds is, typically, rapid it is thought to be connected 
to metabolic stress, as a result of pronounced lipid accumulation, 
and in immature rats results in the division of liver cells, 
which were destined to divide as the animals mature. Thus-, 
the mitotic burst may not be connected with the 
ultimate formation of liver tumours. In mature animals the
a) Is DEHP itself the cause of peroxisome proliferation?
b) Does peroxisome proliferation occur in response to lipid 
accumulation?
As discussed earlier, the accumulation of lipid is, 
undoubtedly, one of the first responses seen in vivo after the
administration of peroxisome proliferating compounds. Indeed, 
there may be a link between agents which produce a substantial 
increase in lipid influx into hepatocytes in vivo and those 
which are classified as non-genotoxic hepatocarcinogens, 
including the hypolipidaemic drugs, e.g. clofibrate, and environ- . 
mental contaminants, e.g. DEHP and trichloroethylene. Each 
provoke a rapid, although temporary,increase in lipid deposition, 
in the form of small droplets of lipid, in the liver. A similar 
accumulation.of lipid is produced by the administration of 
high-fat diets to rats (Neat et al., 1982). A similar dietary 
manipulation causes a mild proliferation of peroxisomes 
(Osmundsen, 1982).
4.7. COMPARISON OF THE IN VIVO AND IN VITRO RESPONSES TO PHTHALATE ESTERS.
The use of freshly isolated and cultured hepatocytes 
provides a rapid and reproducible means for the investigation 
of early mechanisms of toxicity of different compounds, their 
use is becoming established in various areas of research 
PitOt and Sirica, 1980; Suolinna, 1982). Using such isolated 
hepatocytes it may be possible to detect earlier the more 
subtle changes that would perhaps go unnoticed in animal 
experiments, although there are obvious limitations in their 
use.
Consequently, further investigations of the early effects 
of DEHP employed cultured hepatocytes. In order to study the 
relationship between lipid accumulation and peroxisome ..v. 
proliferation the straight chain analogues of DEHP, DnOP and DnHP,
-290-
as well as DEHP, were used.
Treatment of cultured hepatocytes with DEHP, for 72 hours, 
resulted in an increase of cyanide-insensitive palmitoyl CoA 
oxidase activity, which was greatest at a dose of 0.5 mM DEHP 
(Table 3.5.1.). Induction of a-glycerophosphate dehydrogenase 
activity was also observed. There was a dose-dependent induction 
of cyanide-insensitive palmitoyl CoA oxidation, which was greatest 
at a dose of 0.25 mM MEHP, which was twice that observed with 
0.5 mM DEHP. Electron microscopic studies revealed that after 
only 24 hours of treatment with 0.25 mM MEHP there was apronounced 
pronounced proliferation of peroxisomes.
Treatment of cultured hepatocytes with the di- and mono­
esters of the straight chain phthalates gave a different picture. 
There was a limited induction of cyanide-insensitive palmitoyl 
CoA oxidase and of a-glycerophosphate dehydrogenase activity, 
after 72 hours of treatment with DnOP and DnHP. Electron 
microscopic studies of cultured hepatocytes treated with 0.25 mM 
MnOP and MnHP revealed no increase in the number of peroxisomes. 
Interestingly, the induction of cyanide-insensitive palmitoyl 
CoA oxidase activity by DnOP and DnHP was, in contrast to 
MEHP and DEHP, more marked than that observed after treatment 
with MnOP and MnHP. At the low doses of MnOP and MnHP employed 
there appears to be some stimulation of palmitoyl-CoA oxidase 
activity, but this fell to or below control levels as the dose 
level was increased. It is possible that as the dose level was 
raised toxic effects develop which mask the stimulatory effects 
observed at lower doses. It may be predicted from the structure 
of the straight chain diesters, DnOP and DnHP, that they will 
enter cell more readily than the more.polar, charged monoesters, 
MnOP and MnHP, and will tend to accumulate in the lipid rich 
parts of the cell, whence they will undergo enzyme hydrolysis, 
to their respective monoesters. Hydrolysis is a slow, saturable 
process, consequently, there is likely to be a "topping up" 
of the intra-cellular levels of the monoesters, until the diesters
are exhausted. At the same time, further metabolism of the mono­
esters, so produced, will occur: the balance of their formation 
and removal will govern their intra-cellular levels.
Assessment of the effects of phthalate esters has to be based 
on a comparison with control hepatocytes. However, the baseline 
levels of many of the cells biochemical features change with time 
of culture and this may complicate the interpretation of results. 
Gray et at. (1983 ) observed a pronounced induction of cyanide- 
insensitive palmitoyl-CoA oxidation after treatment of cultured 
hepatocytes with 0.2 mM MEHP for 76 hours; however, these a 
authors reported a time-dependent decrease in the level of 
cyanide-insensitive palmitoyl CoA oxidation in control cultures; 
so that although palmitoyl-CoA oxidation in MnOP treated 
cultures was 419% of control, the absolute activity was not 
different from the zero hour level. Lake et al. (1984b) also 
observed marked induction of cyanide-insenitive palmitoyl- 
CoA oxidation after.treatment with 0.2 mM MEHP for 72 hours, 
and a much less marked induction after treatment with 0.2 mM 
MnOP for 72 hours.
Similar findings were reported by Gray et al. (1983) to 
those in the present study, after electron microscopic 
examination Of rat hepatocytes treated with MEHP; these authors 
reported an increased number of peroxisomes, in cultured 
hepatocytes treated with 0.2 mM MEHP, for 48 hours, and no 
difference between control cultured hepatocytes and those 
treated with 0.2 mM MnOP, or with 0.2 mM mono-n-pentylphthalate.
Staining with O.R.O. of cultured hepatocytes treated with 
0.25 mM MEHP, MnOP and MnHP for 24 hours revealed differences 
in response. The distribution and appearance of the lipid 
reflected the changes observed in vivo. The nature of the lipid 
which accumulates is not known and it appears to be different 
after treatment with the straight and branched chain phthalate 
esters.both in vivo and in vitro.
From the above findings, it is reasonable to conclude 
that, at least as far as peroxisome proliferation and changes 
in lipid are concerned, rat hepatocyte cultures provide a good 
model for the rat in vivo responses. This is supported by the 
demonstration that the different phthalate esters evoke 
different responses in vitro which reproduce those observed 
in vivo. ,
In order to assess whether the lack of peroxisomal 
induction after treatment with MnOP or MnHP was due to the 
toxicity of these compounds - the leakage of lactate dehydrogenase, 
into the medium, was assayed. This is a common test for cellular 
damage and parallels a widely used index in vivo (Suolinna, 1982). 
Howe\ar, it demonstrates only membrane leakiness and does not 
give any information about the toxic mechanisms involved. It 
is not unexpected than that there was little difference in 
toxicity, as assessed by measurement of lactate dehydrogenase 
released into the medium, in control and treated cultures.
Such an assay would not be sensitive enough to reveal subtle 
toxicity.
The studies of the effects- of phthalate esters on peroxisomes 
and lipid accumulation in cultured hepatocytes were followed 
by studies concerning aspects of the "active oxygen hypothesis".
First,, unlike the mitotic burst which is observed in vivo 
after treatment with DEHP, there was no increase in DNA synthesis 
in hepatocytes treated for up to 48 hours with doses of up 
to 0.25 mM MEHP. In contrast, nafenopin, which is a much more 
potent peroxisome proliferating agent than DEHP, in vivo and 
in vitro (Lake et al., 1984b), does stimulate a mitotic burst 
in cultured hepatocytes, but only after 72 hours of treatment, 
(Bieri et al., 1982) . After only 24 hours of treatment with
- ‘K--
clofibrate in vivo stimulation of mitosis is seen (Price, 1984).
(N.B. The significance of the initial mitotic, burst
in vivo in the long-term development of hepatic carcinomas is
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not known).
A further difference between the in vivo and in vitro 
response to DEHP was that no loss of glucose-6-phosphatase 
activity was observed in vitro after 72 hours of treatment with 
doses of up to 0.25 mM MEHP- this suggests that the hepatocytes 
in vitro are not damaged in the same way as in vivo.
Thirdly, there was, unexpectedly, no fall in intra-cellular 
glutathione levels, in vitro, unlike the in vivo situation where 
such a fall is reflected in the the fall of the cytosolic 
reductants..It is known that the addition of cysteine to the 
medium leads to an increased synthesis of glutathione thereby 
protecting the cellular components against 1) the attack of 
electrophilic compounds and 2) lipid peroxidation by various 
oxidising agents (Suolinna, 1982). There may be sufficient 
cysteine within the incubation medium to prevent depletion 
of the intra-cellular levels of glutathione, and so, in turn 
to prevent toxic damage by active oxygen radicals which may 
be produced as a result of treatment with MEHP.
Further, there was no evidence-of increased hydrogen peroxide 
production, either by direct measurement of H202, or indirectly, 
as there was no induction of glutathione peroxidase activity, 
which would be expected if H202 was being released into the 
cytosol from peroxisomes.
In conclusion, although the use of cultured hepatocytes 
provides an adequate model of peroxisome proliferation, present 
methodology is not sufficiently advanced to render it suitable 
for investigation of longer term changes. The use of a cysteine- 
free medium may reduce trapping of H202 and oxygen radicals, 
allowing their detection and their ability to produce membrane 
damage , after treatment with MEHP. In order to maximise 
H202-mediated effects further treatment of hepatocytes with 
3-amino,1,2,4-triazole, which inhibits catalase, should be
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carried out. If under these conditions there is no evidence 
for increased H202 production or toxicity, then the validity 
of the "active oxygen " hypothesis must be questioned. It may 
also call into doubt peroxisome proliferation as a crucial 
event in the development of hepatocellular carcinomas.
4.8. DO PHTHALATE ESTERS INTERFERE IN LIPID METABOLISM?
As there was no evidence for increased H202 production 
and there were obvious changes in lipid and in lipid metabolising 
enzymes, i.e. induction of cyanide-insensitive palmitoyl-CoA 
oxidation, the induction of which correlates with the induction 
of lauric acid hydroxylation (to and co-1 fatty acid oxidation ) 
in cultured rat hepatocytes)(Lake et al., 1984b), within 24 hours 
of treatment with MEHP, the biochemical mechanisms underlying 
the lipid accumulation were investigated.
• V
The results (see 3.5.2.) show that MEHP, like clofibrate, 
(Capuzzi et al., 1983 ) perturbs lipid metabolism in a way which 
can explain the accumulation of lipid observed in vivo. 
Administration of diets containing DEHP, to rats, resulted in 
depression of acyl CoA:chloesterol acyl transferase in the same 
way as clofibrate (Bell and Buthala, 1983). Thus, the common 
pattern of toxicity may be due to the same effects on lipid 
metabolism. Treatment with either compound, in vitro, resulted 
in little change in triglyceride and cholesterol ester synthesis 
or in fatty acid oxidation in primary isolates of hepatocytes 
isolated from fed rats. However, in hepatocytes, isolated from 
rats fed at midday, which, although having acess to food tended 
not to have eaten for several hours, there was a marked increase 
in triglyceride synthesis. The effect was even more marked 
in hepatocytes isolated from rats fasted for 18 to 24 hours.
There was an increase in the synthesis of triglyceride and 
cholesterol esters, but there was no increase in the assembly of 
lipoproteins; this probably explains why triglyceride and 
cholesterol esters tend to accumulate in the cells. Both
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clofibrate and MEHP may be acting as allosteric effectors on 
some enzymes involved in triglyceride production.
MEHP, MnOP and MnHP could all perturb lipid metabolism 
in vitro, by mimicking fatty acids and by binding to allosteric 
sites on one or more of the regulated enzymes which control 
fatty acid oxidation and incorporation into triglycerides, 
and thus, interfering with the control of metabolism. It is 
notable in this regard that the structures of MEHP and MnHP 
resemble the structure of an 11-carbon fatty acid,whilst that of 
MnOP resembles a, 13-carbon fatty acid. The straight chain 
phthalate esters may be anticipated to be more effective in 
modifying fatty acid metabolism, as the side chain of MEHP 
may interfere with the binding of MEHP to the allosteric 
effector. Thus, the presence of phthalate esters might result 
in a pattern of fatty acid metabolism, which is appropriate 
to a much greater intra-cellular fatty acid concentration than 
fact occurs.
Such direct early effects of lipid metabolism may be 
expected to precede the chronic effects seen after prolonged 
treatment. However, the mechanism must be more complex. For 
although isolated hepatocytes treated with both branched and 
straight chain phthalate esters showed similar perturbations 
of lipid metabolism, MEHP caused an induction of peroxisomes, 
whilst treatment with MnOP and MnHP did not. It is possible that 
MnOP and MnHP would induce peroxisomal enzymes, but that more 
general hepatotoxicity occurs first. The in vivo fatty necrosis 
observed in rats treated with DnHP and DnOP, together with the 
in vitro cytotoxicity of high doses of MnOP and MnHP, support 
this explanation, although at certain doses either the 
peroxisomes proliferating, ability should predominate. At the 
lowest doses of treatment with MnOP and MnHP this occurred.
A further explanation could be the difference in metabolism 
between MEHP and MnOP (Albro et al., 1973; Albro and Moore, 1974)
which would result in very different intra-cellular concentrations 
of both parent compounds and metabolites.
It is clear that there are several features which need 
investigation in order to determine whether on administration 
of MEHP, MnOP and MnHP, the immediate effect is direct perturbatio 
perturbation of lipid metabolism, and whether this perturbation 
is responsible for the observed lipid accumulation in vivo 
or in cultured hepatocytes. As the lipid that accumulates 
appears to be different after treatment with the straight and 
branched chain phthalates it may be that only accumulation 
of a specific type of lipid or fatty acid will trigger 
peroxisome proliferation.Analysis of lipid extracted from the 
livers of animals treated with DEHP, or its straight chain 
analogues, should provide an answer to this.
If this hypothesis is correct, the peroxisome proliferating 
potency of this group of non-genotoxic hepatocarcinogens should 
parallel the extent to which these compounds perturb lipid 
metabolism. For example, ciprofibrate which, in vivo, is a 
strong peroxisome proliferating agent should cause greater 
perturbations in lipid metabolism than DEHP, which acts as a 
weak peroxisome proliferating agent. Examination of a series 
of compounds and their effects on lipid metabolism in isolated 
hepatocytes may yield insight into whether the early effects 
play a role in the development of long term effects. Such an 
approach does not allow for the problems of mirroring the 
pharmacokinetic factors in vitro, which in vivo may play a role 
in determining the potencies of different compounds.
Another approach would be to use a compound, such as 
clofibrate, which is known to produce peroxisome proliferation 
, and in the long term, hepatocarcinomas in rats but not in 
guinea pigs or man, and examine whether the perturbations of 
lipid metabolism occur in hepatocytes isolated from the "non- 
responsive" species. This may help* to elucidate the underlying
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differences between the responsive and non-responsive species.
In such experiments it will be important to establish that 
the bioavailability, both in terms of total cellular uptake 
and specific location of the compound, is the same in the isolated 
hepatocytes from different species, as differences in bio- 
availability may result in differences in response.
4.9. DOES DEHP INTERFERE IN BILE PRODUCTION?
As mentioned earlier, electron microscopic studies of 
livers of male and female rats treated with DEHP revealed transient 
. alterations in the appearance of bile canaliculi. Biochemical 
studies also showed transient changes in various enzymes in 
bile and in bile flow. Studies of the acute toxicity of MEHP
had revealed, as may be predicted from its structure, that at
a dose of 0.05% (v/v) of MEHP, which corresponds to about 
1.75 mM MEHP, MEHP was capable of detergent-like activity, which 
produced membrane changes.
The observed increase in bile flow caused by DEHP may be a 
passive effect, not related to other changes, but rather to 
increase in liver size, as direct leakage is, presumably, 
directly proportional to the length of the tight junctions.
We observed that both liver size and bile flow increase to about 
150% of control values after treatment with DEHP (1,000 mg/kg
body weight/day for 3 days). Bile flow also increased after
15 days of treatment, as did liver size.
DEHP may be excreted into the bile (see 1.9.). Daniel and 
Bratt (1974) estimated that 6.2% of a dose of 2.6 mg/kg of DEHP 
was excreted into bile, assuming that excretion into bile is 
linear with increasing dose, at a dose of 1,000 mg/kg/day of 
DEHP, the amount of DEHP in the bile will be an average 1.66 
mM (over a 24 hbur period) in a 250 g rat. Interestingly, this 
dose corresponds to that which produced a marked fall in the 
viabilities of primary isolated hepatocytes. However, as rats
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have a diurnal feeding pattern, a much higher dose will probably 
be present immediately after feeding.
The transient changes in bile canaliculi and detergent 
activity of MEHP, the major metabolite of DEHP, may be related.
In support of the above findings, Phillips et al. (19 84 ) reported 
that treatment of CHO cells with doses of 0.5 to 1.5 mM MEHP 
resulted in cytotoxicity and that the cells had an appearance 
similar to that produced by treatment with a detergent, and 
concluded that cytotoxicity was attributable to the detergent­
like activity of MEHP.
If the mechanism of action is via a detergent-like effect 
of DEHP or MEHP the damage produced will depend upon the peak 
excretion rate. The detergent effect will remove lipids from 
the cell surface resulting in the observed increase in myelin 
bodies in the bile canaliculi. After 3 days of treatment there 
was a marked induction of w and w-1 oxidation, the products of 
which are unlikely to act as such effective detergents, this 
may explain the observed early reversal of the bile canalicular 
damage.
4.10. POSSIBLE MECHANISMS OF HEPATOCARCINOGENESIS OF DEHP.
A A scheme depicting the probable sequence of events in the 
the development of hepatocellular carcinomas after treatment with 
with DEHP is shown in Figure 4.1. This takes into consideration 
both the results from the present study and the available 
literature. As the short and middle term changes shown have been 
considered earlier it is pertinent, now, to discuss how these 
events are related to the development of hepatocellular 
carcinomas, an whether, in fact, these events are essential 
to the development of the chronic effects of DEHP.
Most of the available evidence suggests that there is little, 
or no, increase in H202 production in hepatocytes exposed to
DEHP, either in vivo or in vitro. Hence it would seem that DEHP 
itself does not bind to DNA, and that toxic intermediates such 
as H202 or OH’, which could interact with DNA, are not formed.
In considering the possible mechanism of hepatocarcino- 
genicity of DEHP, the most obvious immediate effect of DEHP 
is the interference with lipid metabolism; this results in 
the accumulation of lipid, which, in turn, results in the 
proliferation of peroxisomes, in order to deal with the 
accumulating lipid. Such a perturbation of lipid metabolism 
is also produced by the straight chain phthalates, but in 
this case, as discussed earlier a second set of events, 
hepatotoxicity, e-.g. fatty necrosis, overwhelms peroxisome 
proliferation.
Perturbation of lipid metabolism, as seen in isolated 
hepatocytes treated with MEHP, MnOP and MnHP, may itself 
have profound effects. Triglycerides and phospholipids are 
rarely regulatory molecules per se, but they do play major 
roles in influencing cell membrane permeability and the 
degree of membrane and cellular responses to various stimuli 
(Owen et al.-, 1984 ). Disturbances of lipid metabolism which 
result in changes in lipoprotein concentrations and in 
cholesterol content may cause membrane lipid abnormalities.
Gross disturbance of the surface membranes will have profound 
effects, for example, in liver disease where a number of 
cellular abnormalities and metabolic disturbances can be 
explained by changes in membrane function and composition 
(Harry et al., 1982).
Changes in the fatty acid composition of the lipids in 
organelle and plasma membranes can result in changes in membrane 
lipid fluidity which, in turn, may alter the conformation of 
the active site of some membrane-associated enzymes, influencing 
the rate of reactions catalysed by these enzymes (McMurchie 
and Raison, 1979). These changes may be mediated intrinsically 
by changes in membrane lipid composition or extrinsically by
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compounds which influence membrane lipid fluidity. Both 
branched and straight chain phthalate esters may be capable 
of mediating such changes, which could result in cellular 
dysfunction. It is possible that the straight chain phthalate 
esters cause more marked necrosis than MEHP by producing 
greater disturbances in membrane lipid and so, in turn, greater 
cellular dysfunction.
The accumulation of lipofuscin indicates membrane damage 
has occurred, as a result of treatment of rats with DEHP.
Both perturbation of lipid metabolism and production of H202 
and other active oxygen intermediates would result in damage 
to cell membranes. Such low grade chronic injury will result 
in continual cell turnover, and this could result in an increase 
in spontaneous mutational events and/or in promotional activity. 
Also, changes in the membrane could result in changes in 
growth control; this may result in inappropriate responses in 
cells and, in turn, in the production of tumours. This 
would be a purely non-genotoxic mechanism.
In addition, although the evidence is equivocal, there 
is some indication that DEHP may act as a promoter, although, 
by definition, as DEHP acts as a hepatocarcinogen, this cannot 
be the only mechanism by which it is acting. Such a mechanism 
does not account for the correlation of potency between 
peroxisome proliferation and the incidence of tumour production. 
If DEHP is acting simply as a promoter, together with spontaneous 
mutations, then no consideration of the sequence of hepato­
cellular changes is required.
However, the same sequence of events which occurs as a 
result of DEHP administration is evoked by other peroxisome 
proliferating agents, such as clofibrate (Price, 1984).
Also, there are many similarities between the short-term effects 
of the microsomal enzyme inducers, a class of non-genotoxic 
carcinogens, and the peroxisome proliferating agents. Longer term 
changes appear similar also, in that both types of compounds
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may lead to continual cell turnover, as a result of low 
grad chronic damage, which appears crucial to their mechanism 
of hepatocarcinogenesis. Such chronic low grade damage is 
essential to the hepatocarcinogenesis of another class of 
non-genotoxic carcinogens - implants.
In conclusion, it is clear that the proposal by Reddy et al. 
(1980) that peroxisome proliferating agents constitute a novel 
class of carcinogens needs to be re-evaluated. Although, the 
correlation between the potency of peroxisome proliferation 
induced by peroxisome proliferating agents and the incidence 
of tumours is clearly established, the inability of a compound 
to proliferate peroxisomes is not, in itself, an adequate 
prediction that such a compound will not act as a hepato­
carcinogen. In addition, it would appear that peroxisome 
proliferating agents do not have a unique mechanism of hepato- . 
carcinogenesis, if they can reasonably be included with the 
microsomal enzyme inducers, in a class of non-genotoxic 
carcinogens.
It is obvious that the long-term consequences of treatment 
with DEHP, i.e. the development of hepatic tumours, arise 
from a complex sequence of events, and not simply or directly 
as a result of peroxisome proliferation. This has important 
implications in establishing the possible hazard to man 
from phthalate esters and hypolipidaemic drugs. Thus, although 
it has been shown that patients treated with clofibrate, for 
long periods, develop only a slight peroxisome proliferation 
(Hanefeld et al., 1982) this may be an inadequate basis for 
assessing the risk to man.
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